

CITATION REPORT

List of articles citing

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

DOI: 10.1161/01.res.87.5.e1
Circulation Research, 2000, 87, E1-9.

Source: <https://exaly.com/paper-pdf/32268186/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2217	The angiotensin system elements in invertebrates. 2001 , 36, 35-45		43
2216	The clinical implication of tissue renin angiotensin systems. 2001 , 16, 317-27		34
2215	Bioactive angiotensin peptides: focus on angiotensin IV. 2001 , 2, 205-10		37
2214	Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. 2001 , 276, 17132-9		170
2213	Metabolism of angiotensin I by guinea pig aqueous humor. 2001 , 79, 627-630		4
2212	ACEH/ACE2 is a novel mammalian metallopeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. 2002 , 80, 346-53		131
2211	Angiotensin-converting enzyme 2--a new cardiac regulator. 2002 , 347, 1795-7		98
2210	New aspects on angiotensin-converting enzyme: from gene to disease. 2002 , 40, 256-65		93
2209	Ongoing trials involving angiotensin-converting enzyme inhibitors. 2002 , 11, 1633-43		1
2208	Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. 2002 , 124, 11852-3		133
2207	Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. 2002 , 532, 107-10		550
2206	Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. 2002 , 15, 557-64		70
2205	The angiotensin-converting enzyme gene family: genomics and pharmacology. 2002 , 23, 177-83		311
2204	Formation of angiotensin-(1-7) from angiotensin II by the venom of <i>Conus geographus</i> . 2002 , 105, 101-8		2
2203	Just the beginning: novel functions for angiotensin-converting enzymes. 2002 , 12, R745-52		106
2202	Angiotensin-converting enzyme 2 is an essential regulator of heart function. 2002 , 417, 822-8		1345
2201	Two ACEs and a heart. 2002 , 417, 799-802		34

2200	Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats. 2002 , 135, 1743-8	31
2199	Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. 2002 , 277, 14838-43	1012
2198	Angiotensin converting enzyme-2 (ACE2) and its possible roles in hypertension, diabetes and cardiac function. 2003 , 10, 377-385	9
2197	Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. 2003 , 5, 129-34	43
2196	A story of two ACEs. 2003 , 81, 227-34	58
2195	The role of ACE2 in cardiovascular physiology. 2003 , 13, 93-101	182
2194	Target validation using human tissue: from gene expression to function. 2003 , 2, 58-64	4
2193	Development of intramolecularly quenched fluorescent peptides as substrates of angiotensin-converting enzyme 2. 2003 , 312, 141-7	18
2192	Angiotensin I-converting enzyme and potential substrates in human testis and testicular tumours. 2003 , 111, 234-43; discussion 243-4	16
2191	An ACE structure. 2003 , 10, 155-7	25
2190	Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. 2003 , 426, 450-4	3969
2189	Localization of carboxypeptidase A-like enzyme in rat kidney. 2003 , 24, 1237-40	8
2188	Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function. 2003 , 10, 377-385	9
2187	Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. 2003 , 538, 65-70	84
2186	The secret life of ACE2 as a receptor for the SARS virus. 2003 , 115, 652-3	107
2185	A local pancreatic renin-angiotensin system: endocrine and exocrine roles. 2003 , 35, 838-46	103
2184	The intrarenal renin-angiotensin system and diabetic nephropathy. 2003 , 14, 274-81	176
2183	An essential role in molting and morphogenesis of <i>Caenorhabditis elegans</i> for ACN-1, a novel member of the angiotensin-converting enzyme family that lacks a metallopeptidase active site. 2003 , 278, 52340-6	55

2182	Angiotensin-I-converting enzyme and its relatives. 2003 , 4, 225	164
2181	Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. 2003 , 42, 13185-92	132
2180	Novel peptide inhibitors of angiotensin-converting enzyme 2. 2003 , 278, 15532-40	150
2179	Biphasic effects of angiotensin (1-7) and its interactions with angiotensin II in rat aorta. 2003 , 4, 124-8	16
2178	Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. 2003 , 24, 261-71	445
2177	Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. 2003 , 284, H1985-94	146
2176	[A second angiotensin-converting enzyme for the heart?]. 2003 , 19, 141-3	0
2175	ACE and non-ACE mediated effect of angiotensin I on intracellular calcium mobilization in rat glomerular arterioles. 2003 , 284, H1933-41	4
2174	Enhanced expression of Ang-(1-7) during pregnancy. 2004 , 37, 1255-62	85
2173	Angiotensin-converting enzyme 2. 2004 , 349-351	8
2172	ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. 2004 , 279, 17996-8007	424
2171	Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. 2004 , 5, 203-8	59
2170	Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. 2004 , 383, 45-51	462
2169	Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes. 2004 , 239, 47-97	27
2168	Nonchannel drug targets in atrial fibrillation. 2004 , 102, 17-36	28
2167	ACE2 gene expression is up-regulated in the human failing heart. 2004 , 2, 19	167
2166	Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. 2004 , 500, 467-85	64
2165	Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. 2004 , 6, 117-23	10

2164	Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. 2004 , 6, 124-8	13
2163	Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. 2004 , 203, 631-7	3418
2162	Renal ACE2 expression in human kidney disease. 2004 , 204, 587-93	190
2161	Identification of angiotensin converting enzyme 2 in the rodent retina. 2004 , 29, 419-27	64
2160	Tissue renin angiotensin systems. 2004 , 88, 19-38	81
2159	Interaction of ACE2 and integrin beta1 in failing human heart. 2004 , 1689, 175-8	29
2158	ACE2, a new regulator of the renin-angiotensin system. 2004 , 15, 166-9	230
2157	ACE2: from vasopeptidase to SARS virus receptor. 2004 , 25, 291-4	370
2156	Zinc-metalloproteases in insects: ACE and ECE. 2004 , 34, 501-10	35
2155	Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. 2004 , 89-90, 387-92	388
2154	No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. 2004 , 17, 624-8	58
2153	A model of the ACE2 structure and function as a SARS-CoV receptor. 2004 , 314, 235-41	128
2152	Valsartan. 2004 , 2, 67-101	2
2151	Severe acute respiratory syndrome: an update. 2004 , 17, 287-94	15
2150	Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. 2004 , 22, 1971-6	64
2149	Characterization of the first non-insect invertebrate functional angiotensin-converting enzyme (ACE): leech TtACE resembles the N-domain of mammalian ACE. 2004 , 382, 565-73	17
2148	Renin-angiotensin system intervention to prevent in-stent restenosis: an unclosed chapter. 2005 , 45, 88-98	15
2147	The kallikrein-kinin system: current and future pharmacological targets. 2005 , 99, 6-38	328

2146	Tissue isoforms of angiotensin-converting enzyme. 2005 , 23, 1793-4	
2145	Myocardial infarction increases ACE2 expression in rat and humans. 2005 , 26, 369-75; discussion 322-4	324
2144	Membrane-associated zinc peptidase families: comparing ACE and ACE2. 2005 , 1751, 2-8	64
2143	Angiotensin-Converting Enzymes: Properties and Function. 2005 , 95-99	
2142	Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal Ang II activity. 2005 , 67, 1453-61	31
2141	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. 2005 , S57-65	306
2140	A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. 2005 , 11, 875-9	2294
2139	Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. 2005 , 90, 299-305	30
2138	Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. 2005 , 90, 783-90	186
2137	Angiotensin-converting enzyme 2 protects from severe acute lung failure. 2005 , 436, 112-6	1770
2136	Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. 2005 , 272, 3512-20	74
2135	A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. 2005 , 123, 41-8	20
2134	Proteomic analysis of differential protein expression in response to epidermal growth factor in neonatal porcine pancreatic cell monolayers. 2005 , 95, 769-81	11
2133	Identification of an alternative 5'-untranslated exon and new polymorphisms of angiotensin-converting enzyme 2 gene: lack of association with SARS in the Vietnamese population. 2005 , 136, 52-7	40
2132	Molecular evidence of tissue renin-angiotensin systems: a focus on the brain. 2005 , 7, 135-40	39
2131	Rethinking the renin-angiotensin system and its role in cardiovascular regulation. 2005 , 19, 77-87	47
2130	Angiotensin-(1-7). 2005 , 100-110	6
2129	Cardiovascular actions of angiotensin-(1-7). 2005 , 38, 499-507	126

2128	Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. 2005 , 289, H2281-90	292
2127	Neuropeptide Processing. 2005 , 203-234	4
2126	ACE and ACE2: a tale of two enzymes. 2005 , 26, 322-4	82
2125	Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication. 2005 , 79, 3846-50	116
2124	ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. 2005 , 79, 14614-21	593
2123	Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). 2005 , 280, 30113-9	467
2122	Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. 2005 , 54, 1790-6	215
2121	Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system. 2005 , 3, 717-32	20
2120	Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. 2005 , 280, 39353-62	134
2119	Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. 2005 , 79, 503-11	222
2118	Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors. 2005 , 6, 96-101	13
2117	[The renin-angiotensin system: current data]. 2005 , 63, 144-53	2
2116	Crystal structure of the E. coli dipeptidyl carboxypeptidase Dcp: further indication of a ligand-dependent hinge movement mechanism. 2005 , 349, 99-112	35
2115	Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. 2005 , 29, 427-35	92
2114	Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. 2005 , 37, 1357-67	75
2113	Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. 2005 , 26, 1270-7	151
2112	The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. 2005 , 16, 120-6	197
2111	Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. 2005 , 125, 29-34	43

2110	Role of PGI ₂ and effects of ACE inhibition on the bradykinin potentiation by angiotensin-(1-7) in resistance vessels of SHR. 2005 , 127, 183-9	14
2109	Angiotensin peptides and their pleiotropic actions. 2005 , 6, 121-31	54
2108	Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. 2005 , 14, 1019-31	105
2107	Identification of new participants in the rainbow trout (<i>Oncorhynchus mykiss</i>) oocyte maturation and ovulation processes using cDNA microarrays. 2006 , 4, 39	91
2106	Angiotensin, bradykinin and the endothelium. 2006 , 255-94	13
2105	The renin-angiotensin system in acute respiratory distress syndrome. 2006 , 3, 225-229	21
2104	Localization of angiotensin II, the AT ₁ receptor, angiotensin-converting enzyme, aminopeptidase A, adipocyte-derived leucine aminopeptidase, and vascular endothelial growth factor in the human ovary throughout the menstrual cycle. 2006 , 86, 433-9	29
2103	The effect of angiotensin 1-7 on tyrosine kinases activity in rat anterior pituitary. 2006 , 347, 581-5	9
2102	ACE2 orthologues in non-mammalian vertebrates (<i>Danio</i> , <i>Gallus</i> , <i>Fugu</i> , <i>Tetraodon</i> and <i>Xenopus</i>). 2006 , 377, 46-55	23
2101	Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. 2006 , 38, 737-51	43
2100	Angiotensin-converting enzyme 2 in lung diseases. 2006 , 6, 271-6	272
2099	Age- and gender-related difference of ACE2 expression in rat lung. 2006 , 78, 2166-71	293
2098	Analysis of the mechanisms underlying the vasorelaxant action of angiotensin II in the isolated rat carotid. 2006 , 78, 2676-82	15
2097	Alterations in aortic vascular reactivity to angiotensin 1-7 in 17-beta-estradiol-treated female SD rats. 2006 , 133, 62-7	8
2096	Molecular genetics of human hypertension. 2006 , 110, 315-26	42
2095	Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. 2006 , 111, 333-40	45
2094	The tissue renin-angiotensin system and intracellular signalling. 2006 , 15, 8-13	47
2093	The role of angiotensin(1-7) in renal vasculature of the rat. 2006 , 24, 1971-8	37

2092	Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). 2006 , 16, 43-95	15
2091	Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. 2006 , 24, 239-46	56
2090	Structural diversity of angiotensin-converting enzyme. 2006 , 273, 362-73	16
2089	Testicular isoform of angiotensin I-converting enzyme (ACE, CD143) on the surface of human spermatozoa: revelation and quantification using monoclonal antibodies. 2006 , 55, 54-68	26
2088	ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7). 2006 , 70, 8-10	55
2087	Developmental expression of ACE2 in the SHR kidney: a role in hypertension?. 2006 , 70, 34-41	63
2086	Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. 2006 , 64, 6-12	88
2085	Angiotensin-converting enzyme in systemic sclerosis: from endothelial injury to a genetic polymorphism. 2006 , 1069, 10-9	5
2084	Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. 2006 , 69, 2212-8	153
2083	ARBs or ACEIs, that is the question. 2006 , 29, 837-8	1
2082	Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. 2006 , 29, 865-74	105
2081	Characterization of Angiotensin Converting Enzyme-2 (ACE2) in Human Urine. 2006 , 12, 283-289	17
2080	Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. 2006 , 84, 88-96	78
2079	Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. 2006 , 84, 814-20	105
2078	Interference with the renin-angiotensin system in heart failure. 2006 , 372, 331-4	1
2077	Cardiovascular genomics: a current overview of in vivo and in vitro studies. 2006 , 2, 59-66	1
2076	Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 2006 , 350, 15-25	138
2075	Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. 2006 , 353, 474-81	93

2074	Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. 2006 , 147, 91-5	52
2073	ACE2: A novel therapeutic target for cardiovascular diseases. 2006 , 91, 163-98	70
2072	Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. 2006 , 27, 200-7	162
2071	Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. 2006 , 26, 414-33	22
2070	Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1-7) in end-stage renal disease. 2006 , 60, 734-9	48
2069	Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. 2006 , 2, 335-42	13
2068	Angiotensin-Converting Enzyme-2 (ACE2) A New Player in the Genesis of Glomerular Injury?. 2006 , 17, 2637-2643	
2067	Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. 2006 , 34, 272-83	64
2066	Orchitis: a complication of severe acute respiratory syndrome (SARS). 2006 , 74, 410-6	250
2065	Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. 2006 , 80, 4211-9	206
2064	ACE and ACE2 activity in diabetic mice. 2006 , 55, 2132-9	240
2063	The spleen as a target in severe acute respiratory syndrome. 2006 , 20, 2321-8	31
2062	Intratubular Renin-Angiotensin System in Hypertension. 2006 , 2, 151-157	6
2061	7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. 2006 , 80, 785-93	118
2060	Molecular Mimicry between SARS Coronavirus Spike Protein and Human Protein. 2007 ,	3
2059	ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. 2007 , 72, 614-23	166
2058	Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study. 2007 , 58, 710-6	12
2057	Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. 2007 , 49, 1196-201	70

2056	Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study. 2007 , 9, 602-9	69
2055	Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. 2007 , 9, 594-601	18
2054	ACE2: a new target for cardiovascular disease therapeutics. 2007 , 50, 112-9	132
2053	Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. 2007 , 292, R373-81	280
2052	Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. 2007 , 148, 2453-7	89
2051	Activation of protective and damaging components of the cardiac renin-angiotensin system after myocardial infarction in experimental diabetes. 2007 , 8, 66-73	4
2050	Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. 2007 , 8, 74-80	47
2049	Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus. 2007 , 8, 34-41	22
2048	[Novel signaling mechanism of angiotensin II type 2 receptor]. 2007 , 129, 258-61	1
2047	Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation. 2007 , 293, H182-92	54
2046	Angiotensin-(1-7) and the renin-angiotensin system. 2007 , 16, 122-8	126
2045	The emerging role of angiotensin-converting enzyme-2 in the kidney. 2007 , 16, 116-21	29
2044	Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. 2007 , 25, 25-35	37
2043	Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. 2007 , 55, 341-59	56
2042	Virus-mediated modulation of the host endocrine signaling systems: clinical implications. 2007 , 18, 159-66	10
2041	Evidence for an angiotensin-converting enzyme (ACE) polymorphism in the crayfish <i>Astacus leptodactylus</i> . 2007 , 28, 1368-74	2
2040	Collectrin, a homologue of ACE2, its transcriptional control and functional perspectives. 2007 , 363, 1-5	17
2039	Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active. 2007 , 399, 81-90	24

2038	Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. 2007 , 47, 387-95	122
2037	Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. 2007 , 81, 916-23	49
2036	Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. 2007 , 581, 526-34	37
2035	Renin-angiotensin system and cardiovascular risk. 2007 , 369, 1208-19	507
2034	Local Angiotensin Generation and AT2 Receptor Activation. 2007 , 247-272	
2033	The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. 2007 , 59, 251-87	930
2032	The renin-angiotensin system and diabetic nephropathy. 2007 , 27, 144-52	96
2031	New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. 2007 , 82, 113-35	56
2030	Oxidative Stress and Radiation-Induced Late Normal Tissue Injury. 2007 , 135-164	
2029	Retinoic acid and the heart. 2007 , 75, 257-83	65
2028	Liver fibrosis: a balance of ACEs?. 2007 , 113, 109-18	85
2027	Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. 2007 , 101, 1278-91	66
2026	The emerging role of ACE2 in physiology and disease. 2007 , 212, 1-11	282
2025	Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. 2007 , 82, 187-96	78
2024	Effect of enalapril treatment on the sensitivity of cardiopulmonary reflexes in rats with myocardial infarction. 2007 , 34, 606-11	8
2023	Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. 2007 , 25, 162-74	89
2022	Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. 2007 , 8, 194	21
2021	The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure. 2007 , 9, 150-8	14

2020	Angiotensin metabolites can stimulate receptors of the Mas-related genes family. 2008 , 319, 115-23	61
2019	Brain renin angiotensin in disease. 2008 , 86, 715-22	145
2018	Update on tissue renin-angiotensin systems. 2008 , 86, 615-21	204
2017	Are we poised to target ACE2 for the next generation of antihypertensives?. 2008 , 86, 685-90	23
2016	Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. 2008 , 51, 1062-7	42
2015	Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease. 2008 , 10, 70-7	16
2014	Angiotensin-(1-7) as an antihypertensive, antifibrotic target. 2008 , 10, 227-32	32
2013	Pharmacologic modulation of ACE2 expression. 2008 , 10, 410-4	50
2012	Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?. 2008 , 25, 1141-74	44
2011	siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells. 2008 , 27, 709-15	20
2010	Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. 2008 , 215, 273-9	82
2009	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. 2008 , 18, 732-7	17
2008	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. 2008 , 18, 1681-7	5
2007	Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. 2008 , 51, 2216-26	43
2006	Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. 2008 , 29, 829-37	61
2005	Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. 2008 , 275, 6033-42	27
2004	Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. 2008 , 93, 538-42	52
2003	The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. 2008 , 93, 543-8	219

2002	Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts. 2008 , 93, 579-88	30
2001	Co-localization of angiotensin-converting enzyme 2-, octomer-4- and CD34-positive cells in rabbit atherosclerotic plaques. 2008 , 93, 564-9	16
2000	Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. 2008 , 93, 613-21	48
1999	Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice. 2008 , 93, 665-75	36
1998	Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. 2008 , 93, 685-93	94
1997	Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. 2008 , 93, 622-30	69
1996	Angiotensin-converting enzyme 2 and the kidney. 2008 , 93, 549-56	30
1995	Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. 2008 , 93, 648-57	83
1994	RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2. 2008 , 93, 676-84	28
1993	Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. 2008 , 93, 519-27	328
1992	Angiotensin-converting enzyme 2 in the brain: properties and future directions. 2008 , 107, 1482-94	222
1991	Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. 2008 , 23, 1327-38	88
1990	Angiotensin converting enzyme 2 in the kidney. 2008 , 35, 420-5	33
1989	Renin-angiotensin system revisited. 2008 , 264, 224-36	394
1988	An immunosuppressed Syrian golden hamster model for SARS-CoV infection. 2008 , 380, 312-21	59
1987	Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. 2008 , 582, 385-90	96
1986	Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. 2008 , 75, 781-6	80
1985	Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. 2008 , 585, 303-12	101

1984	Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. 2008 , 51, 613-23	154
1983	AT2 receptors: functional relevance in cardiovascular disease. 2008 , 120, 292-316	195
1982	Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. 2008 , 151, 208-16	40
1981	[Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system]. 2008 , 131, 230-6	17
1980	Pathophysiology of Primary Hypertension. 2008 , 794-895	1
1979	Renin-angiotensin system blockade in diabetic nephropathy. 2008 , 2, 135-158	1
1978	Vascular biology of angiotensin and the impact of physical activity. 2008 , 33, 162-72	47
1977	Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort. 2008 , 156, 752-8	19
1976	Les effets secondaires aigus des inhibiteurs de l'enzyme de conversion de l'angiotensine dont l'angiotensine, différents dans leur biologie clinique, partagent une physiopathologie semblable. 2008 , 48, 434-440	0
1975	Angiotensin processing is partially carried out by carboxypeptidases in the rat mesenteric arterial bed perfusate. 2008 , 151, 135-8	6
1974	The renin-angiotensin system and malignancy. 2008 , 29, 1675-84	224
1973	Gene expression patterns in glucose-stimulated podocytes. 2008 , 370, 514-8	17
1972	Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. 2008 , 172, 1174-83	206
1971	[Structure and function of angiotensin converting enzyme and its inhibitors]. 2008 , 24, 171-6	18
1970	Does the renin-angiotensin system also regulate intra-ocular pressure?. 2008 , 40, 418-27	31
1969	The Renal Microcirculation. 2008 , 550-683	6
1968	The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. 2008 , 283, 2363-72	312
1967	Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. 2008 , 57, 340-7	198

1966	The Renal Microcirculation. 2008 , 550-683	20
1965	Pathophysiology of Primary Hypertension. 2008 , 794-895	3
1964	A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. 2008 , 29, 133-54	144
1963	Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. 2008 , 31, 1953-61	33
1962	Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response. 2008 , 325, 17-26	16
1961	Intradermal angiotensin II administration attenuates the local cutaneous vasodilator heating response. 2008 , 295, H327-34	18
1960	MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. 2008 , 295, C1169-74	84
1959	Regulation of ACE2 in cardiac myocytes and fibroblasts. 2008 , 295, H2373-9	175
1958	ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. 2008 , 295, R781-8	135
1957	The angiotensin converting enzyme 2/Ang-(1-7) axis in the heart: a role for MAS communication?. <i>Circulation Research</i> , 2008 , 103, 1197-9	15.7 21
1956	Cardiovascular protection by angiotensin-converting enzyme 2: a new paradigm. 2008 , 4, 175-82	4
1955	Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. 2008 , 31, 553-9	69
1954	New insight of angiotensin II receptor blocker treatment in cardiac dysfunction using angiotensin-converting enzyme 2-deficient mice. 2008 , 31, 1833-4	
1953	Sex differences in response to chronic heart failure therapies. 2008 , 6, 555-65	15
1952	Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. 2008 , 72, 1346-50	40
1951	New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. 2008 , 17, 250-7	26
1950	Targeting genes in the renin-angiotensin system. 2008 , 17, 57-63	17
1949	Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy. 2008 , 121, 27-31	26

1948	Cardiorenal Physiology of the Mouse: From Loss of Genome to Gain of Phenome. 2008 , 15-39	
1947	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. 2008 , 4, 971-81	62
1946	Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS). 2008 , 107-127	
1945	Renin Angiotensin system as a regulator of cell volume. Implications to myocardial ischemia. 2009 , 5, 65-8	4
1944	Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes. Focus on Ramipril. 2009 , 1, CMT.S2095	
1943	Renin-angiotensin system in the pathogenesis of liver fibrosis. 2009 , 15, 2579-86	57
1942	Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. 2009 , 25, 23-8	46
1941	Gonadotropin stimulation increases the expression of angiotensin-(1--7) and MAS receptor in the rat ovary. 2009 , 16, 1165-74	58
1940	Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. 2009 , 24, 1766-73	68
1939	The role of ACE2 in pulmonary diseases--relevance for the nephrologist. 2009 , 24, 1362-5	23
1938	The identification of a calmodulin-binding domain within the cytoplasmic tail of angiotensin-converting enzyme-2. 2009 , 150, 2376-81	26
1937	Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli. 2009 , 53, 790-7	46
1936	Cardiovascular effects of losartan and its relevant clinical application. 2009 , 16, 3841-57	21
1935	Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. 2009 , 297, L84-96	222
1934	Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. 2009 , 297, C1318-29	50
1933	Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. 2009 , 297, L631-40	151
1932	The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. 2009 , 2009, 752406	65
1931	Olmесartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. 2009 , 3, 103-11	21

1930	Defects in cutaneous angiotensin-converting enzyme 2 and angiotensin-(1-7) production in postural tachycardia syndrome. 2009 , 53, 767-74	51
1929	Angiotensin II reduces membranous angiotensin-converting enzyme 2 in pressurized human aortic endothelial cells. 2009 , 10, 210-5	10
1928	The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. 2009 , 78, 933-40	48
1927	Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. 2009 , 50, 929-38	100
1926	Left ventricular hypertrophy and renin-angiotensin system blockade. 2009 , 11, 167-72	38
1925	Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. 2009 , 58, 819-27	44
1924	Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. 2009 , 35, 1471-8	46
1923	SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. 2009 , 39, 618-25	576
1922	Polymorphisms of angiotensin-converting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients. 2009 , 30, 1237-44	20
1921	The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats. 2009 , 214, 736-43	44
1920	Catalytic properties of recombinant dipeptidyl carboxypeptidase from Escherichia coli: a comparative study with angiotensin I-converting enzyme. 2009 , 390, 931-40	4
1919	Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. 2009 , 32, 533-6	202
1918	Opposite effects of angiotensin II and angiotensin (1-7) on impulse propagation, excitability and cardiac arrhythmias. Is the overexpression of ACE2 arrhythmogenic?. 2009 , 153, 7-10	11
1917	Acute modulation of myocardial function by angiotensin 1-7. 2009 , 30, 1714-9	8
1916	Seven decades of angiotensin (1939-2009). 2009 , 30, 1945-50	36
1915	Functional interactions between 7TM receptors in the renin-angiotensin system--dimerization or crosstalk?. 2009 , 302, 203-12	33
1914	The sweeter side of ACE2: physiological evidence for a role in diabetes. 2009 , 302, 193-202	155
1913	Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. 2009 , 46, 355-61	51

1912	Statins, ACE inhibitors and ARBs in cardiovascular disease. 2009 , 23, 389-400	18
1911	Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. 2009 , 136, 872-82	186
1910	Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. 2009 , 75, 1184-1193	113
1909	The vasoactive peptide angiotensin-(1-7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium. 2009 , 16, 247-56	79
1908	La mđula renal normal y patolđica. 2009 , 42, 263-275	
1907	High expression of angiotensin-converting enzyme and angiotensin-converting enzyme 2 in preservation injury after liver transplantation in rats. 2009 , 39, 1118-24	5
1906	Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. 2009 , 18, 79-84	53
1905	[Angiotensin-converting enzyme: a protein conserved during evolution]. 2009 , 203, 281-93	6
1904	Linking diabetes and atherosclerosis. 2009 , 4, 603-624	6
1903	Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. 2009 , 117, 375-86	79
1902	Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. 2010 , 28, 1054-64	65
1901	Brain angiotensin peptides regulate sympathetic tone and blood pressure. 2010 , 28, 1599-610	50
1900	Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. 2010 , 28, 1471-81	39
1899	Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. 2010 , 38, 596-601	84
1898	Renin-angiotensin system in human coronavirus pathogenesis. 2010 , 5, 145-161	40
1897	Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. 2010 , 118, 269-79	47
1896	ACE2-angiotensin-(1-7)-Mas axis in renal ischaemia/reperfusion injury in rats. 2010 , 119, 385-94	75
1895	Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. 2010 , 74, 405-10	123

1894	Not just angiotensinases: new roles for the angiotensin-converting enzymes. 2010 , 67, 89-98	69
1893	Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. 2010 , 47, 193-9	589
1892	Angiotensin-converting enzyme 2: central regulator for cardiovascular function. 2010 , 12, 170-5	94
1891	Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. 2010 , 12, 212-9	36
1890	Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. 2010 , 128, 119-28	295
1889	Review: Sex specific programming: a critical role for the renal renin-angiotensin system. 2010 , 31 Suppl, S40-6	92
1888	The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. 2010 , 29, 284-311	106
1887	Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. 2010 , 165, 218-23	19
1886	Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. 2010 , 10, 134	64
1885	Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. 2010 , 15, 332-41	54
1884	The crosstalk between thyroid hormones and the Renin-Angiotensin System. 2010 , 52, 166-70	38
1883	Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17βestradiol-dependent and sex chromosome-independent. 2010 , 1, 6	169
1882	The renin-angiotensin system and cancer: old dog, new tricks. 2010 , 10, 745-59	341
1881	Investigation of ACE, ACE2 and AGTR1 genes for association with nephropathy in Type 1 diabetes mellitus. 2010 , 27, 1188-94	14
1880	Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. 2010 , 37, e1-6	63
1879	ACE2 activation promotes antithrombotic activity. 2010 , 16, 210-5	108
1878	Novel neurohormonal insights with therapeutic potential in chronic heart failure. 2010 , 6, 361-72	2
1877	Simultaneous administration of Ang(1-7) or A-779 does not affect the chronic hypertensive effects of angiotensin II in normal rats. 2010 , 11, 99-102	11

1876	Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. 2010 , 56, 1561-9		55
1875	Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. <i>Circulation Research</i> , 2010 , 107, 888-97	15.7	179
1874	Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. 2010 , 185, 5569-76		130
1873	Human recombinant ACE2 reduces the progression of diabetic nephropathy. 2010 , 59, 529-38		234
1872	Vascular angiotensin-converting enzyme 2: lord of the ring?. <i>Circulation Research</i> , 2010 , 107, 822-4	15.7	5
1871	ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. 2010 , 21, 1545-54		67
1870	New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. 2010 , 55, 445-52		92
1869	Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. 2010 , 59, 2540-8		151
1868	The highly cited SARS research literature. 2010 , 36, 299-317		11
1867	Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas. 2010 , 38, 558-69		24
1866	Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. 2010 , 299, G70-80		17
1865	Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. 2010 , 23, 687-93		48
1864	Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. 2010 , 55, 90-8		226
1863	Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27. 2010 , 33, 123-8		14
1862	Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). 2010 , 59, 197-233		51
1861	New pathways of the renin-angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. 2010 , 14, 485-96		23
1860	Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. 2010 , 33, 118-22		28
1859	Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. 2010 , 33, 298-307		43

1858	Role of the ACE2/angiotensin1-7/Mas axis in the cardiovascular system. 2010 , 33, 1108-9	2
1857	Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. 2010 , 145, 333-334	36
1856	Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. 2010 , 16, 157-63	39
1855	Effects of ACE2 inhibition in the post-myocardial infarction heart. 2010 , 16, 777-85	35
1854	Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts. 2010 , 31, 1334-40	19
1853	Altered cardiovascular reflexes responses in conscious Angiotensin-(1-7) receptor Mas-knockout mice. 2010 , 31, 1934-9	25
1852	Angiotensin (1-7) reduces the cell volume of swollen cardiac cells and decreases the swelling-dependent chloride current. Implications for cardiac arrhythmias and myocardial ischemia. 2010 , 31, 2322-4	7
1851	Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. 2010 , 162, 73-8	27
1850	Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. 2010 , 50, 439-65	240
1849	The renin angiotensin system and the metabolic syndrome. 2010 , 100, 525-34	133
1848	Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach?. 2010 , 14, 11-20	47
1847	Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity. 2010 , 53, 7251-63	47
1846	Signal transduction in CHO cells stably transfected with domain-selective forms of murine ACE. 2010 , 391, 235-244	3
1845	ACE2 and diabetes: ACE of ACEs?. 2010 , 59, 2994-6	69
1844	Physiology of kidney renin. 2010 , 90, 607-73	188
1843	ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. 2011 , 34, 154-60	117
1842	Beneficial effects of angiotensin (1-7) in diabetic rats with cardiomyopathy. 2011 , 5, 159-67	23
1841	The role of the renin-angiotensin system in liver fibrosis. 2011 , 236, 557-66	45

1840	ACE2, a promising therapeutic target for pulmonary hypertension. 2011 , 11, 150-5	79
1839	Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. 2011 , 307, 18-25	20
1838	Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. 2011 , 95, 176-81	108
1837	Purification and characterization of angiotensin converting enzyme 2 (ACE2) from murine model of mesangial cell in culture. 2011 , 49, 79-84	15
1836	Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling. 2011 , 146, 364-70	33
1835	Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. 2011 , 51, 542-7	51
1834	An update on the islet renin-angiotensin system. 2011 , 32, 1087-95	29
1833	New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. 2011 , 32, 1551-65	108
1832	Identifying the regulatory element for human angiotensin-converting enzyme 2 (ACE2) expression in human cardiofibroblasts. 2011 , 32, 1832-9	23
1831	ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. 2011 , 300, R804-17	194
1830	Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. 2011 , 57, 314-22	183
1829	The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. 2011 , 34, 413-22	41
1828	Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints. 2011 , 50, 5182-94	33
1827	(Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. 2011 , 216, 35-43	23
1826	Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. 2011 , 17, 59-69	91
1825	ACE2 and Angiotensin-(1-7) in Hypertensive Renal Disease. 2011 , 9, 41-4	8
1824	Alternative pathways for angiotensin II generation in the cardiovascular system. 2011 , 44, 914-9	29
1823	ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. 2011 , 6, e22682	86

1822	A crucial role in fertility for the oyster angiotensin-converting enzyme orthologue CgACE. 2011 , 6, e27833	13
1821	ACE2: more of Ang-(1-7) or less Ang II?. 2011 , 20, 1-6	111
1820	Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. 2011 , 29, 706-15	47
1819	Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. 2011 , 29, 2236-45	24
1818	Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. 2011 , 20, 62-8	108
1817	Angiotensin-converting enzyme and Angiotensin-converting enzyme 2 are involved in sinoaortic denervation-induced cardiovascular hypertrophy in rats. 2011 , 34, 1398-403	7
1816	Review article: pancreatic renin-angiotensin systems in health and disease. 2011 , 34, 840-52	32
1815	Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. 2011 , 589, 939-51	69
1814	Novel aspects of angiotensin II action in the heart. Implications to myocardial ischemia and heart failure. 2011 , 166, 9-14	18
1813	Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays. 2011 , 301, R1293-9	48
1812	Enhanced angiotensin-converting enzyme 2 attenuates angiotensin II-induced collagen production via AT1 receptor-phosphoinositide 3-kinase-Akt pathway. 2011 , 39, 139-47	9
1811	Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. 2011 , 8, 176-83	54
1810	Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. 2011 , 225, 618-27	232
1809	ΔAmino acid substitution to investigate the recognition of angiotensin II (AngII) by angiotensin converting enzyme 2 (ACE2). 2011 , 24, 235-44	5
1808	A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project. 2011 , 12, 504-9	18
1807	Angiotensin peptides and lung cancer. 2011 , 11, 394-404	40
1806	The Renin-angiotensin system and reactive oxygen species: implications in pancreatitis. 2011 , 15, 2743-55	23
1805	Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. 2011 , 32, 2739-47	83

1804	Gene transfer of angiotensin-converting enzyme 2 in the nucleus tractus solitarius improves baroreceptor heart rate reflex in spontaneously hypertensive rats. 2011 , 12, 456-61	23
1803	Renin-angiotensin system may trigger kidney damage in NOD mice. 2011 , 12, 15-22	14
1802	Loss of Angiotensin-converting enzyme-related (ACER) peptidase disrupts night-time sleep in adult <i>Drosophila melanogaster</i> . 2011 , 214, 680-6	21
1801	Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. 2011 , 2011, 521076	45
1800	Regulation of angiotensin-converting enzyme 2 and Mas receptor by Ang-(1-7) in heart and kidney of spontaneously hypertensive rats. 2011 , 12, 413-9	32
1799	Translational success stories: angiotensin receptor 1 antagonists in heart failure. <i>Circulation Research</i> , 2011 , 109, 437-52	15:7 49
1798	Prediction of off-target effects on angiotensin-converting enzyme 2. 2011 , 16, 878-85	82
1797	The angiotensin-(1-7)/Mas receptor axis is expressed in sinoatrial node cells of rats. 2011 , 59, 761-8	28
1796	Blood pressure and renal hemodynamic effects of angiotensin fragments. 2011 , 34, 674-83	15
1795	Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. 2011 , 24, 89-101	21
1794	Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. 2011 , 31, 758-65	62
1793	Role of angiotensin-(1-7) in rostral ventrolateral medulla in blood pressure regulation via sympathetic nerve activity in Wistar-Kyoto and spontaneous hypertensive rats. 2011 , 33, 223-30	18
1792	Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. 2011 , 120, 335-45	58
1791	Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. 2011 , 121, 297-303	209
1790	(Pro)renin Receptor in Kidney Development and Disease. 2011 , 2011, 247048	11
1789	Mineralocorticoid hypertension. 2011 , 15 Suppl 4, S298-312	11
1788	Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. 2011 , 300, F749-55	55
1787	Vitamin D and the Renin-Angiotensin System. 2011 , 707-723	

1786	Upregulation of ACE2-ANG-(1-7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport. 2012 , 303, E669-81	33
1785	Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. 2012 , 302, F840-52	51
1784	Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling. 2012 , 2012, 594361	39
1783	Angiotensin-(1-7)-mediated signaling in cardiomyocytes. 2012 , 2012, 493129	34
1782	Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. 2012 , 123, 519-29	40
1781	The arterial depressor response to chronic low-dose angiotensin II infusion in female rats is estrogen dependent. 2012 , 302, R159-65	50
1780	Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. 2012 , 302, F1606-15	67
1779	Angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor axis and related mechanisms. 2012 , 2012, 690785	12
1778	Angiotensin-(1-7) in kidney disease: a review of the controversies. 2012 , 123, 333-46	75
1777	The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study. 2012 , 2, 379-86	23
1776	Renal Modulation. 2012 , 155-177	1
1775	Lack of Association of ACE2 G8790A Gene Mutation with Essential Hypertension in the Chinese Population: A Meta-Analysis Involving 5260 Subjects. 2012 , 3, 364	10
1774	Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. 2012 , 302, F784-90	48
1773	Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension. 2012 , 2012, 124758	15
1772	Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. 2012 , 2012, 192567	31
1771	Biosynthetic pathways and the role of the MAS receptor in the effects of Angiotensin-(1-7) in smooth muscles. 2012 , 2012, 121740	5
1770	Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. 2012 , 2012, 256294	350
1769	Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. 2012 , 93, 1924-1929	110

1768	Possible mechanism of the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, in diabetic rats. 2012 , 13, 334-40	17
1767	Polymorphisms of ACE2 are associated with blood pressure response to cold pressor test: the GenSalt study. 2012 , 25, 937-42	12
1766	Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. 2012 , 59, 300-7	77
1765	Ontogeny of angiotensin-converting enzyme 2. 2012 , 71, 13-9	38
1764	Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. 2012 , 82, 292-303	88
1763	Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site. 2012 , 287, 114-122	28
1762	Molecular characterization and regulation of the angiotensin-converting enzyme type 2/angiotensin-(1-7)/MAS receptor axis during the ovulation process in cattle. 2012 , 13, 91-8	34
1761	Angiotensin converting enzyme 2, Angiotensin-(1-7), and receptor MAS axis in the kidney. 2012 , 2012, 414128	33
1760	The renin-angiotensin system in the breast and breast cancer. 2012 , 19, R1-19	47
1759	New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. 2012 , 2012, 147825	51
1758	Angiotensin-converting enzyme 2: the first decade. 2012 , 2012, 307315	147
1757	Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System. 2012 , 2012, 428950	36
1756	Propofol increases angiotensin-converting enzyme 2 expression in human pulmonary artery endothelial cells. 2012 , 90, 342-7	9
1755	Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. 2012 , 30, 375-83	151
1754	The renin-angiotensin system, bone marrow and progenitor cells. 2012 , 123, 205-23	54
1753	Severe acute pancreatitis is associated with upregulation of the ACE2-angiotensin-(1-7)-Mas axis and promotes increased circulating angiotensin-(1-7). 2012 , 12, 451-7	17
1752	Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. 2012 , 60, 730-40	76
1751	Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system. 2012 , 105, 373-85	91

1750	The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. 2012 , 27, 1835-45	58
1749	Tissue specific localization of angiotensin-(1-7) and its receptor Mas in the uterus of ovariectomized rats. 2012 , 43, 597-602	18
1748	Counteraction between angiotensin II and angiotensin-(1-7) via activating angiotensin type I and Mas receptor on rat renal mesangial cells. 2012 , 177, 12-20	36
1747	Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. 2012 , 177, 107-15	61
1746	Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure. 2012 , 9, e141-e148	3
1745	Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. 2012 , 59, 1195-203	81
1744	Carboxypeptidases A1 and A2 from the perfusate of rat mesenteric arterial bed differentially process angiotensin peptides. 2012 , 33, 67-76	11
1743	Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. 2012 , 34, 380-8	42
1742	Role of angiotensin-converting enzyme (ACE and ACE2) imbalance on tourniquet-induced remote kidney injury in a mouse hindlimb ischemia-reperfusion model. 2012 , 36, 60-70	26
1741	Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia. 2012 , 23, 24-30	26
1740	Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. 2012 , 123, 649-58	102
1739	Evidence that angiotensin-(1-7) is an intermediate of gonadotrophin-induced oocyte maturation in the rat preovulatory follicle. 2012 , 97, 642-50	42
1738	Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. 2012 , 97, 477-85	44
1737	Angiotensin-converting enzyme 2 polymorphisms and cardiovascular risk. 2012 , 42, 1167	1
1736	An ACE for my sweet heart. 2012 , 59, 748-50	1
1735	Upregulation of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in the heart and the kidney of growth hormone receptor knock-out mice. 2012 , 22, 224-33	15
1734	Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. 2012 , 38, 54-61	26
1733	Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. 2012 , 66, 269-75	51

1732	Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. 2012 , 7, e48910	36
1731	Nonclassical renin-angiotensin system and renal function. 2012 , 2, 2733-52	79
1730	Altered regional blood flow distribution in Mas-deficient mice. 2012 , 6, 201-11	31
1729	Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. 2012 , 81, 520-8	86
1728	Cardiovascular Neuroendocrinology. 2012 , 307-327	2
1727	LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system. 2012 , 46, 641-50	39
1726	Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. 2012 , 7, e37649	42
1725	The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. 2012 , 108, 1089-96	57
1724	Novel roles of nuclear angiotensin receptors and signaling mechanisms. 2012 , 302, R518-30	104
1723	ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. 2012 , 487, 477-81	756
1722	Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. 2012 , 123, 225-39	64
1721	Angiotensin-(1-7) induces peripheral antinociception through mas receptor activation in an opioid-independent pathway. 2012 , 89, 137-44	26
1720	Role of ACE2 in diastolic and systolic heart failure. 2012 , 17, 683-91	50
1719	ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. 2012 , 39, 6581-9	58
1718	Postnatal ontogeny of angiotensin receptors and ACE2 in male and female rats. 2012 , 9, 21-32	58
1717	Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. 2012 , 348, 104-11	41
1716	Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. 2012 , 351, 208-19	47
1715	Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages. 2012 , 227, 2117-22	78

1714	Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. 2013 , 63, 98-106	39
1713	The renin angiotensin aldosterone system and insulin resistance in humans. 2013 , 15, 59-70	118
1712	Vasoactive Factors and Blood Pressure in Children. 2013 , 25-41	
1711	Peptidyl-Dipeptidase A/Angiotensin I-Converting Enzyme. 2013 , 480-494	10
1710	Update on the angiotensin AT(2) receptor. 2013 , 15, 25-30	47
1709	Pharmacological characterization of a novel non-AT1, non-AT2 angiotensin binding site identified as neurolysin. 2013 , 44, 525-31	3
1708	ACE2, angiotensin-(1 $\bar{7}$), and Mas: the other side of the coin. 2013 , 465, 79-85	103
1707	Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. 2013 , 52, 783-92	251
1706	Novel approaches for the identification of inhibitors of leishmanial dipeptidylcarboxypeptidase. 2013 , 8, 1127-34	2
1705	Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. 2013 , 145, 874-884.e5	76
1704	Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design. 2013 , 40, 535-41	4
1703	Osthole protects lipopolysaccharide-induced acute lung injury in mice by preventing down-regulation of angiotensin-converting enzyme 2. 2013 , 48, 819-24	39
1702	Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. 2013 , 7, 128-36	51
1701	Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. 2013 , 19, 605-10	19
1700	The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. 2013 , 378, 15-22	58
1699	The role of renin-angiotensin system in cellular differentiation: implications in pancreatic islet cell development and islet transplantation. 2013 , 381, 261-71	16
1698	Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. 2013 , 18, 138-51	45
1697	ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. 2013 , 15, 866-73	135

1696	Receptor recognition and cross-species infections of SARS coronavirus. 2013 , 100, 246-54	166
1695	Angiotensin converting enzyme 2: a new important player in the regulation of glycemia. 2013 , 65, 731-8	33
1694	The Concise Guide to PHARMACOLOGY 2013/14: enzymes. 2013 , 170, 1797-867	412
1693	Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. 2013 , 304, C945-53	35
1692	The discovery of the ACE2 gene. <i>Circulation Research</i> , 2013 , 112, 1307-9	15.7 15
1691	ACE2 alterations in kidney disease. 2013 , 28, 2687-97	84
1690	Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension. 2013 , 15, 31-8	44
1689	Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. 2013 , 216, R1-R17	349
1688	Angiotensin-(1-7): beyond the cardio-renal actions. 2013 , 124, 443-56	156
1687	Angiotensin converting enzyme 2 and atherosclerosis. 2013 , 226, 3-8	39
1686	The ACE2 gene: its potential as a functional candidate for cardiovascular disease. 2013 , 124, 65-76	64
1685	Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats. 2013 , 373, 189-94	32
1684	Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL ₄ 2013 , 95, 54-8	13
1683	ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. 2013 , 169, 477-92	331
1682	The Renin-Angiotensin System. 2013 , 427-450	
1681	Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?. 2013 , 40, 551-9	65
1680	Circulating angiotensin-converting enzyme 2 activity in kidney transplantation: a longitudinal pilot study. 2012 , 121, c144-50	21
1679	Neuroimmune communication in hypertension and obesity: a new therapeutic angle?. 2013 , 138, 428-40	39

1678	Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system. 2013 , 9, 23-38	14
1677	Angiotensin peptides and nitric oxide in cardiovascular disease. 2013 , 19, 1121-32	34
1676	The effects of para-chloromercuribenzoic acid and different oxidative and sulfhydryl agents on a novel, non-AT1, non-AT2 angiotensin binding site identified as neurolysin. 2013 , 184, 104-14	4
1675	Changes in gene expression in the frontal cortex of rats with pilocarpine-induced status epilepticus after sleep deprivation. 2013 , 27, 378-84	11
1674	Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats. 2013 , 106, 196-201	20
1673	High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. 2013 , 168, 203-10	33
1672	It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems. 2013 , 27, 133-8	7
1671	Angiotensin II-independent angiotensin-(1-7) formation in rat hippocampus: involvement of thimet oligopeptidase. 2013 , 62, 879-85	31
1670	Another ace up the sleeve. 2013 , 124, 246-7	
1669	Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?. 2013 , 28, 2200-2	14
1668	Angiotensin-converting enzyme 2 activation for treatment of pulmonary hypertension. 2013 , 187, 569-71	7
1667	Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries. 2013 , 154, 4768-76	7
1666	Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice. 2013 , 304, F1335-46	32
1665	Angiotensin-Converting Enzyme 2 Deficiency Aggravates Glucose Intolerance via Impairment of Islet Microvascular Density in Mice with High-Fat Diet. 2013 , 2013, 405284	18
1664	Angiotensin-converting enzymes play a dominant role in fertility. 2013 , 14, 21071-86	61
1663	Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. 2013 , 305, R1323-30	26
1662	Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. 2013 , 62, 444-9	7
1661	Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. 2013 , 28, 2287-94	46

1660	Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. <i>Circulation Research</i> , 2013 , 112, 1104-11	15.7	250
1659	Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas. 2013 , 591, 2275-85		26
1658	Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. 2013 , 36, 342-8		22
1657	Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. 2013 , 60, 563-70		12
1656	Silencing of angiotensin-converting enzyme by RNA interference prevents H9c2 cardiomyocytes from apoptosis induced by anoxia/reoxygenation through regulation of the intracellular renin-angiotensin system. 2013 , 32, 1380-6		6
1655	High glucose activates the alternative ACE2/Ang-(1-7)/Mas and APN/Ang IV/IRAP RAS axes in pancreatic β cells. 2013 , 32, 795-804		24
1654	The association between the Angiotensin-Converting Enzyme-2 gene and blood pressure in a cohort study of adolescents. 2013 , 14, 117		32
1653	Pancreatic angiotensin-converting enzyme 2 improves glycemia in angiotensin II-infused mice. 2013 , 304, E874-84		47
1652	Angiotensin-(1-7) protects from experimental acute lung injury. 2013 , 41, e334-43		87
1651	Glomerular angiotensin-converting enzyme 2 in pediatric IgA nephropathy. 2013 , 38, 355-67		5
1650	Apelin is a positive regulator of ACE2 in failing hearts. 2013 , 123, 5203-11		114
1649	Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension. 2013 , 11, 41-5		49
1648	Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice. 2013 , 8, e67192		52
1647	Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. 2013 , 54, 4296-306		55
1646	Renin Angiotensin System in Cognitive Function and Dementia. 2013 , 2013, 1-18		25
1645	Angiotensin-Converting Enzyme-2. 2013 , 499-504		4
1644	Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats. 2014 , 9, e98012		51
1643	The application of Gaussian mixture models for signal quantification in MALDI-TOF mass spectrometry of peptides. 2014 , 9, e111016		10

1642	Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. 2014 , 2014, 603409	62
1641	Beyond the circulating Renin-Angiotensin aldosterone system. 2014 , 5, 104	8
1640	Angiotensin-Converting Enzyme 2, the Cellular Receptor for Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. 2014 , 147-156	
1639	Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. 2014 , 126, 815-27	89
1638	Correlativity between blood measures related to blood stasis blocking collaterals and gene expression of angiotensin-converting enzyme of renal cortex in diabetic rats and effect of stasis removing and collaterals dredging. 2014 , 34, 597-603	2
1637	Protective axis of the renin-angiotensin system in the brain. 2014 , 127, 295-306	46
1636	From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. 2014 , 5, 227	88
1635	The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. 2014 , 126, 695-706	89
1634	An evolving story of angiotensin-II-forming pathways in rodents and humans. 2014 , 126, 461-9	75
1633	Cerebroprotective action of angiotensin peptides in stroke. 2014 , 126, 195-205	41
1632	Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. 2014 , 126, 471-82	59
1631	Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems. 2014 , 5, 16	36
1630	Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. 2014 , 101, 236-46	55
1629	Elevated systolic blood pressure in male GH transgenic mice is age dependent. 2014 , 155, 975-86	25
1628	ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney. 2014 , 2, e00264	44
1627	Heterodimerization of apelin receptor and neurotensin receptor 1 induces phosphorylation of ERK(1/2) and cell proliferation via Gβ-mediated mechanism. 2014 , 18, 2071-81	36
1626	Classical Renin-Angiotensin system in kidney physiology. 2014 , 4, 1201-28	281
1625	The functional study of human umbilical cord mesenchymal stem cells harbouring angiotensin-converting enzyme 2 in rat acute lung ischemia-reperfusion injury model. 2014 , 32, 580-9	14

1624	Angiotensin-(1-7) prevent atrial tachycardia induced sodium channel remodeling. 2014 , 37, 1349-56	5
1623	Angiotensin (1-7) prevents angiotensin II-induced nociceptive behaviour via inhibition of p38 MAPK phosphorylation mediated through spinal Mas receptors in mice. 2014 , 18, 1471-9	29
1622	Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure. 2014 , 116, 1342-9	17
1621	Angiotensin-converting enzyme-2 overexpression attenuates inflammation in rat model of chronic obstructive pulmonary disease. 2014 , 26, 14-22	26
1620	Conversion of A β 3 to A β 0 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme. 2014 , 92, 1178-86	31
1619	Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice. 2014 , 55, 3809-18	59
1618	Angiotensin-(1-9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis. 2014 , 15, 13-21	22
1617	Receptor MAS protects mice against hypothermia and mortality induced by endotoxemia. 2014 , 41, 331-6	27
1616	Emerging biomarkers for heart failure: an update. 2014 , 8, 833-40	4
1615	ACE for all - a molecular perspective. 2014 , 8, 195-210	20
1614	Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. 2014 , 127, 549-57	54
1613	Ang (1-7) protects islet endothelial cells from palmitate-induced apoptosis by AKT, eNOS, p38 MAPK, and JNK pathways. 2014 , 2014, 391476	20
1612	The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. 2014 , 2014, 689360	212
1611	Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting angiotensin-converting enzyme 1. 2014 , 63, 453-60	25
1610	Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. 2014 , 32, 771-83	63
1609	Early life perfluorooctanesulphonic acid (PFOS) exposure impairs zebrafish organogenesis. 2014 , 150, 124-32	38
1608	Biological therapies in the acute respiratory distress syndrome. 2014 , 14, 969-81	20
1607	Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. 2014 , 11, 58-63	73

1606	Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. 2014 , 66, 167-76	211
1605	Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. 2014 , 11, 413-26	254
1604	Angiotensin-(1-7). 2014 , 63, 1138-47	157
1603	Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. 2014 , 51, 26-33	7
1602	The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. 2014 , 62, 189-96	68
1601	Novel role of aminopeptidase-A in angiotensin-(1-7) metabolism post myocardial infarction. 2014 , 306, H1032-40	14
1600	Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. 2014 , 34, 2617-23	42
1599	Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. 2014 , 64, 1248-59	107
1598	Interference of angiotensin II and enalapril with hepatic blood flow regulation. 2014 , 307, G655-63	9
1597	Regulation of cell volume and water transport--an old fundamental role of the renin angiotensin aldosterone system components at the cellular level. 2014 , 58, 74-7	8
1596	Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. 2014 , 63, 774-82	84
1595	Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. 2014 , 64, 157-64	70
1594	A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular pathophysiology. 2014 , 26, 2147-60	125
1593	Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. 2014 , 306, F629-39	73
1592	Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. 2014 , 88, 13221-30	189
1591	ACE2/Ang-(1-7) signaling and vascular remodeling. 2014 , 57, 802-8	30
1590	Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. 2014 , 92, 847-58	28
1589	ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. 2014 , 16, 420	83

1588	Functional analysis of the receptor binding domain of SARS coronavirus S1 region and its monoclonal antibody. 2014 , 36, 387-397	1
1587	Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats. 2014 , 16, 1689-96	24
1586	Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. 2014 , 92, 558-65	24
1585	Angiotensin (1-7) increases the potassium current and the resting potential of arterial myocytes from vascular resistance vessels of normal adult rats: Pathophysiological implications. 2014 , 8, 14-20	5
1584	Hemodynamic regulator and mitogenic growth factor: re-visiting the age old question with ACE2 and Jak2. 2014 , 189, v-vi	
1583	UVB-induced gene expression in the skin of <i>Xiphophorus maculatus</i> Jp 163 B. 2014 , 163, 86-94	13
1582	The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects the function of pancreatic β cells by improving the function of islet microvascular endothelial cells. 2014 , 34, 1293-300	35
1581	Intrarenal distributions and changes of Angiotensin-converting enzyme and Angiotensin-converting enzyme 2 in feline and canine chronic kidney disease. 2014 , 76, 45-50	11
1580	Reply: dissociating angiotensin 1-9 antihypertensive remodeling effects from those on blood pressure. 2014 , 32, 1719-21	2
1579	The association between angiotensin-converting enzyme 2 polymorphisms and essential hypertension risk: A meta-analysis involving 14,122 patients. 2015 , 16, 1240-4	31
1578	Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury. 2015 , 11, 2387-96	51
1577	Angiotensin-(1-7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice. 2015 , 128, 649-63	66
1576	Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. 2014 , 4, 7027	195
1575	ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. 2015 , 66, 540-50	67
1574	Association Between Angiotensin-Converting Enzyme 2 and Coronary Artery Calcification in Patients on Maintenance Hemodialysis Therapy. 2015 , 19, 466-70	5
1573	Combination therapy with human umbilical cord mesenchymal stem cells and angiotensin-converting enzyme 2 is superior for the treatment of acute lung ischemia-reperfusion injury in rats. 2015 , 33, 113-20	10
1572	The effect of renin angiotensin system genetic variants in acute pancreatitis. 2015 , 261, 180-8	11
1571	Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation. 2015 , 43, 395-404	61

1570	The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension. 2015 , 36, 1151-5	5
1569	Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?. 2015 , 6,	28
1568	Chemical Communication between Heart Cells is Disrupted by Intracellular Renin and Angiotensin II: Implications for Heart Development and Disease. 2015 , 6, 72	15
1567	Hydration and beyond: neuropeptides as mediators of hydromineral balance, anxiety and stress-responsiveness. 2015 , 9, 46	15
1566	Inhibition of RAS in diabetic nephropathy. 2015 , 8, 29-40	40
1565	Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy. 2015 , 10, e0118758	24
1564	Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. 2015 , 36, 219-24	44
1563	Role of Mas Receptor Antagonist A799 in Renal Blood Flow Response to Ang 1-7 after Bradykinin Administration in Ovariectomized Estradiol-Treated Rats. 2015 , 2015, 801053	9
1562	Angiotensin-Converting Enzyme 2 Improves Arterial Hypoxemia in Meconium-Induced Acute Lung Injury in Piglets. 2015 , 2015, 1-7	
1561	Diabetic Nephropathy Induced by Increased Ace Gene Dosage Is Associated with High Renal Levels of Angiotensin (1-7) and Bradykinin. 2015 , 2015, 674047	15
1560	Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis. 2015 , 28, 1418-26	24
1559	Role of upstream stimulatory factor 2 in diabetic nephropathy. 2015 , 10, 221-229	5
1558	Angiotensin-(1-7) protects against the development of aneurysmal subarachnoid hemorrhage in mice. 2015 , 35, 1163-8	29
1557	Impact of interaction of cigarette smoking with angiotensin-converting enzyme polymorphisms on end-stage renal disease risk in a Han Chinese population. 2015 , 16, 203-10	12
1556	Angiotensin-converting enzyme-2 overexpression improves atrial remodeling and function in a canine model of atrial fibrillation. 2015 , 4, e001530	14
1555	Effects of the angiotensin-(1-7)/Mas/PI3K/Akt/nitric oxide axis and the possible role of atrial natriuretic peptide in an acute atrial tachycardia canine model. 2015 , 16, 1069-77	16
1554	Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients with chronic heart failure. 2015 , 16, 553-8	18
1553	Characterization of the renal renin-angiotensin system in transgenic mice that express rat tonin. 2015 , 16, 947-55	5

1552	The renin-angiotensin system and prevention of age-related functional decline: where are we now?. 2015 , 37, 9753	23
1551	Effects of apelin on the cardiovascular system. 2015 , 20, 505-18	52
1550	The normal and pathologic renal medulla: a comprehensive overview. 2015 , 211, 271-80	6
1549	Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis. 2015 , 45, 274-87	24
1548	Receptor recognition mechanisms of coronaviruses: a decade of structural studies. 2015 , 89, 1954-64	358
1547	Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. 2015 , 16, 159-64	20
1546	Renin-angiotensin system: an old player with novel functions in skeletal muscle. 2015 , 35, 437-63	96
1545	Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease. 2015 , 75, 421-7	9
1544	Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. 2015 , 30, 1176-85	66
1543	Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). 2015 , 25, 1175-90	4
1542	ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. 2016 , 65, 85-95	138
1541	Angiotensin-(1-7) through Mas receptor activation induces peripheral antinociception by interaction with adrenoceptors. 2015 , 69, 80-5	8
1540	Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2. 2015 , 6, 5	11
1539	Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome. 2015 , 41, 1468-77	44
1538	Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells. 2015 , 308, C767-77	14
1537	The role of renin-angiotensin-aldosterone system genes in the progression of chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. 2015 , 30, 1711-8	16
1536	ACE2 and Glycemic Control. 2015 , 219-223	
1535	Mas in the Kidney. 2015 , 207-212	1

1534	ACE2 Cell Biology, Regulation, and Physiological Functions. 2015 , 185-189	45
1533	Angiotensin-(1-7) and Mas. 2015 , 155-159	3
1532	The effect of angiotensin-(1-7) in mouse unilateral ureteral obstruction. 2015 , 185, 729-40	14
1531	Generation of outbred Ace2 knockout mice by RNA transfection of TALENs displaying colitis reminiscent pathophysiology and inflammation. 2015 , 24, 433-46	13
1530	Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. 2015 , 3, 44	70
1529	Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2. 2015 , 93, 1003-13	34
1528	Role of non-classical renin-angiotensin system axis in renal fibrosis. 2015 , 6, 117	23
1527	Angiotensin II in septic shock. 2015 , 19, 98	59
1526	Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF- κ B pathways. 2015 , 5, 8209	74
1525	A hypothesis on the conflicting results of angiotensin converting enzyme inhibitor in the prevention of contrast-induced nephropathy. 2015 , 85, 874-7	
1524	The effect of angiotensin-converting enzyme inhibition throughout a superovulation protocol in ewes. 2015 , 103, 205-10	6
1523	Modulation of cardiac L-type Ca ²⁺ current by angiotensin-(1-7): normal versus heart failure. 2015 , 9, 342-53	18
1522	Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus. 2015 , 40, 101-10	22
1521	The Renin-Angiotensin System and the Kidney:New Insights and Perspectives. 2015 , 7, 1-61	
1520	Mas receptor deficiency exacerbates lipopolysaccharide-induced cerebral and systemic inflammation in mice. 2015 , 220, 1311-21	14
1519	ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. 2015 , 9, 217-37	97
1518	Role of neurons and glia in the CNS actions of the renin-angiotensin system in cardiovascular control. 2015 , 309, R444-58	38
1517	Multifaceted interplay among mediators and regulators of intestinal glucose absorption: potential impacts on diabetes research and treatment. 2015 , 309, E887-99	8

1516	Impact of hepatic immunoreactivity of angiotensin-converting enzyme 2 on liver fibrosis due to non-alcoholic steatohepatitis. 2015 , 39, 692-8	3
1515	Renin-angiotensin system within the diabetic podocyte. 2015 , 308, F1-10	39
1514	Association of polymorphisms of angiotensin I converting enzyme 2 with retinopathy in type 2 diabetes mellitus among Chinese individuals. 2015 , 29, 266-71	13
1513	Salt feedback on the renin-angiotensin-aldosterone system. 2015 , 467, 565-76	37
1512	The intrathecal administration of losartan, an AT1 receptor antagonist, produces an antinociceptive effect through the inhibition of p38 MAPK phosphorylation in the mouse formalin test. 2015 , 585, 17-22	14
1511	Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. 2015 , 93, 343-51	117
1510	Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. 2015 , 16, 559-69	51
1509	Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. 2015 , 28, 15-21	174
1508	N-domain angiotensin-I converting enzyme is expressed in immortalized mesangial, proximal tubule and collecting duct cells. 2015 , 72, 380-90	3
1507	Angiotensin Converting Enzymes. 2016 , 263-e29D-4	1
1506	Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. 2016 , 2016, 8917578	45
1505	Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice. 2016 , 2016, 6731093	72
1504	Pivotal Cytoprotective Mediators and Promising Therapeutic Strategies for Endothelial Progenitor Cell-Based Cardiovascular Regeneration. 2016 , 2016, 8340257	8
1503	Angiotensin converting enzyme 2 and the kidney. 2016 , 25, 59-66	22
1502	Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. 2016 , 43, 438-49	22
1501	Characterization of key genes of the renin-angiotensin system in mature feline adipocytes and during <i>in vitro</i> adipogenesis. 2016 , 100, 1139-1148	12
1500	Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures. 2016 , 138, 74-85	59
1499	Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. 2016 , 67, 503-9	22

1498	Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells. 2016 , 24, 1342-50	54
1497	Sequential activation of the intrarenal renin-angiotensin system in the progression of hypertensive nephropathy in Goldblatt rats. 2016 , 311, F195-206	16
1496	Blood Pressure, Proteases and Inhibitors. 2016 , 746-752	
1495	Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1-7) Mas receptor knockout mice. 2016 , 311, L1141-L1148	24
1494	Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction. 2016 , 17,	6
1493	Pathogenesis of Macrovascular Complications in Diabetes. 2016 , 599-628	1
1492	Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction. 2016 , 68, 2652-2666	24
1491	Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity. 2016 , 50, 229-240	22
1490	Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. 2016 , 25, 384-95	29
1489	Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production. 2016 , 6, 19771	24
1488	Screening and analysis of breast cancer genes regulated by the human mammary microenvironment in a humanized mouse model. 2016 , 12, 5261-5268	3
1487	Angiotensins processing activities in the venom and epidermic mucus of <i>Scorpaena plumieri</i> . 2016 , 119, 92-8	3
1486	Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. 2016 , 310, F534-46	42
1485	Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. <i>Circulation Research</i> , 2016 , 118, 1313-26	15.7 478
1484	Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. 2016 , 774, 25-33	25
1483	Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. 2016 , 186, 1688-700	40
1482	Ramipril restores PPAR α and PPAR β expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat. 2016 , 791, 244-253	18
1481	A Novel Mechanism of Action for Angiotensin-(1-7) via the Angiotensin Type 1 Receptor. 2016 , 68, 1342-1343	10

1480	Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid- β and tau pathology. 2016 , 8, 50	107
1479	Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease. 2016 , 253, 135-143	28
1478	Epochs in the depressor/pressor balance of the renin-angiotensin system. 2016 , 130, 761-71	24
1477	New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?. 2016 , 241, 1888-1899	16
1476	Angiotensin-(1-7) Selectively Induces Relaxation and Modulates Endothelium-Dependent Dilation in Mesenteric Arteries of Salt-Fed Rats. 2016 , 53, 105-118	10
1475	The Ovarian Renin-Angiotensin System (OVRAS): A Major Factor in Ovarian Function and Disease. 2016 , 23, 1644-1655	28
1474	Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. 2016 , 6, 33678	47
1473	Association between circulating levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients. 2016 , 95, e3876	25
1472	FGF23 from bench to bedside. 2016 , 310, F1168-74	49
1471	Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease. 2017 , 32, 287-298	30
1470	The potential role of atrial natriuretic peptide in the effects of Angiotensin-(1-7) in a chronic atrial tachycardia canine model. 2016 , 17, 1470320315627409	6
1469	Fructose-rich diet induces gender-specific changes in expression of the renin-angiotensin system in rat heart and upregulates the ACE/AT1R axis in the male rat aorta. 2016 , 17, 1470320316642915	18
1468	ACE2/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. 2016 , 5, 306-11	72
1467	Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies. 2016 , 16, 11	22
1466	Estradiol, acting through ER β induces endothelial non-classic renin-angiotensin system increasing angiotensin 1-7 production. 2016 , 422, 1-8	44
1465	ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. 2016 , 107, 154-162	141
1464	New and old agents in the management of diabetic nephropathy. 2016 , 25, 232-9	29
1463	Pathophysiological role of osteopontin and angiotensin II in atherosclerosis. 2016 , 471, 5-9	20

1462	Cardiac ACE2/angiotensin 1-7/Mas receptor axis is activated in thyroid hormone-induced cardiac hypertrophy. 2016 , 10, 192-202	20
1461	A Review of Potential Marine-derived Hypotensive and Anti-obesity Peptides. 2016 , 56, 92-112	50
1460	Effects of Neuroprotectants Before and After Stroke: Statins and Anti-hypertensives. 2017 , 349-399	2
1459	Evaluation of Endothelial Dysfunction In Vivo. 2017 , 1527, 355-367	2
1458	Angiotensin-(1-7) administration attenuates Alzheimer's disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation. 2017 , 346, 267-277	32
1457	The intrauterine renin-angiotensin system: Sex-specific effects on the prevalence of spontaneous preterm birth. 2017 , 44, 605-610	5
1456	Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients. 2017 , 90, 63-68	17
1455	The correlation between inflammatory injury induced by LPS and RAS in EpH4-Ev cells. 2017 , 46, 23-30	5
1454	Macrophages in neuroinflammation: role of the renin-angiotensin-system. 2017 , 469, 431-444	23
1453	Severe acute dehydration in a desert rodent elicits a transcriptional response that effectively prevents kidney injury. 2017 , 313, F262-F272	20
1452	Angiotensin-(1-7) in human follicular fluid correlates with oocyte maturation. 2017 , 32, 1318-1324	27
1451	A Primer to Angiotensin Peptide Isolation, Stability, and Analysis by Nano-Liquid Chromatography with Mass Detection. 2017 , 1614, 175-187	9
1450	Analysis of Angiotensin Metabolism in the Kidney Using Mass Spectrometry. 2017 , 1614, 189-197	1
1449	Use of a Fluorescent Substrate to Measure ACE2 Activity in the Mouse Abdominal Aorta. 2017 , 1614, 61-67	0
1448	A Brief Introduction into the Renin-Angiotensin-Aldosterone System: New and Old Techniques. 2017 , 1614, 1-19	3
1447	The effects of angiotensin-(1-7) on the exchanger NHE3 and on [Ca] in the proximal tubules of spontaneously hypertensive rats. 2017 , 313, F450-F460	5
1446	The ACE-2/Ang1-7/Mas cascade enhances bone structure and metabolism following angiotensin-II type 1 receptor blockade. 2017 , 807, 44-55	17
1445	Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. 2017 , 121, 225-233	8

1444	Effects of Antihypertensive Agents on Intestinal Contractility in the Spontaneously Hypertensive Rat: Angiotensin Receptor System Downregulation by Losartan. 2017 , 360, 260-266	12
1443	ACE2 and the Homolog Collectrin in the Modulation of Nitric Oxide and Oxidative Stress in Blood Pressure Homeostasis and Vascular Injury. 2017 , 26, 645-659	16
1442	Kidney-brain axis inflammatory cross-talk: from bench to bedside. 2017 , 131, 1093-1105	35
1441	Clinical Relevance and Role of Neuronal AT Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension. <i>Circulation Research</i> , 2017 , 121, 43-55	15.7 114
1440	ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats. 2017 , 92, 58-68	22
1439	Future drug discovery in renin-angiotensin-aldosterone system intervention. 2017 , 12, 827-848	21
1438	Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. 2017 , 125, 57-71	71
1437	Chymase-dependent production of angiotensin II: an old enzyme in old hearts. 2017 , 312, H223-H231	18
1436	The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. 2017 , 125, 21-38	243
1435	Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis. 2017 , 25, 543	17
1434	Regulation of the prorenin - angiotensin system by oxygen and miRNAs; parallels between placentation and tumour development?. 2017 , 56, 27-33	0
1433	Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy. 2017 , 91, 1336-1346	41
1432	The hemoglobin derived peptide LVV-hemorphin-7 evokes behavioral effects mediated by oxytocin receptors. 2017 , 66, 59-68	10
1431	Pattern of Mas expression in acute and post-acute stage of nerve injury in mice. 2017 , 96, 15-19	5
1430	Intrarenal Angiotensin-Converting Enzyme: the Old and the New. 2017 , 19, 80	15
1429	Effects of Taurine on ACE, ACE2 and HSP70 Expression of Hypothalamic-Pituitary-Adrenal Axis in Stress-Induced Hypertensive Rats. 2017 , 975 Pt 2, 871-886	11
1428	The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?. 2017 , 64, 237-240	1
1427	The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?. 2017 , 64, 237-240	1

1426	Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. 2017 , 11, 842-852	15
1425	Imbalanced plasma ACE and ACE2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session. 2017 , 39, 719-728	12
1424	Renin angiotensin system deregulation as renal cancer risk factor. 2017 , 14, 5059-5068	26
1423	Revisiting the mechanisms of ACE inhibitory peptides from food proteins. 2017 , 69, 214-219	87
1422	miRNA-200c-3p is crucial in acute respiratory distress syndrome. 2017 , 3, 17021	63
1421	Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?. 2017 , 40, 903-909	26
1420	The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke. 2017 , 31,	40
1419	Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients. 2017 , 32, 584-590	2
1418	Extrarenal effects of FGF23. 2017 , 32, 753-765	31
1417	Local Renin Angiotensin Aldosterone Systems and Cardiovascular Diseases. 2017 , 101, 117-127	38
1416	Renin angiotensin system in liver diseases: Friend or foe?. 2017 , 23, 3396-3406	52
1415	Regulation of the Renin-Angiotensin-Aldosterone System by Reactive Oxygen Species. 2017 ,	4
1414	Involvement of the Renin-Angiotensin System in Atherosclerosis. 2017 ,	1
1413	The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. 2017 , 8, 276	57
1412	Hydrogen Sulfide Attenuates Atherosclerosis in a Partially Ligated Carotid Artery Mouse model via Regulating Angiotensin Converting Enzyme 2 Expression. 2017 , 8, 782	33
1411	Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension. 2017 , 15, 3905-3911	33
1410	Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. 2017 , 18,	155
1409	Angiotensin-(1-7) Promotes Resolution of Neutrophilic Inflammation in a Model of Antigen-Induced Arthritis in Mice. 2017 , 8, 1596	29

1408	[Pyr]Apelin-13 Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr]Apelin-13. 2017 , 11, 92	36
1407	Alamandine reduces leptin expression through the c-Src/p38 MAP kinase pathway in adipose tissue. 2017 , 12, e0178769	21
1406	The role of ACE2, angiotensin-(1-7) and Mas1 receptor axis in glucocorticoid-induced intrauterine growth restriction. 2017 , 15, 97	37
1405	Angiotensin-converting enzyme-2 overexpression improves atrial electrical remodeling through TRPM7 signaling pathway. 2017 , 8, 78726-78733	6
1404	Influence of antihypertensive drugs on aortic and coronary effects of Ang-(1-7) in pressure-overloaded rats. 2017 , 50, e5520	3
1403	Renin Angiotensin Aldosterone System and Heart Function. 2017 , 229-248	
1402	Role of the ACE2-Ang-(1-7)-Mas axis in blood pressure regulation and its potential as an antihypertensive in functional foods (Review). 2017 , 16, 4403-4412	7
1401	The Brain Renin-Angiotensin System. 2017 , 417-430	
1400	FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. 2018 , 27, 1323-1337.e5	58
1399	The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. 2018 , 41, 394-405	25
1398	Angiotensin peptides in the non-gravid uterus: Paracrine actions beyond circulation. 2018 , 101, 145-149	3
1397	The protective effect of resveratrol on vascular aging by modulation of the renin-angiotensin system. 2018 , 270, 123-131	67
1396	The angiotensin type 2 receptor in the human adrenocortical zona glomerulosa and in aldosterone-producing adenoma: low expression and no functional role. 2018 , 132, 627-640	10
1395	Changes in Renal Peritubular Capillaries in Canine and Feline Chronic Kidney Disease. 2018 , 160, 79-83	4
1394	Loss of angiotensin converting enzyme II (ACE2) accelerates the development of liver injury induced by thioacetamide. 2018 , 67, 41-49	17
1393	Effects of a novel curcumin derivative on the functions of kidney in streptozotocin-induced type 2 diabetic rats. 2018 , 26, 1257-1264	13
1392	Alamandine injected into the paraventricular nucleus increases blood pressure and sympathetic activation in spontaneously hypertensive rats. 2018 , 103, 98-102	16
1391	Impact of meal fatty acid composition on postprandial lipaemia, vascular function and blood pressure in postmenopausal women. 2018 , 31, 193-203	6

1390	Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders. 2018 , 20, 19	40
1389	Angiotensin converting enzyme 2 polymorphisms and postexercise hypotension in hypertensive medicated individuals. 2018 , 38, 206-212	4
1388	Four decades of ocular renin-angiotensin and kallikrein-kinin systems (1977-2017). 2018 , 166, 74-83	13
1387	Angiotensin-converting enzyme 2 and renal disease. 2018 , 27, 35-41	38
1386	Angiotensin-(1-7) prevents atrial tachycardia induced-heat shock protein 27 expression. 2018 , 51, 117-120	3
1385	Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. 2018 , 107, 756-763	15
1384	Activation pattern of ACE2/Ang-(1-7) and ACE/Ang II pathway in course of heart failure assessed by multiparametric MRI in vivo in Tgβ*44 mice. 2018 , 124, 52-65	11
1383	Angiotensin 1-7 in the rostro-ventrolateral medulla increases blood pressure and splanchnic sympathetic nerve activity in anesthetized rats. 2018 , 247, 103-111	10
1382	Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. 2018 , 314, L17-L31	220
1381	Angiotensin-converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment. 2018 , 32, 14-25	25
1380	Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites. 2018 , 43, 189-195	36
1379	Hypertension regulating angiotensin peptides in the pathobiology of cardiovascular disease. 2018 , 40, 344-352	27
1378	DKK3 overexpression attenuates cardiac hypertrophy and fibrosis in an angiotensin-perfused animal model by regulating the ADAM17/ACE2 and GSK-3β/E-catenin pathways. 2018 , 114, 243-252	27
1377	Favorable Vascular Actions of Angiotensin-(1-7) in Human Obesity. 2018 , 71, 185-191	29
1376	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. 2018 , 64, 597-608	27
1375	Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin. 2018 , 59, 1445-1453	5
1374	Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. 2018 , 33, 453-461	44
1373	Investigating the RAS can be a fishy business: interdisciplinary opportunities using Zebrafish. 2018 , 132, 2469-2481	5

1372	Egg White-Derived Tripeptide IRW (Ile-Arg-Trp) Is an Activator of Angiotensin Converting Enzyme 2. 2018 , 66, 11330-11336	22
1371	The Renin-Angiotensin-Aldosterone System as a Therapeutic Target in Late Injury Caused by Ischemia-Reperfusion. 2018 , 2018, 3614303	4
1370	Renin-Angiotensin System and Cardiovascular Functions. 2018 , 38, e108-e116	67
1369	ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. 2018 , 51,	27
1368	The Association Between ACE2 Gene Polymorphism and the Stroke Recurrence in Chinese Population. 2018 , 27, 2770-2780	14
1367	The binding of captopril to angiotensin I-converting enzyme triggers activation of signaling pathways. 2018 , 315, C367-C379	1
1366	Renin Angiotensin Aldosterone System Blockers. 2018 , 230-241	1
1365	The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). 2018 , 98, 505-553	494
1364	Modulation of the renin-angiotensin system in white adipose tissue and skeletal muscle: focus on exercise training. 2018 , 132, 1487-1507	35
1363	Vitamin D and the Renin-Angiotensin System. 2018 , 825-847	2
1362	Protection of the myocardium against ischemia/reperfusion injury by angiotensin-(1-9) through an ATR and Akt-dependent mechanism. 2018 , 135, 112-121	17
1361	Angiotensin-(1-7) Promotes Resolution of Eosinophilic Inflammation in an Experimental Model of Asthma. 2018 , 9, 58	47
1360	Intratubular and intracellular renin-angiotensin system in the kidney: a unifying perspective in blood pressure control. 2018 , 132, 1383-1401	22
1359	Propofol prevents human umbilical vein endothelial cell injury from Ang II-induced apoptosis by activating the ACE2-(1-7)-Mas axis and eNOS phosphorylation. 2018 , 13, e0199373	13
1358	Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. 2018 , 13, e0198144	117
1357	Impact of angiotensin-converting enzyme 2 levels on postoperative pneumonia after esophagectomy. 2018 , 224, 200-206	6
1356	Angiotensin II: a new therapeutic option for vasodilatory shock. 2018 , 14, 1287-1298	14
1355	Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. 2020 , 35, 130-138	6

1354	Nicotine and the renin-angiotensin system. 2018 , 315, R895-R906	156
1353	Genetic deletion of the Angiotensin-(1-7) receptor Mas leads to a reduced ovulatory rate. 2018 , 107, 83-88	6
1352	Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System. 2018 , 6,	15
1351	Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGF β 2019 , 20,	6
1350	Expression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice. 2019 , 14, 161-170	50
1349	Soluble angiotensin converting enzyme 2 levels in chronic heart failure is associated with decreased exercise capacity and increased oxidative stress-mediated endothelial dysfunction. 2019 , 212, 80-88	7
1348	Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease. 2019 , 33, 1571-1584	17
1347	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. 2019 , 71, 539-570	146
1346	The combination of ACE I/D and ACE2 G8790A polymorphisms reveals susceptibility to hypertension: A genetic association study in Brazilian patients. 2019 , 14, e0221248	57
1345	Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells. 2019 , 187, 107770	3
1344	New Molecules for Treating Resistant Hypertension: a Clinical Perspective. 2019 , 21, 80	1
1343	Expression of Renin-Angiotensin System Components in the Taste Organ of Mice. 2019 , 11,	38
1342	Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill. 2019 , 35, 213-227	44
1341	Effect of blockade of nitric oxide in heart tissue levels of Renin Angiotensin System components in acute experimental Chagas disease. 2019 , 219, 336-342	3
1340	Naringenin Ameliorates Renovascular Hypertensive Renal Damage by Normalizing the Balance of Renin-Angiotensin System Components in Rats. 2019 , 16, 644-653	17
1339	Role of Renin-Angiotensin-System in Human Breast Cancer Cells: Is There a Difference in Regulation of Angiogenesis between Hormone-Receptor Positive and Negative Breast Cancer Cells?. 2019 , 79, 626-634	2
1338	Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction. 2019 , 74, 285-294	14
1337	Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1-7)/MAS receptor axes in human mesangial cells. 2019 , 7, e14105	15

1336	High Fructose Intake and Adipogenesis. 2019 , 20,	19
1335	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. 2019 , 96, 906-917	23
1334	Sex Differences in the Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure. 2019 , 73-103	3
1333	ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. 2019 , 38, 173	103
1332	Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. 2019 , 14, e0215896	12
1331	Angiotensin II in septic shock. 2019 , 37, 1169-1174	11
1330	Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study. 2019 , 14, e0213096	63
1329	Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide. 2019 , 73, 900-909	13
1328	Egg White-Derived Antihypertensive Peptide IRW (Ile-Arg-Trp) Reduces Blood Pressure in Spontaneously Hypertensive Rats via the ACE2/Ang (1-7)/Mas Receptor Axis. 2019 , 63, e1900063	37
1327	Vitamin D supplementation alters the expression of genes associated with hypertension and did not induce DNA damage in rats. 2019 , 82, 299-313	9
1326	Mas receptor deficiency augments angiotensin II-induced atherosclerosis and aortic aneurysm ruptures in hypercholesterolemic male mice. 2019 , 70, 1658-1668.e1	15
1325	Effect of Prolonged Infusion of Alamandine on Cardiovascular Parameters and Cardiac ACE2 Expression in a Rat Model of Renovascular Hypertension. 2019 , 42, 960-967	7
1324	Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. 2019 , 225, 39-45	39
1323	Loss of angiotensin-converting enzyme-related (ACER) peptidase disrupts behavioural and metabolic responses to diet in. 2019 , 222,	4
1322	An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. 2019 , 6,	109
1321	Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation. 2019 , 8,	18
1320	Spirolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. 2019 , 51, 755-764	20
1319	The renin-angiotensin system: going beyond the classical paradigms. 2019 , 316, H958-H970	134

1318	Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin Pathways as Novel Upstream Targets Regulating Aldosterone. 2019 ,	1
1317	Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. 2019 , 9,	31
1316	Fiend and friend in the renin angiotensin system: An insight on acute kidney injury. 2019 , 110, 764-774	36
1315	Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models. 2019 , 112, 78-84	14
1314	ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models. 2019 , 44, 1323-1329	82
1313	Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data. 2019 , 133, 55-74	61
1312	Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling. 2019 , 20,	25
1311	Renal Modulation. 2019 , 165-188	1
1310	ACE2 and ACE in acute and chronic rejection after human heart transplantation. 2019 , 275, 59-64	7
1309	Evidence for a role of angiotensin converting enzyme 2 in proteinuria of idiopathic nephrotic syndrome. 2019 , 39,	7
1308	Counter-regulatory renin-angiotensin system in cardiovascular disease. 2020 , 17, 116-129	198
1307	Expression and Function of Mas-Related G Protein-Coupled Receptor D and Its Ligand Alamandine in Retina. 2020 , 57, 513-527	5
1306	Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis and coronary heart disease. 2020 , 35, 153-161	18
1305	Hypertensive urgencies and emergencies: Misconceptions and pitfalls. 2020 , 71, 15-17	5
1304	The Physiological Roles of the Renin-Angiotensin Aldosterone System and Vasopressin in Human Pregnancy. 2020 , 129-145	6
1303	Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe Myocardial Fibrosis. 2020 , 13, 655-664	53
1302	The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. 2020 , 41,	29
1301	Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyl oligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. 2020 , 75, 173-182	110

1300	Renin angiotensin system molecules and nitric oxide local interactions in the adrenal gland of Trypanosoma cruzi infected rats. 2020 , 119, 333-337	1
1299	The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. 2020 , 47, 751-758	44
1298	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. 2020 , 76, 1350-1367	36
1297	Angiotensin-Converting Enzyme 2 as a Possible Correlation between COVID-19 and Periodontal Disease. 2020 , 10, 6224	13
1296	Drug Weaponry to Fight Against SARS-CoV-2. 2020 , 7, 204	2
1295	Endothelial Cell Contributions to COVID-19. 2020 , 9,	12
1294	Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19). 2020 , 16, 2906-2923	20
1293	ACE2 enhance viral infection or viral infection aggravate the underlying diseases. 2020 , 18, 2100-2106	4
1292	A computational and bioinformatic analysis of ACE2: an elucidation of its dual role in COVID-19 pathology and finding its associated partners as potential therapeutic targets. 2020 , 1-17	6
1291	The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection. 2020 , 76, 397-406	9
1290	PI3K inhibition as a Potential Therapeutic Target in COVID-19. 2020 , 11, 2094	15
1289	ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. 2020 , 11, 576745	98
1288	The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation. 2020 , 693, 108562	8
1287	Potential use of polyphenols in the battle against COVID-19. 2020 , 32, 149-155	52
1286	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. 2020 , 50, 1313-1324	41
1285	Amaranth as a Source of Antihypertensive Peptides. 2020 , 11, 578631	10
1284	Structural and functional modelling of SARS-CoV-2 entry in animal models. 2020 , 10, 15917	37
1283	Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. 2020 , 262, 118496	3

1282	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. 2020 , 15, 56	1
1281	Immunity Against COVID-19: Potential Role of Ayush Kwath. 2020 , 13, 100350-100350	34
1280	Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies. 2020 , 260, 118313	27
1279	Viral replication of SARS-CoV-2 could be self-limitative - The role of the renin-angiotensin system on COVID-19 pathophysiology. 2020 , 145, 110330	3
1278	Identifying pathophysiological bases of disease in COVID-19. 2020 , 5, 15	4
1277	In-silico design of a potential inhibitor of SARS-CoV-2 S protein. 2020 , 15, e0240004	25
1276	Metabolic impact of weight loss induced reduction of adipose ACE-2 - Potential implication in COVID-19 infections?. 2020 , 113, 154401	14
1275	Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?. 2020 , 7, 100052	11
1274	ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. 2020 , 11, 5165	31
1273	Molecular basis of COVID-19 pathogenesis. 2020 , 89, 858-878	11
1272	Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. 2020 , 26, 1787-1795	10
1271	The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. 2020 , 37, 779-785	8
1270	The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. 2020 , 375, 498-509	15
1269	Projected supportive effects of Pycnogenol in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection. 2020 , 56, 106191	2
1268	GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies. 2020 , 132, 110816	7
1267	Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. 2020 , 319, H1059-H1068	13
1266	Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!. 2021 , 179, 31-71	2
1265	Hepatorenal syndrome in children: a review. 2021 , 36, 2203-2215	6

1264	Circulating ACE2: a novel biomarker of cardiovascular risk. 2020 , 396, 937-939	10
1263	COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease. 2020 , 40, 2045-2053	15
1262	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721	63
1261	Covid-19, ACE2 and the kidney. 2020 , 230, e13539	14
1260	Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. 2020 , 24, 422	378
1259	COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. 2020 , 9,	125
1258	Lessons learned from the mechanisms of posttraumatic inflammation extrapolated to the inflammatory response in COVID-19: a review. 2020 , 14, 28	3
1257	Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. 2020 , 5, 871-883	26
1256	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. 2020 , 257, 118075	57
1255	COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease. 2020 , 144, 110024	36
1254	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. 2020 , 21,	22
1253	Gene expression and protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. 2020 , 56,	93
1252	Uso terapéutico de los inhibidores de la enzima convertidora de angiotensina en pacientes con COVID-19: las «dos caras de la moneda». 2020 , 27, 212-222	
1251	Endocrine Significance of SARS-CoV-2's Reliance on ACE2. 2020 , 161,	72
1250	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. 2020 , 9,	23
1249	ACE2, the Receptor that Enables Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators. 2020 , 15, 1682-1690	17
1248	TWIRLS, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via ACE2. 2020 , 81, 1004	7
1247	The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. 2020 , 8, e00623	7

1246	COVID-19 during Pregnancy and Postpartum. 2020 , 1-28	8
1245	Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity. 2020 , 11, 599729	3
1244	Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2. 2021 , 25, 1761-1773	12
1243	Impact of SARS-CoV-2 on Male Reproductive Health: A Review of the Literature on Male Reproductive Involvement in COVID-19. 2020 , 7, 594364	12
1242	Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model. 2020 , 12,	9
1241	Cardiovascular Manifestations of COVID-19 Infection. 2020 , 9,	49
1240	Exploring nature's bounty: identification of as a promising source of therapeutic agents against COVID-19 by virtual screening and evaluation. 2020 , 1-51	8
1239	The counter regulatory axis of the renin angiotensin system in the brain and ischaemic stroke: Insight from preclinical stroke studies and therapeutic potential. 2020 , 76, 109809	5
1238	Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Protease. 2020 , 25,	23
1237	Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. 2020 , 12,	8
1236	A Novel Angiotensin Converting Enzyme 2 (ACE2) Activating Peptide: A Reflection of 10 Years of Research on a Small Peptide Ile-Arg-Trp (IRW). 2020 , 68, 14402-14408	5
1235	Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for Antihypertensive Drug in Renal Cell Carcinoma. 2020 , 2020, 2054376	2
1234	Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease. 2020 , 1	3
1233	The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease. 2020 , 15, 2633105520975743	4
1232	Challenges of SARS-CoV-2 and conflicting PPE guidelines. 2020 , 12, 436-442	2
1231	COVID-19 during Pregnancy and Postpartum. 2020 , 1-37	8
1230	SARS-CoV-2 and interferon blockade. 2020 , 26, 103	0
1229	Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. 2020 , 21,	8

1228	Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies. 2020 , 17, 3125-3145	3
1227	Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity. 2020 , 68, 13982-13989	26
1226	Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. 2020 , 12,	20
1225	Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2. 2020 , 8, 3	13
1224	Characterization of changes in global gene expression in the hearts and kidneys of transgenic mice overexpressing human angiotensin-converting enzyme 2. 2020 , 36, 23	0
1223	SARS-CoV-2 and the Nervous System: From Clinical Features to Molecular Mechanisms. 2020 , 21,	73
1222	Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor. 2020 , 34, e22594	2
1221	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. 2020 , 1	13
1220	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. 2020 , 88, 106885	20
1219	The concern about ACE/ARB and COVID-19: Time to hold your horses!. 2020 , 60, e88-e90	3
1218	Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2. 2020 , 259, 118219	14
1217	Heightened ACE Activity and Unfavorable Consequences in COVID-19 Diabetic Subjects. 2020 , 2020, 7847526	8
1216	SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. 2020 , 12,	7
1215	Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. 2020 , 100, 107697	32
1214	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. 2020 , 116, 2185-2196	13
1213	The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. 2020 , 9,	21
1212	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169	19
1211	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. 2020 , 28, 683-699	17

1210	COVID-19 and hydatidiform mole. 2020 , 84, e13310	1
1209	Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes. 2020 , 94,	36
1208	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. 2020 , 11, 820	12
1207	Analysis of ACE2 Gene-Encoded Proteins Across Mammalian Species. 2020 , 7, 457	5
1206	Ruptured cerebral pseudoaneurysm in an adolescent as an early onset of COVID-19 infection: case report. 2020 , 162, 2725-2729	11
1205	COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients. 2020 , 15, 1231-1240	18
1204	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). 2020 , 58, 102887	78
1203	The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation. 2020 , 34, 10505-10515	25
1202	Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. 2020 , 11, 530	43
1201	Design of an engineered ACE2 as a novel therapeutics against COVID-19. 2020 , 505, 110425	8
1200	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. 2020 , 1,	10
1199	SARS 2 human coronavirus (COVID -19, SARS CoV2). 2020 , 66, 101063	1
1198	Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. 2020 , 8, 9-19	69
1197	Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives. 2020 , 20,	41
1196	Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. 2020 , 41, 1141-1149	739
1195	Is pregnancy an immunological contributor to severe or controlled COVID-19 disease?. 2020 , 84, e13317	20
1194	Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019. 2020 , 598, 4181-4195	3
1193	Studying the Effects of ACE2 Mutations on the Stability, Dynamics, and Dissociation Process of SARS-CoV-2 S1/hACE2 Complexes. 2020 , 19, 4609-4623	12

1192	Is it infection or rather vascular inflammation? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19. 2020 , 9, 110-120	11
1191	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. 2020 , 13, 1-26	4
1190	Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome. 2020 , 21,	20
1189	Vascular underpinning of COVID-19. 2020 , 10, 200208	16
1188	Role of Kinins in Hypertension and Heart Failure. 2020 , 13,	9
1187	The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection. 2021 , 288, 5055-5070	2
1186	Race to arsenal COVID-19 therapeutics: Current alarming status and future directions. 2020 , 332, 109298	5
1185	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. 2020 , 7, 588618	49
1184	Implications of COVID-19 Pandemic on Evolution of Diabetes in Malaria-Endemic African Region. 2020 , 2020, 8205261	0
1183	SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications. 2020 , 11, 562913	5
1182	Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age. 2020 , 11, 590787	17
1181	Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology. 2021 , 21, 13-127	16
1180	Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic. 2020 , 16, 3023-3033	4
1179	Central Nervous System Manifestations Associated with COVID-19. 2020 , 20, 60	32
1178	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. 2020 , 113, 797-810	1
1177	Neurotropism of SARS-CoV-2 and its neuropathological alterations: Similarities with other coronaviruses. 2020 , 119, 184-193	25
1176	Atypical manifestations of COVID-19 in general practice: a case of gastrointestinal symptoms. 2020 , 13,	4
1175	COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?. 2020 , 196, 143-151	41

1174	AI (Artificial Intelligence) and Hypertension Research. 2020 , 22, 70	3
1173	SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. 2020 , 34, 14103-14119	20
1172	Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in Corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW. 2020 , 79, 153336	38
1171	Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. 2020 , 3, 790-800	14
1170	Environmental Nanoparticles, SARS-CoV-2 Brain Involvement, and Potential Acceleration of Alzheimer's and Parkinson's Diseases in Young Urbanites Exposed to Air Pollution. 2020 , 78, 479-503	15
1169	Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 2020 , 11, 8008-8016	15
1168	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. 2020 , 76, 1339-1349	86
1167	A Review on Novel Drug Targets and Future Directions for COVID-19 Treatment. 2020 , 14, 77-82	9
1166	The Immune Response and Immunopathology of COVID-19. 2020 , 11, 2037	61
1165	Impact of COVID-19 on Alzheimer's Disease Risk: Viewpoint for Research Action. 2020 , 8,	20
1164	The Actin Bundling Protein Fascin-1 as an ACE2-Accessory Protein. 2020 , 1	3
1163	Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System. 2020 , 8, 559841	23
1162	Ferritin Nanocage-Based Methyltransferase SETD6 for COVID-19 Therapy. 2020 , 30, 2006110	3
1161	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. 2020 , 72, 2313-2330	7
1160	Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147). 2020 , 47, 8229-8233	29
1159	The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. 2020 , 15, e0239508	44
1158	Localization of angiotensin-(1-7) and Mas receptor in the rat ovary throughout the estrous cycle. 2020 , 51, 639-647	1
1157	The Importance of Redox Status in the Frame of Lifestyle Approaches and the Genetics of the Lung Innate Immune Molecules, SP-A1 and SP-A2, on Differential Outcomes of COVID-19 Infection. 2020 , 9,	11

1156	From ACE2 to COVID-19: A multiorgan endothelial disease. 2020 , 100, 425-430	6
1155	Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. 2021 , 8, 973-980	15
1154	Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. 2020 , 83, 812-816	10
1153	[ACE2 - the hijacked all-rounder]. 2020 , 15, 1-4	0
1152	Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. 2020 , 2020, 6175964	116
1151	Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. 2020 , 21,	49
1150	A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. 2020 , 28, 1141-1152	28
1149	Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications. 2020 , 9, 121-124	8
1148	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2. 2020 , 76, 651-661	38
1147	The Genetic Dissection of Expression Variation in the Heart of Murine Genetic Reference Population. 2020 , 7, 582949	4
1146	COVID-19-related myocarditis and cholinergic anti-inflammatory pathways. 2021 , 62, 265-269	3
1145	Contemplating on the Etiology of COVID-19 Severity and Mortality Sex Differences. 2020 , 4, 247028972097020	
1144	Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2. 2020 , 11, 584158	6
1143	Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets. 2020 , 11, 586892	13
1142	Neurotensins and their therapeutic potential: research field study. 2020 , 12, 1779-1803	0
1141	Statins in COVID-19: Is there any foundation?. 2020 , 32, 278-281	1
1140	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. 2020 , 85, 104510	6
1139	How Does SARS-CoV-2 Affect the Central Nervous System? A Working Hypothesis. 2020 , 11, 582345	15

1138	The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. 2020 , 21,	10
1137	Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways. 2020 , 2020, 8896536	5
1136	Osmotic Adaptation by Na-Dependent Transporters and ACE2: Correlation with Hemostatic Crisis in COVID-19. 2020 , 8,	6
1135	SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle. 2020 , 21,	12
1134	Regulation of Male Fertility by the Renin-Angiotensin System. 2020 , 21,	6
1133	Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. 2020 , 7,	22
1132	Small Resistance Artery Disease and ACE2 in Hypertension: A New Paradigm in the Context of COVID-19. 2020 , 7, 588692	5
1131	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. 2020 , 1, 270	11
1130	ACE2: The Major Cell Entry Receptor for SARS-CoV-2. 2020 , 198, 867-877	88
1129	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. 2020 , 177, 4942-4966	51
1128	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. 2020 , 19, 102567	375
1127	Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. 2020 , 53, 33-37	84
1126	Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan). 2020 , 6, 252	1
1125	Potential influence of COVID-19/ACE2 on the female reproductive system. 2020 , 26, 367-373	146
1124	Is there an impact of the COVID-19 pandemic on male fertility? The ACE2 connection. 2020 , 318, E878-E880	33
1123	An Overview of the Potential Use of Ethno-Medicinal Plants Targeting the Renin-Angiotensin System in the Treatment of Hypertension. 2020 , 25,	3
1122	Coronavirus Disease 2019: The Role of the Fibrinolytic System from Transmission to Organ Injury and Sequelae. 2020 , 46, 841-844	29
1121	COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. 2020 , 21,	183

1120	COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. 2020 , 42, 1021-1049	78
1119	The ACE-2 in COVID-19: Foe or Friend?. 2020 , 52, 257-263	84
1118	COVID-19 and hypertension. 2020 , 21, 1470320320927851	14
1117	Neurological manifestations associated with COVID-19: a review and a call for action. 2020 , 267, 1573-1576	68
1116	Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). 2020 , 57, 339-350	18
1115	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. 2020 , 41, 1810-1817	277
1114	Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. 2020 , 115, 36	33
1113	Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review. 2020 , 14, 509-512	9
1112	ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. 2020 , 53, 425-435	264
1111	Coronavirus Disease 2019 and the Cerebrovascular-Cardiovascular Systems: What Do We Know So Far?. 2020 , 9, e016793	25
1110	Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. 2020 , 53, 43-52	58
1109	Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection. 2020 , 130, 106680	31
1108	Glycemic control of type 2 diabetic patients with coronavirus disease during hospitalization: a proposal for early insulin therapy. 2020 , 318, E835-E837	7
1107	Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice. 2020 , 100, 1169-1183	14
1106	Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review. 2020 , 179, 1079-1087	70
1105	An Isothermal Method for Sensitive Detection of Mycobacterium tuberculosis Complex Using Clustered Regularly Interspaced Short Palindromic Repeats/Cas12a Cis and Trans Cleavage. 2020 , 22, 1020-1029	9
1104	Chemical renal denervation-induced upregulation of the ACE2/Ang (1-7)/Mas axis attenuates blood pressure elevation in spontaneously hypertensive rats. 2020 , 42, 661-668	6
1103	COVID-19: ACE2centric Infective Disease?. 2020 , 76, 294-299	39

1102	Roles of angiotensin II as vasopressor in vasodilatory shock. 2020 , 16, 569-583	1
1101	Oral submucous fibrosis and COVID-19: Perspective on comorbidity. 2020 , 107, 104811	6
1100	Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?. 2020 , 38, 1196-1197	5
1099	Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. 2020 , 256, 117905	77
1098	Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. 2020 , 42, 656-660	39
1097	COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. 2020 , 22, 957-966	137
1096	Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. 2020 , 47, 4383-4392	87
1095	Is the kidney a target of SARS-CoV-2?. 2020 , 318, F1454-F1462	105
1094	Diminazene aceturate extenuate the renal deleterious consequences of angiotensin-II induced by Irradiation through boosting ACE2 signaling cascade. 2020 , 253, 117749	3
1093	Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. 2020 , 6, 98-105	25
1092	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094	152
1091	Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients. 2020 , 28, 721-725	138
1090	Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. 2020 , 73, 366-369	83
1089	Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. 2020 , 1	13
1088	Diabetes and metabolic syndrome as risk factors for COVID-19. 2020 , 14, 671-677	43
1087	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. 2020 , 109, 1446-1459	34
1086	ACE2 and COVID-19 and the resulting ARDS. 2020 , 96, 403-407	63
1085	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. 2020 , 61, 381-395	29

1084	Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug. 2020 , 256, 117970	30
1083	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. 2020 , 63, 12256-12274	111
1082	Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. 2020 , 144, 109988	12
1081	Sex-Specific Modulation of Blood Pressure and the Renin-Angiotensin System by ACE (Angiotensin-Converting Enzyme) 2. 2020 , 76, 478-487	12
1080	Biological sex impacts COVID-19 outcomes. 2020 , 16, e1008570	136
1079	Understanding the age divide in COVID-19: why are children overwhelmingly spared?. 2020 , 319, L39-L44	51
1078	Cerebrovascular and Neurological Dysfunction under the Threat of COVID-19: Is There a Comorbid Role for Smoking and Vaping?. 2020 , 21,	17
1077	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. 2020 , 9, 1397-1406	31
1076	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?. 2020 , 28, 213-216	8
1075	COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. 2020 , 14, 20	49
1074	Biomarkers associated with COVID-19 disease progression. 2020 , 57, 389-399	263
1073	[The RAAS and SARS-CoV-2: A riddle to solve]. 2020 , 37, 169-175	1
1072	COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response. 2020 , 7,	5
1071	ACE2, Much More Than Just a Receptor for SARS-COV-2. 2020 , 10, 317	144
1070	COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. 2020 , 32, 1599-1608	138
1069	2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications. 2020 , 6, 246-250	3
1068	Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection. 2020 , 11, 730	23
1067	Giovanni Di Guardo: Animal Models and Pathogenetic Insights to Covid-19. 2020 , 179, e1	3

1066	Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury. 2020 , 235, 9884-9894	42
1065	Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience. 2020 , 11, 659	27
1064	Cytokine storm induced by SARS-CoV-2. 2020 , 509, 280-287	247
1063	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. 2020 , 56,	177
1062	COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer. 2020 , 6, 1086-1096	15
1061	The ACE2/Ang (1-7)/MasR axis as an emerging target for antihypertensive peptides. 2021 , 61, 2572-2586	9
1060	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. 2020 , 6, 315-331	716
1059	Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. 2020 , 367, 1444-1448	2938
1058	Angiotensin-(1-9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway. 2020 , 27, 2586-2604	15
1057	Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. 2020 , 22, 221-225	128
1056	Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. 2020 , 16, 1724-1731	275
1055	The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. 2020 , 505, 192-193	105
1054	Coronavirus uses as binding site in humans angiotensin-converting enzyme 2 functional receptor that is involved in arterial blood pressure control and fibrotic response to damage and is a drug target in cardiovascular disease. Is this just a phylogenetic coincidence?. 2020 , 92, 1713-1714	4
1053	Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. 2020 , 21,	15
1052	Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. 2020 , 92, 726-730	271
1051	Virology, Epidemiology, Pathogenesis, and Control of COVID-19. 2020 , 12,	707
1050	Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. 2020 , 14, 185-192	1238
1049	Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. 2020 , 22, 44	5

1048	The neurological significance of COVID-19: Lesson learn from the pandemic. 2020 , 22, 100809	1
1047	The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?. 2020 , 1-8	7
1046	Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection. 2020 , 30, e2122	24
1045	SARS-CoV-2 Does Not Replicate in Aedes Mosquito Cells nor Present in Field-Caught Mosquitoes from Wuhan. 2020 , 35, 355-358	7
1044	CORDITE: The Curated CORona Drug InTERactions Database for SARS-CoV-2. 2020 , 23, 101297	19
1043	The Impact of SARS-Cov-2 Virus Infection on the Endocrine System. 2020 , 4, bvaa082	36
1042	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. 2020 , 9,	46
1041	Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. 2020 , 39, 1209-1220	73
1040	Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences. 2020 , 14, 1053-1060	9
1039	Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. 2020 , 319, L325-L336	40
1038	The Impact of COVID-19 on Cancer Risk and Treatment. 2020 , 13, 1-7	18
1037	Serum Iron Level as a Potential Predictor of Coronavirus Disease 2019 Severity and Mortality: A Retrospective Study. 2020 , 7, ofaa250	51
1036	Men more vulnerable to COVID-19: explained by ACE2 on the X chromosome?. 2020 , 41, 3096	7
1035	Could SARS-CoV-2 affect male fertility?. 2020 , 52, e13712	37
1034	A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19. 2020 , 30, e2119	59
1033	ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System. 2020 , 9,	19
1032	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. 2020 , 14, 601-612	28
1031	COVID-19 and the Digestive System. 2020 , 115, 1003-1006	68

1030	Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus. 2020 , 1	43
1029	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. 2020 , 81, 919	17
1028	Statins in COVID-19: is there any foundation?. 2020 , 32, 278-281	11
1027	Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France. 2020 , 71, 2447-2456	33
1026	Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. 2020 , 16, 2382-2391	41
1025	Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury. 2020 , 35, 256-258	61
1024	The Other Angiotensin II Receptor: ATR as a Therapeutic Target. 2020 , 63, 1978-1995	16
1023	Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice. 2020 , 8, e14364	6
1022	CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome. 2020 , 21,	5
1021	The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. 2020 , 92, 552-555	1291
1020	Kinin B1 receptor: A target for neuroinflammation in hypertension. 2020 , 155, 104715	13
1019	B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. 2020 , 11, 1058	32
1018	The 2019 coronavirus: Learning curves, lessons, and the weakest link. 2020 , 74, e13488	19
1017	Two protocols of aerobic exercise modulate the counter-regulatory axis of the renin-angiotensin system. 2020 , 6, e03208	24
1016	Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. 2020 , 27, 484-511	10
1015	Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. 2020 , 39, 1021-1026	50
1014	Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. 2020 , 11, 1022	111
1013	ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?. 2020 , 12,	84

1012	Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. 2020 , 95, 1222-1230	94
1011	Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. 2020 , 43, 588-590	52
1010	The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease. 2020 , 116, 1932-1936	41
1009	COVID-19: Risk groups, mechanistic insights and challenges. 2020 , 74, e13512	15
1008	Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review. 2020 , 52, 191-206	13
1007	Letter: The Risk of COVID-19 Infection During Neurosurgical Procedures: A Review of Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2) Modes of Transmission and Proposed Neurosurgery-Specific Measures for Mitigation. 2020 , 87, E178-E185	25
1006	Emergence of institutional antithrombotic protocols for coronavirus 2019. 2020 , 4, 510-517	37
1005	Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?. 2020 , 6, 248-251	18
1004	The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients. 2020 , 92, 786-790	41
1003	Renin-angiotensin-aldosterone system and COVID-19 infection. 2020 , 81, 63-67	45
1002	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. 2020 , 47, 107228	77
1001	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. 2020 , 76, 14-20	652
1000	Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. 2020 , 112, 102463	160
999	Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. 2020 , 30, 1061-1067	52
998	COVID-19 and globalization. 2020 , 9, 100132	27
997	Biological plausibility for interactions between dietary fat, resveratrol, , and SARS-CoV illness severity. 2020 , 318, E830-E833	42
996	Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers. 2020 ,	8
995	Prognostic value of NT-proBNP in patients with severe COVID-19. 2020 , 21, 83	159

994	The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. 2020 , 15, e0230295	216
993	Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. <i>Circulation Research</i> , 2020 , 126, 1456-1474 ^{15,7} 1012	15.7 395
992	COVID-19 and the Heart. <i>Circulation Research</i> , 2020 , 126, 1443-1455	15.7 395
991	Targeting Angiotensin-Converting Enzyme-2/Angiotensin-(1-7)/Mas Receptor Axis in the Vascular Progenitor Cells for Cardiovascular Diseases. 2021 , 99, 29-38	14
990	Renin-angiotensin system molecules are associated with subclinical atherosclerosis and disease activity in rheumatoid arthritis. 2021 , 31, 119-126	10
989	An update on ACE2 amplification and its therapeutic potential. 2021 , 231, e13513	12
988	Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox. 2021 , 42, 118-119	7
987	Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. 2021 , 62, 13-23	19
986	Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology. 2021 , 35, 932-943	1
985	Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). 2021 , 37, e3377	111
984	Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. 2021 , 31, 410-424	62
983	Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease. 2021 , 35, 33-42	3
982	Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV. 2021 , 68, 1046-1053	9
981	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?. 2021 , 17, 275-284	3
980	Association of Coronavirus Disease (COVID-19) With Large Vessel Occlusion Strokes: A Case-Control Study. 2021 , 216, 150-156	30
979	Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2). 2021 , 74, 285-290	17
978	Advances in research on ACE2 as a receptor for 2019-nCoV. 2021 , 78, 531-544	50
977	An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. 2021 , 17, 92-97	3

976	Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2. 2021 , 68, 318-332	4
975	2020 update on the renin-angiotensin-aldosterone system in pediatric kidney disease and its interactions with coronavirus. 2021 , 36, 1407-1426	13
974	The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI). 2021 , 218, 107684	7
973	Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. 2021 , 160, 287-301.e20	50
972	Overexpression of the SARS-CoV-2 receptor ACE2 is induced by cigarette smoke in bronchial and alveolar epithelia. 2021 , 253, 17-30	23
971	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. 2021 , 890, 173620	16
970	Renin-angiotensin system at the interface of COVID-19 infection. 2021 , 890, 173656	12
969	Potential neurological manifestations of COVID-19: a narrative review. 2021 , 1-11	10
968	Drug screening and development from the affinity of S protein of new coronavirus with ACE2. 2021 , 40, 715-723	2
967	The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. 2021 , 135, 170428	5
966	Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. 2021 , 11, 1-12	40
965	Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update. 2021 , 147, 111887	6
964	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. 2021 , 221, 107750	16
963	Higher ACE2 expression levels in epicardial cells than subcutaneous stromal cells from patients with cardiovascular disease: Diabetes and obesity as possible enhancer. 2021 , 51, e13463	9
962	Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): In silico analysis. 2021 , 891, 173781	21
961	ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. 2021 , 150, 104621	30
960	The flexibility of ACE2 in the context of SARS-CoV-2 infection. 2021 , 120, 1072-1084	52
959	Neurological manifestations of coronavirus infections: role of angiotensin-converting enzyme 2 in COVID-19. 2021 , 1-8	8

958	Prefusion spike protein stabilization through computational mutagenesis. 2021 , 89, 399-408	1
957	The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. 2021 , 180, 169-177	38
956	COVID-19: A review of therapeutic strategies and vaccine candidates. 2021 , 222, 108634	109
955	Relevance of angiotensin-(1-7) and its receptor Mas in pneumonia caused by influenza virus and post-influenza pneumococcal infection. 2021 , 163, 105292	3
954	Protein microcapsules integrated hierarchical scaffolds for local treatment of acute myocardial infarction model. 2021 , 22, 100901	1
953	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. 2021 , 20, 139-153	6
952	Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. 2021 , 20, 49-59	12
951	The cardiovascular aspect of COVID-19. 2021 , 53, 227-236	16
950	Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. 2021 , 9, 1	16
949	Is highly expressed ACE 2 in pregnant women "a curse" in times of COVID-19 pandemic?. 2021 , 264, 118676	17
948	Dysregulation of Angiotensin Converting Enzyme 2 Expression and Function in Comorbid Disease Conditions Possibly Contributes to Coronavirus Infectious Disease 2019 Complication Severity. 2021 , 99, 17-28	9
947	Translating bioactive peptides for COVID-19 therapy. 2021 , 890, 173661	6
946	Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation. 2021 , 25, 421-433	14
945	Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein. 2021 , 35, 195-207	23
944	COVID-19 and Major Organ Thromboembolism: Manifestations in Neurovascular and Cardiovascular Systems. 2021 , 30, 105427	10
943	Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. 2021 , 72, 122-130	13
942	ACE2: Its potential role and regulation in severe acute respiratory syndrome and COVID-19. 2021 , 236, 2430-2442	18
941	Alpha-1-antitrypsin: A possible host protective factor against Covid-19. 2021 , 31, e2157	27

940	Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. 2021 , 99, 192-205	1
939	Physiological implications of COVID-19 in reproduction: angiotensin-converting enzyme 2 a key player. 2021 , 33, 381-391	0
938	Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension. 2021 , 1	2
937	The renin-angiotensin system in pediatric kidney disease: from pathophysiology to the novel therapeutic approach. 2021 , 34, 7-12	
936	The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. 2021 , 26, 961-971	2
935	COVID-19 and Renin Angiotensin Aldosterone System: A Pharmacogenomic View. 2021 , 28, e136-e139	
934	Pathomorphological and Molecular Biological Aspects of Blood Vessel Injury in COVID-19. 2021 , 9, 9-18	1
933	Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. 2021 , 53, 273-282	9
932	Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach. 2021 , 24, 100597	13
931	Cardiovascular disease in SARS-CoV-2 infection. 2021 , 10, e1343	8
930	COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. 2021 , 1	5
929	Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 From Hawaii Reveals the Worldwide Emerging P681H Mutation. 2021 ,	13
928	A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. 2021 , 53, 205-214	64
927	ACE2 in the second act of COVID-19 syndrome: Peptide dysregulation and possible correction with oestrogen. 2021 , 33, e12935	7
926	SARS-CoV-2 and the reproductive system: known and the unknown...!. 2021 , 26, 1	14
925	Neuropathogenesis of SARS-CoV-2 Infection. 2021 , 25-43	1
924	SARS-CoV-2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism. 2021 , 58, 2465-2480	21
923	Exploring G protein-coupled receptors and yeast surface display strategies for viral detection in baker's yeast: SARS-CoV-2 as a case study. 2021 , 21,	2

922	ACE2 gene transfer ameliorates vasoreparative dysfunction in CD34+ cells derived from diabetic older adults. 2021 , 135, 367-385	2
921	A Potential Role of the Renin-Angiotensin-System for Disturbances of Respiratory Chemosensitivity in Acute Respiratory Distress Syndrome and Severe Acute Respiratory Syndrome. 2020 , 11, 588248	2
920	Angiotensin converting enzyme. 2021 , 505-508	1
919	Recent Findings on Cell-Based Therapies for COVID19-Related Pulmonary Fibrosis. 2021 , 30, 963689721996217	2
918	Photobiomodulation and Antiviral Photodynamic Therapy in COVID-19 Management. 2021 , 1318, 517-547	7
917	A review on potential of natural products in the management of COVID-19.. 2021 , 11, 16711-16735	19
916	Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis. 2021 , 47, 392-399	17
915	Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles. 2021 , 40, 100356	5
914	High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis. 2021 , 27, 100321	3
913	Characteristics of Angiotensin I-converting enzyme 2, type II transmembrane serine protease 2 and 4 in tree shrew indicate it as a potential animal model for SARS-CoV-2 infection. 2021 , 12, 2836-2850	2
912	Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. 2021 , 22, 71	14
911	A scoping review of the pathophysiology of COVID-19. 2021 , 35, 20587384211048026	11
910	The Central Role of Fibrinolytic Response in COVID-19-A Hematologist's Perspective. 2021 , 22,	20
909	Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2. 2021 , 36, 1-20	5
908	ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues. 2021 , 15, 8	16
907	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. 2021 , 28, 9	52
906	Receptors Angiotensin Receptors. 2021 , 110-121	
905	The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. 2021 , 48, 1763-1771	2

904	Human Viruses: Infection, Prevention and Potential Target(s) for Therapy [A Comprehensive Review. 2021 , 3-54	
903	The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients. 2021 , 22, 1470320320987118	4
902	Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. 2021 , 44, 99-116	33
901	The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients. 2020 , 11, 612268	5
900	Special Features of Human Lung ACE2 Sensitivity to SARS-CoV-2 Spike Glycoprotein. 2021 , 583-599	
899	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. 2021 , 32, 285-289	9
898	The Clinical Characteristics and Risk Factors of Severe COVID-19. 2021 , 67, 255-266	25
897	The role of SARS-CoV-2 target ACE2 in cardiovascular diseases. 2021 , 25, 1342-1349	7
896	Artificial Intelligence-Mediated Medical Diagnosis of COVID-19. 2021 , 37-54	
895	Therapy with RAS inhibitors during the COVID-19 pandemic. 2021 , 22, 329-334	4
894	Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism. 2021 , 26,	19
893	ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. 2021 , 135, 387-407	13
892	The Balance between Two Branches of RAS Can Protect from Severe COVID-19 Course. 2021 , 15, 36-51	1
891	Proteomics-Based Insights Into the SARS-CoV-2-Mediated COVID-19 Pandemic: A Review of the First Year of Research. 2021 , 20, 100103	7
890	Ecological Analysis of the Influence of ACEIs and ARBs on the COVID-19 Prevalence and Death from COVID-19. 2021 , 13, 619-628	0
889	Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. 2021 , 135, 1-17	11
888	Mesenchymal Stem Cell-Derived Extracellular Vesicles: Promising Treatment for COVID-19 Pandemic. 2021 ,	
887	Androgens, the kidney, and COVID-19: an opportunity for translational research. 2021 , 320, F243-F248	4

886	A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. 2021 ,	38
885	A cross-talk between gut microbiome, salt and hypertension. 2021 , 134, 111156	20
884	COVID-19 and Dentistry in 72 Questions: An Overview of the Literature. 2021 , 10,	6
883	Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. 2021 , 11, 110	2
882	Renin-angiotensin system: role in the development and progression of prostate cancer. 2021 , 16, 181-190	
881	Impact of coronavirus disease 2019 on diabetic patients: An endocrinological perspective for better management. 2, 85-91	
880	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. 2021 , 24, 102021	18
879	Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities. 2021 , 34, 187-198	1
878	Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options. 2021 , 10,	5
877	Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic. 2021 , 12, 624052	8
876	Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. 2021 , 100, 1	26
875	The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection. 2021 , 12, 616993	6
874	[CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice]. 2021 , 110, 1-5	
873	Peripheral Nervous System Manifestations Associated with COVID-19. 2021 , 21, 9	38
872	SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. 2021 , 13, 102-125	11
871	Efficacy of Serum Angiotensin II Levels in Prognosis of Patients With Coronavirus Disease 2019. 2021 , 49, e613-e623	13
870	NO, ROS, RAS, and PVAT: More Than a Soup of Letters. 2021 , 12, 640021	4
869	Expression of ACE2 receptor, soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin (1-7), is modulated in COVID-19 patients.	1

868	Ginsenoside Rc Ameliorates Endothelial Insulin Resistance via Upregulation of Angiotensin-Converting Enzyme 2. 2021 , 12, 620524	2
867	SARS-CoV-2 infection: Understanding the immune system abnormalities to get an adequate diagnosis. 2021 , 21, 503-514	2
866	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. 2021 , 22, 254-281	17
865	[CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice]. 2021 , 110, 60-64	
864	Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?. 2021 , 10,	5
863	A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. 2021 , 35, e21419	3
862	ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders. 2021 , 135, 535-554	8
861	Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19. 2021 , 12, 598925	7
860	Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms. 2021 , 74, 1740-1751	10
859	SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. 2021 , 9, e14726	58
858	Determining available strategies for prevention and therapy: Exploring COVID-19 from the perspective of ACE2 (Review). 2021 , 47,	3
857	Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications. 2021 , 267, 118923	14
856	Targeting the Renin-Angiotensin-Aldosterone System to Prevent Hypertension and Kidney Disease of Developmental Origins. 2021 , 22,	19
855	Association of Ang-(1-7) and des-ArgBK as new biomarkers of obesity and cardiometabolic risk factors in adolescents. 2021 , 44, 969-977	1
854	Structural analysis of COVID-19 spike protein in recognizing the ACE2 receptor of different mammalian species and its susceptibility to viral infection. 2021 , 11, 109	13
853	New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. 2021 , 8, 640073	23
852	The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?. 2021 , 10,	13
851	Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. 2021 , 476, 2917-2942	10

850	Angiotensin-Converting Enzyme Type 2 as a Molecular Mediator for Infection of Cells with SARS-CoV and SARS-CoV-2 Viruses. 2021 , 51, 381-389	1
849	Genetic and epigenetic factors associated with increased severity of Covid-19. 2021 , 45, 1158-1174	18
848	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. 2021 , 213, 113157	15
847	In-Silico Drug Designing of Spike Receptor with Its ACE2 Receptor and Nsp10/Nsp16 MTase Complex Against SARS-CoV-2. 2021 , 27, 1-8	2
846	Docking and toxicity assessment of compounds as potential antiviral agents against SARS-CoV-2. 2021 , 33, 1-24	12
845	Metabolism of angiotensin peptides by angiotensin converting enzyme 2 (ACE2) and analysis of the effect of excess zinc on ACE2 enzymatic activity. 2021 , 137, 170477	2
844	Effects of Pennyroyal (<i>Mentha pulegium</i> L.) on Angiotensin Converting Enzyme-2 (ACE-2) and Antioxidant Parameters in Rabbits.	0
843	Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). 2021 , 21, 689-703	3
842	Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies. 2021 , 12, 619524	9
841	COVID-19 pandemic: what about the gonads?. 2021 , 20, 259-268	5
840	Renal Manifestations of Covid-19: Physiology and Pathophysiology. 2021 , 10,	9
839	HiSpike: A high-throughput cost effective sequencing method for the SARS-CoV-2 spike gene.	3
838	Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review. 2021 , 7, 73	3
837	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.	
836	High-Flow Nasal Cannula, a Boon or a Bane for COVID-19 Patients? An Evidence-Based Review. 2021 , 11, 1-6	0
835	An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2. 2021 , 125, 2533-2550	7
834	The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. 2021 , 23, 17	1
833	Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019. 2021 , 36, 247-262	1

832	Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2. 2021 , 2, 025024	7
831	COVID-19-A Theory of Autoimmunity Against ACE-2 Explained. 2021 , 12, 582166	20
830	Dual role for angiotensin-converting enzyme 2 in Severe Acute Respiratory Syndrome Coronavirus 2 infection and cardiac fat. 2021 , 22, e13225	3
829	Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. 2021 , 9,	7
828	The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on ischemic stroke and the possible underlying mechanisms. 2021 , 1-20	2
827	Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease. 2021 , 8, 600385	5
826	The laboratory findings and different COVID-19 severities: a systematic review and meta-analysis. 2021 , 20, 17	9
825	SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. 2021 , 22,	15
824	Nervous System Involvement in COVID-19: a Review of the Current Knowledge. 2021 , 58, 3561-3574	7
823	Multi-schema computational prediction of the comprehensive SARS-CoV-2 vs. human interactome. 2021 , 9, e11117	2
822	SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.	2
821	COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays. 2021 , 1-14	8
820	ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. 2021 , 224, S631-S641	1
819	Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. 2021 , 27, 1531-1552	4
818	Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. 2021 , 9,	53
817	COVID-19 and thrombosis: From bench to bedside. 2021 , 31, 143-160	39
816	The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling. 2021 , 22,	7
815	Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis. 2021 , 9, e1672	8

814	COVID-19 and Cancer: Biological Interconnection and Treatment.	
813	Differential expression of angiotensin-converting enzyme-2 in human paranasal sinus mucosa in patients with chronic rhinosinusitis. 2021 , 135, 773-778	0
812	COVID-19-related arrhythmias and the possible effects of ranolazine. 2021 , 149, 110545	0
811	Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19. 2021 , 8, 634291	3
810	Drugs acting on the renin-angiotensin system and SARS-CoV-2. 2021 , 26, 870-874	22
809	Aging versus youth: Endocrine aspects of vulnerability for COVID-19. 2021 , 1	3
808	Diabetes and Renin-Angiotensin-Aldosterone System: Pathophysiology and Genetics.	
807	Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. 2021 , 379, 23	2
806	The Involvement of MicroRNAs in SARS-CoV-2 Infection Comorbid with HIV-Associated Preeclampsia. 2021 , 23, 20	4
805	Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. 2021 , 136, 111193	14
804	Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors. 2021 ,	1
803	The fight against COVID-19: Striking a balance in the renin-angiotensin system. 2021 , 26, 2214-2220	7
802	Neurotropic Viruses, Astrocytes, and COVID-19. 2021 , 15, 662578	19
801	Myocardial Angiotensin Metabolism in End-Stage Heart Failure. 2021 , 77, 1731-1743	8
800	Impact of COVID-19 Pandemic on Patients With Neurodegenerative Diseases. 2021 , 13, 664965	12
799	Angiotensin-(3-4) modulates the overweight- and undernutrition-induced ACE2 downregulation in renal proximal tubule cells: implications for COVID-19?.	0
798	The homology analysis of ACE2 gene and its distinct expression in laboratory and wild animals.	
797	[Angiotensin-converting enzyme 2 (ACE2): role in the pathogenesis of diseases outside of COVID-19]. 2021 , 16, 1-3	0

796	Dysregulation of the Renin-Angiotensin-Aldosterone System (RAA) in Patients Infected with SARS-CoV-2-Possible Clinical Consequences. 2021 , 22,	7
795	Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study. 2021 , 896, 173899	11
794	Biochemical, molecular genetic and clinical aspects of COVID-2019. 2021 , 20, 147-157	1
793	Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. 2021 , 118,	46
792	Recovery of new-onset kidney disease in COVID-19 patients discharged from hospital. 2021 , 21, 397	4
791	COVID-19 and Cardiovascular Disease: From Bench to Bedside. <i>Circulation Research</i> , 2021 , 128, 1214-1236;7	57
790	Kidney-accumulating olmesartan-loaded nanomicelles ameliorate the organ damage in a murine model of Alport syndrome. 2021 , 600, 120497	2
789	Angiotensin System Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study. 2021 , 14, 621-629	13
788	ACE2-based decoy receptors for SARS coronavirus 2. 2021 , 89, 1065-1078	4
787	Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs. 2021 , 94, 458-462	3
786	Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2. 2021 , 93, 5487-5504	4
785	Cardiovascular Impacts on COVID-19 Infected Patients. 2021 , 8, 670659	4
784	The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy. 2021 , 22,	8
783	Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. 2021 , 7, 37	3
782	The understanding of the immunopathology in COVID-19 infection. 2021 , 81, 255-263	1
781	An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods. 2021 , 75, 1-24	2
780	Cardio-protective effects of angiotensin-(1-5) via mas receptor in rats against ischemic-perfusion injury. 2021 , 139, 170516	1
779	Hydroelectrolytic Disorder in COVID-19 patients: Evidence Supporting the Involvement of Subfornical Organ and Paraventricular Nucleus of the Hypothalamus. 2021 , 124, 216-223	4

778	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. 2021 , 44, 499-513	4
777	Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the ACE2 Receptor. 2021 , 9, 661230	50
776	Pulmonary rehabilitation principles in SARS-COV-2 infection (COVID-19): The revised guideline for the acute, subacute, and post-COVID-19 rehabilitation. 2021 , 67, 129-145	1
775	Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins. 2021 , 29, 249-262	0
774	Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets. 2021 , 34, 510-521	0
773	Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management. 2021 , 7, e07068	9
772	Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. 2021 , 166, 2089-2108	13
771	Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity. 2021 , 93, 5285-5294	14
770	Structural Basis for the Understanding of Entry Inhibitors Against SARS Viruses. 2021 ,	0
769	Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients. 2021 , 10, 86-96	1
768	COVID-19 and Hypertension: The What, the Why, and the How. 2021 , 12, 665064	8
767	Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. 2021 , 334, 129663	4
766	ACE2 expression in rat brain: implications for COVID-19 associated neurological manifestations.	2
765	Mechanism of Ligand Recognition by Human ACE2 Receptor. 2021 , 12, 4814-4822	3
764	The Cholinergic and ACE-2-Dependent Anti-Inflammatory Systems in the Lung: New Scenarios Emerging From COVID-19. 2021 , 12, 653985	1
763	Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. 2021 , 106, 2208-2220	15
762	From small molecules to dinosaurs - Recent advances in blood pressure research. 2021 , 232, e13677	
761	Insights into SARS-CoV-2 Persistence and Its Relevance. 2021 , 13,	13

760	SARS CoV2 infection _The longevity study perspectives. 2021 , 67, 101299	11
759	The classical and potential novel healthy functions of rice bran protein and its hydrolysates. 2021 , 1-13	4
758	Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies. 2021 , 12, 629935	6
757	Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. 2021 , 137, 111363	18
756	Role of the Renin-Angiotensin-Aldosterone System in Various Disease Processes: An Overview.	4
755	Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?. 2021 , 27, 2270-2280	2
754	The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses. 2021 , 73, 1005-1015	3
753	Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. 2021 , 27, 206	6
752	Current status of the COVID-19 and male reproduction: A review of the literature. 2021 , 9, 1066-1075	5
751	Increased colonic expression of ACE2 associates with poor prognosis in Crohn's disease. 2021 , 11, 13533	2
750	The Significance of Angiotensin-Converting Enzyme-2 (ACE2) in SARSCov- 2 Infection and COVID-19. 2021 , 2,	
749	Variants in ACE2; potential influences on virus infection and COVID-19 severity. 2021 , 90, 104773	28
748	Covid-19 Infection and Parkinsonism: Is There a Link?. 2021 , 36, 1737-1743	9
747	Angiotensin-converting enzyme-1 gene insertion/deletion polymorphism may be associated with COVID-19 clinical severity: a prospective cohort study. 2021 , 41, 141-146	7
746	Exosomes Protect Against Acute Myocardial Infarction in Rats by Regulating the Renin-Angiotensin System. 2021 , 30, 622-631	3
745	["Prioritization and triage" in the context of cardiovascular diseases : Rational organization of safe care during and outside the corona pandemic]. 2021 , 62, 706-717	0
744	The Immunopathobiology of SARS-CoV-2 Infection. 2021 , 45,	1
743	The key role of the level of ACE2 gene expression in SARS-CoV-2 infection. 2021 , 13, 14552-14556	5

742	The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. 2021 , 394, 1589-1593	5
741	Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. 2021 , 73, 1539-1550	4
740	The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications. 2021 , 70, 877-889	2
739	Role of SARS-CoV-2 and ACE2 variations in COVID-19. 2021 , 44, 235-244	8
738	High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 Outcome. 2021 , 32, 2517-2528	10
737	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. 2021 , 3, 1257-1272	3
736	Does Hypofractionated Radiotherapy Regimens Increase the Vulnerability to SARS- COV-2 by Influencing ACE-2 Activity?. 2021 , 2, 419-421	
735	Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature. 2021 , 126, 1-46	3
734	Bovine Colostrum Derived Antibodies Against SARS-CoV-2 Show Great Potential to Serve as a Prophylactic Agent.	2
733	Pathogenesis-based preexposure prophylaxis associated with a low risk of SARS-CoV-2 infection in healthcare workers at a designated COVID-19 hospital: a pilot study. 2021 , 21, 536	2
732	Do Changes in Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms. 2021 , 22,	6
731	Cutaneous manifestations associated with anosmia, ageusia and enteritis in SARS-CoV-2 infection - A possible pattern? Observational study and review of the literature. 2021 , 107, 72-77	2
730	Emerging importance of ACE2 in external stratified epithelial tissues. 2021 , 529, 111260	0
729	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19. 2021 , 6, 37	10
728	Risk factors for the delayed viral clearance in COVID-19 patients. 2021 , 23, 1483-1489	2
727	Angiotensin-converting enzyme 2: a key enzyme in key organs. 2022 , 23, 1-11	1
726	ACE2 and Apelin-13: Biomarkers with a Prognostic Value in Congestive Heart Failure. 2021 , 2021, 5569410	1
725	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. 2021 , 6, 233	60

724	The Role of Renin: Angiotensin: Aldosterone System in the Pathogenesis and Pathophysiology of COVID-19.	
723	ACE2: At the crossroad of COVID-19 and lung cancer. 2021 , 23, 101077	9
722	Angiotensin receptors in the kidney and vasculature in hypertension and kidney disease. 2021 , 529, 111259	2
721	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. 2021 , 53, 508-541	
720	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. 2021 , 344, 77-110	3
719	Sex and kidney ACE2 expression in primary focal segmental glomerulosclerosis: A NEPTUNE study. 2021 , 16, e0252758	1
718	The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer's Disease Pathology. 2021 , 9, 684874	5
717	Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients. 2021 , 12, 625732	22
716	SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. 2021 , 12, 658428	9
715	Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19. 2021 , 320, R925-R937	4
714	Coronary microvascular dysfunction pathophysiology in COVID-19. 2021 , 28, e12718	10
713	Role of ACE 2 and Vitamin D: The Two Players in Global Fight against COVID-19 Pandemic.	
712	New perspectives on angiotensin-converting enzyme 2 and its related diseases. 2021 , 12, 839-854	1
711	Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles. 2021 , 22,	3
710	In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. 2021 , 2021, 8856018	3
709	Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19. 2021 , 39, 713-726	7
708	A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. 2021 , 58, 4535-4563	5
707	Association of Interleukin-6 Levels with Morbidity and Mortality in Patients with Coronavirus Disease 2019 (COVID-19). 2021 , 74, 293-298	5

706	The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy. 2021 , 10,	9
705	Angiotensin-Converting Enzyme 2 (ACE2) as a Potential Diagnostic and Prognostic Biomarker for Chronic Inflammatory Lung Diseases. 2021 , 12,	2
704	Computational Chemistry to Repurposing Drugs for the Control of COVID-19. 2021 , 1, 111-128	1
703	Extracellular Matrix Remodeling in Chronic Liver Disease. 2021 , 2, 1-12	5
702	Glycosylation of SARS-CoV-2: structural and functional insights. 2021 , 413, 7179-7193	11
701	SARS-CoV-2 and pathological matrix remodeling mediators. 2021 , 70, 847-858	3
700	Alterations in Gene Expression of Renin-Angiotensin System Components and Related Proteins in Colorectal Cancer. 2021 , 2021, 9987115	2
699	Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2021 , 8, 676554	4
698	Are Lactobacillus Bulgaricus and Bacillus Calmette-Guérin vaccine suitable for patient protection against SARS-CoV-2 infection?. 2021 , 11, 101-110	
697	Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. 2021 , 22,	10
696	Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach. 2021 , 1-13	4
695	Development of flexible electrochemical impedance spectroscopy-based biosensing platform for rapid screening of SARS-CoV-2 inhibitors. 2021 , 183, 113213	12
694	Hypotheses and facts for genetic factors related to severe COVID-19. 2021 , 10, 137-155	1
693	Mathematical Model of SARS-Cov-2 Propagation Versus ACE2 Fits COVID-19 Lethality Across Age and Sex and Predicts That of SARS. 2021 , 8, 706122	5
692	DNA Damage and Expression Profile of Genes Associated with Nephrotoxicity Induced by Butralin and Ameliorating Effect of Arabic Gum in Female Rats. 2021 , 193, 3454-3468	1
691	Diabetes Mellitus during the Pandemic Covid-19: Prevalence, Pathophysiology, Mechanism, and Management: An updated overview.. 2021 ,	0
690	Editorial: The Role of the Renin-Angiotensin System in the Central Nervous System. 2021 , 15, 733084	1
689	Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?. 2021 , 1	6

688	ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients. 2021 , 191, 1154-1164	9
687	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. 2021 , 58, 530-545	2
686	Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19. 2021 , 1	6
685	Remarkable gastrointestinal and liver manifestations of COVID-19: A clinical and radiologic overview. 2021 , 9, 4969-4979	2
684	Hide and seek in a pandemic: review of SARS-CoV-2 infection and sequelae in children. 2021 ,	1
683	Susceptibilities of human ACE2 genetic variants in coronavirus infection.	0
682	RAAS, ACE2 and COVID-19; a mechanistic review. 2021 , 28, 6465-6470	2
681	The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence. 2021 , 12, 677957	1
680	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. 2021 , 93, 5908-5916	17
679	The signal pathways and treatment of cytokine storm in COVID-19. 2021 , 6, 255	84
678	Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19. 2021 , 4,	2
677	Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients. 2021 , 12, 700220	2
676	Clinical laboratory evaluation of COVID-19. 2021 , 519, 172-182	8
675	An unexpected biomaterial against SARS-CoV-2: Bio-polyphosphate blocks binding of the viral spike to the cell receptor. 2021 , 51, 504-504	2
674	In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry. 2021 , 45, 442-458	0
673	Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?. 2021 , 1-10	2
672	Effects of COVID-19 on vital organs in patients infected with SARS-CoV-2. 2021 , 1, 12-19	
671	Epidemiological Features of the Novel Coronavirus Disease in the Lipetsk Region in 2020. 2021 , 63-68	0

670	Ovulatory upregulation of angiotensin-converting enzyme 2, a receptor for SARS-CoV-2, in dominant follicles of the human ovary. 2021 , 116, 1631-1640	1
669	COVID-19 and metabolic comorbidities: An update on emerging evidences for optimal therapies. 2021 , 140, 111685	3
668	Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. 2021 , 11, 16843	1
667	Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility. 2021 , 135, 1805-1824	5
666	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. 2021 , 6, 317	17
665	SARS-CoV-2 infection and ACE2 inhibition. 2021 , 39, 1555-1558	5
664	JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules. 2021 , 24, 102928	2
663	Myocardial fibrosis reversion via rhACE2-electrospun fibrous patch for ventricular remodeling prevention. 2021 , 6, 44	3
662	Covid-19 pandemic: Perspectives on management. 2021 , 146, 103344	2
661	Pathophysiology of COVID-19: Everywhere You Look You Will See ACE!. 2021 , 8, 694029	1
660	The therapeutic potential of apelin in kidney disease. 2021 , 17, 840-853	8
659	Cardiovascular ACE2 receptor expression in patients undergoing heart transplantation. 2021 , 8, 4119-4129	3
658	An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models. 2021 , 434, 167213	0
657	SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients. 2021 , 13,	3
656	Risk Factors of COVID-19 Critical Outcomes in the Eastern Mediterranean Region: A Multicountry Retrospective Study (Preprint).	
655	Mechanisms of Coupling between Angiotensin Converting Enzyme 2 and Nicotinic Acetylcholine Receptors.	
654	Abnormal Indexes of Liver and Kidney Injury Markers Predict Severity in COVID-19 Patients. 2021 , 14, 3029-3040	1
653	Expression pattern and function of SARS-CoV-2 Receptor ACE2. 2021 , 3, 312-312	1

652	Interaction between spike protein of SARS-CoV-2 and human virus receptor ACE2 using two-color fluorescence cross-correlation spectroscopy.	
651	Updates on renin-angiotensin system blockers in hypertensive patients with COVID-19. 2021 ,	1
650	Detecting SARS-CoV-2 Orf3a and E ion channel activity in COVID-19 blood samples. 2021 , 5, e196	3
649	SARS-CoV-2 Spike Protein Regulation of Angiotensin Converting Enzyme 2 and Tissue Renin-Angiotensin Systems: Influence of Biologic Sex. 2021 ,	0
648	Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis. 2021 , 98, 107806	11
647	Health concerns regarding the effect of the COVID-19 pandemic on male fertility. 2021 , 48, 189-193	2
646	An analysis of chronic kidney disease as a prognostic factor in pediatric cases of COVID-19. 2021 , 43, 400-409	
645	Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19. 2021 , 22,	0
644	Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF- κ B pathway. 2021 , 98, 107841	8
643	Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. 2021 , 46, 101807	1
642	COVID-19 and obesity: fighting two pandemics with intermittent fasting. 2021 , 32, 706-720	6
641	Coronavirus Disease-2019 (COVID-19): Course and Long-term Consequences. 2021 , 7, 271-291	1
640	Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study.	4
639	Epigenetic Mechanisms Underlying COVID-19 Pathogenesis. 2021 , 9,	4
638	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. 2021 , 93, 28-34	7
637	Impact of air pollution and smoking on COVID-19: a review. 2021 , 15,	
636	Status of Kidney Function in Hospitalised COVID-19 Patients in the Southern Gyeonggi Province, South Korea. 2021 , 53, 208-216	
635	Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value. 2021 , 99, 1741-1753	1

634	Angiotensin-Converting Enzyme 2 (SARS-CoV-2 receptor) expression in human skeletal muscle. 2021 , 31, 2249-2258	3
633	ACE2 in the Gut: The Center of the 2019-nCoV Infected Pathology. 2021 , 8, 708336	3
632	Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. 2021 , 95, e0143721	5
631	Development and application of a SARS-CoV-2 colorimetric biosensor based on the peroxidase-mimic activity of FeO nanoparticles. 2021 , 188, 335	4
630	Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management. 2021 , 174, 105916	0
629	Mechanisms of Damage to the Cardiovascular System in COVID-19. 2021 , 76, 287-297	3
628	Coronavirus disease 2019 and the gut-lung axis. 2021 , 113, 300-307	3
627	2019 novel Coronavirus: current knowledge, cardiovascular implications and management. 2021 , 69, 377-388	
626	Human genetic basis of coronavirus disease 2019. 2021 , 6, 344	4
625	The impact of ACE2 genetic polymorphisms (rs2106809 and rs2074192) on gender susceptibility to COVID-19 infection and recovery: A systematic review. 2021 , 2, 166-179	2
624	Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection. 2021 , 48, 116389	2
623	Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2). 2021 , 192, 114724	2
622	Know your enemy and know yourself - the case of SARS-CoV-2 host factors. 2021 , 50, 159-170	2
621	A novel hypothesis for COVID-19 pathogenesis: Retinol depletion and retinoid signaling disorder. 2021 , 87, 110121	3
620	Binding of SARS-COV-2 (COVID-19) and SARS-COV to human ACE2: Identifying binding sites and consequences on ACE2 stiffness. 2021 , 551, 111353	0
619	Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: Epigenetic modifications and therapeutic interventions by epidrugs. 2021 , 143, 112095	7
618	ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations. 2021 , 345, 113837	14
617	The physiologic and physiopathologic roles of perivascular adipose tissue and its interactions with blood vessels and the renin-angiotensin system. 2021 , 173, 105890	6

616	COVID-19 Infection in the Human Reproductive Tract of Men and Nonpregnant Women. 2021,	7
615	Computational insights into the membrane fusion mechanism of SARS-CoV-2 at the cellular level. 2021, 19, 5019-5028	0
614	Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study. 2021, 1	7
613	SARS-CoV-2 infection in K18-ACE2 transgenic mice replicates human pulmonary disease in COVID-19. 2021, 18, 513-514	13
612	Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients. 2021, 31, 1-12	22
611	Neurological and Neuropsychological Changes Associated with SARS-CoV-2 Infection: New Observations, New Mechanisms. 2021, 1073858420984106	13
610	Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. 2021, 1	4
609	Interferon-regulated genetic programs and JAK/STAT pathway activate the intronic promoter of the short ACE2 isoform in renal proximal tubules. 2021,	0
608	Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS). 2020, 7, 624093	5
607	Does SARS-CoV-2 Threaten Male Fertility?. 2021, 1321, 139-146	2
606	SARS-CoV-2 Infection of Airway Epithelial Cells. 2021, 21, e3	18
605	Angiotensin Converting Enzyme 2: A Critical Regulator of the Renin-Angiotensin System. 2006, 129-142	1
604	Insights from the association of SARS-CoV S-protein with its receptor, ACE2. 2006, 581, 209-18	16
603	Infection of human airway epithelia by SARS coronavirus is associated with ACE2 expression and localization. 2006, 581, 479-84	22
602	Proteases and Arrhythmias. 2003, 191-218	2
601	Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. 2014, 259-289	4
600	Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2). 2017, 1527, 101-115	19
599	The Intrarenal Renin-Angiotensin System. 2007, 3-22	4

598	Systemic Versus Local Renin Angiotensin Systems. An Overview. 2009 , 1-5	3
597	The Angiotensin-(1-7) Axis: Formation and Metabolism Pathways. 2019 , 1-26	9
596	Brain. 2019 , 55-71	1
595	Kidney. 2019 , 117-130	2
594	Effects of Taurine on Blood Index of Hypothalamic Pituitary Adrenal (HPA) Axis of Stress-Induced Hypertensive Rat. 2015 , 803, 613-21	5
593	The Renin Angiotensin System and Diabetes. 2017 , 275-291	3
592	Pathophysiology of Hypertension. 2009 , 1485-1518	10
591	SARS Coronavirus Pathogenesis and Therapeutic Treatment Design. 2010 , 195-230	0
590	Angiotensin-(1 β). Its Contribution to Arterial Pressure Control Mechanisms. 2004 , 477-518	5
589	Knockout Models of the Renin-Angiotensin System. 2004 , 207-227	1
588	Role of the Renin-Angiotensin System in ARDS. 2012 , 171-181	1
587	Peptidyl-dipeptidase A/angiotensin I-converting enzyme. 2004 , 332-346	45
586	Angiotensinogen and Angiotensins. 2019 , 483-489	1
585	The Renin-Angiotensin System. 2008 , 343-357	2
584	Vitamin D and the Renin-Angiotensin System. 2005 , 871-881	3
583	Vasoactive Molecules and the Kidney. 2012 , 384-420	2
582	SARS-CoV-2 and diabetes: New challenges for the disease. 2020 , 164, 108228	39
581	Fetal Growth Restriction and Hypertension in the Offspring: Mechanistic Links and Therapeutic Directions. 2020 , 224, 115-123.e2	9

580	Drugs acting on renin angiotensin system and use in ill patients with COVID-19. 2020 , 75, 319-325	4
579	A historical perspective on ACE2 in the COVID-19 era. 2021 , 35, 935-939	15
578	Identification and characterization of adipose surface epitopes. 2020 , 477, 2509-2541	6
577	AMPK: a balancer of the renin-angiotensin system. 2019 , 39,	32
576	ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. 2020 , 134, 747-750	41
575	Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19. 2020 , 134, 2489-2501	10
574	ACE2 in the renin-angiotensin system. 2020 , 134, 3063-3078	7
573	Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications. 2020 , 134, 2319-2336	10
572	Brain angiotensin converting enzyme-2 in central cardiovascular regulation. 2020 , 134, 2535-2547	8
571	ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. 2020 , 134, 2791-2805	7
570	ACE2 as therapeutic agent. 2020 , 134, 2581-2595	4
569	Angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) and Mas receptor in gonadal and reproductive functions. 2020 , 134, 2929-2941	5
568	ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. 2020 , 134, 2851-2871	19
567	Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease. 2020 , 134, 2645-2664	6
566	ACE2: from protection of liver disease to propagation of COVID-19. 2020 , 134, 3137-3158	15
565	ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19. 2020 , 134, 3229-3232	4
564	Design and study of the novel coumarin derivatives against SARS-CoV-2 main enzymes. 2020 , 1-16	4
563	Effects of exercise training on renal interstitial fibrosis and renin-angiotensin system in rats with chronic renal failure. 2021 , 39, 143-152	4

562	Subarachnoid hemorrhage and COVID-19: Association or coincidence?. 2020 , 99, e23862	17
561	Epidemiological approximation of the enteric manifestation and possible fecal-oral transmission in COVID-19: a preliminary systematic review. 2021 , 33, e21-e29	6
560	Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. 2021 , 30, 252-263	2
559	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis.	11
558	Structure of dimeric full-length human ACE2 in complex with B0AT1.	20
557	TWIRLS, an automated topic-wise inference method based on massive literature, suggests a possible mechanism via ACE2 for the pathological changes in the human host after coronavirus infection.	1
556	TWIRLS, an automated topic-wise inference method based on massive literature, suggests a possible mechanism via ACE2 for the pathological changes in the human host after coronavirus infection.	5
555	The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single cell transcriptome study.	9
554	Establishing Prokaryotic Expression System of Angiotensin-Converting Enzyme 2 (ACE2) gene in pigs.	1
553	Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study.	23
552	Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis.	28
551	Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis.	48
550	Single-cell RNA Analysis on ACE2 Expression Provides Insight into SARS-CoV-2 Blood Entry and Heart Injury.	2
549	ACE2 fragment as a decoy for novel SARS-Cov-2 virus.	4
548	Functional Immune Deficiency Syndrome via Intestinal Infection in COVID-19.	4
547	The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2.	6
546	Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue.	16
545	Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2.	2

544	Delayed clearance of SARS-CoV2 in male compared to female patients: High ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs.	45
543	ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study.	8
542	Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2.	20
541	SARS-CoV-2 Spike Glycoprotein and ACE2 interaction reveals modulation of viral entry in wild and domestic animals.	1
540	Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19.	2
539	Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease.	7
538	Detailed phylogenetic analysis of SARS-CoV-2 reveals latent capacity to bind human ACE2 receptor.	2
537	The SARS-CoV-2 receptor, Angiotensin converting enzyme 2 (ACE2) is required for human endometrial stromal cell decidualization. 2020,	7
536	Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.	18
535	A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection.	9
534	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. 2020,	6
533	Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells. 2020,	8
532	The flexibility of ACE2 in the context of SARS-CoV-2 infection. 2020,	6
531	SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients.	2
530	Increased Colonic Expression of ACE2 Associates with Poor Prognosis in Crohn's disease. 2020,	1
529	Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region.	6
528	Gene-targeting studies of the renin-angiotensin system: mechanisms of hypertension and cardiovascular disease. 2002, 67, 451-7	16
527	A Study on Understanding Potential Gold and Silver Nanoparticle : An Overview. 2021, 20, 2150009	3

526	Renal Autocrine and Paracrine Signaling: A Story of Self-protection. 2020 , 100, 1229-1289	5
525	Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients. 2020 , 2020, 6653851	2
524	Coronavirus infection and kidney disease: a review of current and emerging evidence. 2020 , 37, 149	3
523	Angiotensin-(1-7) Expressed From Lactobacillus Bacteria Protect Diabetic Retina in Mice. 2020 , 9, 20	5
522	Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. 2006 , 116, 2218-25	260
521	Naturally Occurring Animal Coronaviruses as Models for Studying Highly Pathogenic Human Coronaviral Disease. 2021 , 58, 438-452	12
520	Phosphatidylserine inside out: a possible underlying mechanism in the inflammation and coagulation abnormalities of COVID-19. 2020 , 18, 190	10
519	Neurological consequences of COVID-19: what have we learned and where do we go from here?. 2020 , 17, 286	39
518	COVID-19 susceptibility: potential of ACE2 polymorphisms. 2020 , 21,	12
517	Preface. 2006 , 14-15	8
516	Management of Atrial Fibrillation in COVID-19 Pandemic. 2020 , 84, 1679-1685	9
515	Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. 2012 , 7, e40110	42
514	The effects of angiotensin II and angiotensin-(1-7) in the rostral ventrolateral medulla of rats on stress-induced hypertension. 2013 , 8, e70976	29
513	Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury. 2013 , 8, e71433	47
512	Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. 2014 , 9, e84683	36
511	Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells. 2014 , 9, e85958	42
510	New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. 2014 , 9, e87845	60
509	ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. 2014 , 9, e93449	43

508	Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy. 2014 , 9, e101270	22
507	Loss of prolyl carboxypeptidase in two-kidney, one-clip goldblatt hypertensive mice. 2015 , 10, e0117899	9
506	The ACE2/Ang-(1-7)/Mas Axis Regulates the Development of Pancreatic Endocrine Cells in Mouse Embryos. 2015 , 10, e0128216	23
505	Epistasis Test in Meta-Analysis: A Multi-Parameter Markov Chain Monte Carlo Model for Consistency of Evidence. 2016 , 11, e0152891	6
504	Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease. 2016 , 11, e0161760	10
503	Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. 2017 , 12, e0171975	8
502	Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. 2020 , 15, e0240647	17
501	Kidney ACE2 expression: Implications for chronic kidney disease. 2020 , 15, e0241534	11
500	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. 2020 , 16, e1009163	12
499	Pathophysiological background and clinical practice of lung ultrasound in COVID-19 patients: A short review. 2020 , 24, 76-80	6
498	Impact of hyperthyroidism on cardiac hypertrophy. 2020 ,	11
497	Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19. 2020 , 19, 2580	4
496	ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2. 2020 , 43, e20200104	17
495	The role of the renin-angiotensin system in the appearance and progression of renal cell carcinoma: a literature review. 2019 , 15, 143-149	1
494	ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. 2020 , 12, 6518-6535	49
493	SARS-CoV-2, immunosenescence and inflammaging: partners in the COVID-19 crime. 2020 , 12, 18778-18789	23
492	Influence of aging on deterioration of patients with COVID-19. 2020 , 12, 26248-26262	6
491	Insufficient hypothalamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats. 2017 , 8, 20244-20251	8

490	Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity. 2018 , 9, 35500-35511	13
489	Fibrosis and renin-angiotensin-aldosterone system activity. Reality and future prospects. 2012 , 18, 449-458	6
488	Renin-angiotensin-aldosterone system in new coronavirus infection 2019. 2020 , 26, 240-247	7
487	COVID-19 - Endothelial Axis and Coronary Artery Bypass Graft Patency: a Target for Therapeutic Intervention?. 2020 , 35, 757-763	4
486	Beneficial Effects of the Angiotensin-Converting Enzyme 2 Activator Dize in Renovascular Hypertension. 2019 , 26, 523-531	5
485	The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence. 2020 , 27, 463-475	13
484	The Renin Angiotensin System and Bipolar Disorder: A Systematic Review. 2020 , 27, 520-528	4
483	Angiotensin II blockade and renal protection. 2013 , 19, 3033-42	53
482	ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors. 2020 , 21, 892-901	8
481	Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2. 2020 , 20, 2362-2378	4
480	Angiotensin-converting Enzyme 2 roles in the Pathogenesis of COVID-19. 2020 ,	4
479	Cellular Mechanisms of Valvular Thickening in Early and Intermediate Calcific Aortic Valve Disease. 2018 , 14, 264-271	15
478	Many Faces of Renin-angiotensin System - Focus on Eye. 2017 , 11, 122-142	79
477	The renin angiotensin system and the metabolic syndrome. 2010 , 3, 1-13	11
476	Epidemiological situation of a new coronavirus infection (COVID-19) in the Rostov region: analysis and forecast. 2020 , 11, 69-78	5
475	COVID-19 y su asociaci3n con los inhibidores de la enzima convertidora de angiotensina y los antagonistas de los receptores para angiotensina II. 2020 , 63, 30-34	2
474	Distribution of COVID-19 and Phylogenetic Tree Construction of SARS-CoV-2 in Indonesia. 2020 , 14, 1035-10426	
473	The Use of Core Warming as a Treatment for Coronavirus Disease 2019 (COVID-19): an Initial Mathematical Model. 2020 , 33, 6-15	1

472	Coronavirus disease 2019 infection and the cardiovascular system. 2020 , 21, 403-405	9
471	COVID-19 and vascular disorders (literature review). 2020 , 19, 90-98	16
470	ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review. 2020 , 9, 97-105	11
469	Coronavirus Disease 2019: Latest Data on Neuroinvasive Potential. 2020 , 45, 325-332	2
468	Perindoprilat changes ANG (1-9) production in renal arteries isolated from young spontaneously hypertensive rats after ANG I incubation. 2016 , 65, 561-570	1
467	The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection. 2021 , 12, 627260	14
466	A Guide to the Short, Long and Circular RNAs in Hypertension and Cardiovascular Disease. 2020 , 21,	8
465	Bibliometric analysis of global scientific research on Coronavirus (COVID-19). 2020 , 34, 51	28
464	COVID-19, Renin-Angiotensin System, Angiotensin-Converting Enzyme 2, and Nicotine: What is the Interrelation?. 2020 , 115, 708-711	2
463	Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. 2009 , 15, 942-54	141
462	Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. 2020 , 26, 6111-6140	8
461	Lung Pathology in COVID-19: A Systematic Review. 2020 , 10, 226-233	9
460	Effects on Cell Viability and on Apoptosis in Tumoral (MCF-7) and in Normal (MCF10A) Epithelial Breast Cells after Human Chorionic Gonadotropin and Derivated-Angiotensin Peptides Treatments. 2013 , 04, 65-69	2
459	Role of the renin angiotensin system in diabetic nephropathy. 2010 , 1, 141-5	63
458	COVID-19: Critical Role of Angiotensin 1-7 in ACE2 Modulation. 2020 , 49, 398-400	5
457	Ocular renin-angiotensin system with special reference in the anterior part of the eye. 2015 , 5, 110	2
456	The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role?. 2020 , 74, 134-138	30
455	Oxidative stress-mediated effects of angiotensin II in the cardiovascular system. 2012 , 2, 34-44	55

454	ACE and ACE2 in kidney disease. 2015 , 4, 74-82	107
453	Pulmonary rehabilitation principles in SARS-CoV-2 infection (COVID-19): A guideline for the acute and subacute rehabilitation. 2020 , 66, 104-120	30
452	Comparative molecular docking analysis of the SARS CoV-2 Spike glycoprotein with the human ACE-2 receptors and thrombin. 2020 , 16, 532-538	3
451	ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. 2020 , 9,	143
450	Basal Ganglia Involvement and Altered Mental Status: A Unique Neurological Manifestation of Coronavirus Disease 2019. 2020 , 12, e7869	24
449	Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS. 2020 , 12, e8411	5
448	Respiratory epithelium: Place of entry and / or defense against SARS-CoV-2 virus. 2021 , 50, 35-43	
447	Risk Factors of COVID-19 Critical Outcomes in the Eastern Mediterranean Region: A Multicountry Retrospective Study. 2021 ,	0
446	Purification of Angiotensin-Converting Enzyme (ACE) from Sheep Kidney and Inhibition Effect of Reduced Nicotinamide Adenine Dinucleotide (NADH) on Purified ACE Activity. 2021 , 1	0
445	SARS-CoV-2 multi-variant graphene biosensor based on engineered dimeric ACE2 receptor.	1
444	A novel method for producing functionalized vesicles that efficiently deliver oligonucleotides in vitro in cancer cells and in vivo in mice.	0
443	The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. 2021 , 49, 647	3
442	ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. 2021 , 22,	1
441	Mechanisms of SARS-CoV-2 entry into cells. 2021 ,	228
440	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. 2021 , 33, e2103471	16
439	Malaria, COVID-19 and angiotensin-converting enzyme 2: what does the available population data say?. 2021 , 11, 210213	0
438	Peptides and peptidomimetics as therapeutic agents for Covid-19.. 2021 , e24245	2
437	There is no "origin" to SARS-CoV-2. 2021 , 112173	2

- 436 Angiotensin converting enzyme 2 (ACE2) is expressed in murine cutaneous under single-cell transcriptome resolution.
- 435 The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.. **2021**, 14, 2705-2713
- 434 Role of ACE2-Ang (1-7)-Mas axis in post-COVID-19 complications and its dietary modulation. **2021**, 477, 225 0
- 433 ACE2: a key modulator of the renin-angiotensin system and pregnancy. **2021**, 321, R833-R843 4
- 432 COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. **2021**, 7
- 431 Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?. **2021**, 12, 725967 3
- 430 Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity. **2021**, 14, 1686-1692 2
- 429 Genetics of the Human Renin-Angiotensin System. **2004**, 173-206
- 428 The Role of the Renin-Angiotensin System in Hepatic Fibrosis. **2007**, 113-134 1
- 427 Angiotensin-Converting Enzyme-2 (ACE2). **2007**, 1-4 1
- 426 Role of ACE, ACE2 and Neprilysin in the Kidney. **2007**, 1-20
- 425 Regulation of Cardiovascular Control Mechanisms by Angiotensin-(1 α) and Angiotensin-Converting Enzyme 2. **2007**, 43-59 1
- 424 ACE Inhibition in Heart Failure and Ischaemic Heart Disease. **2007**, 21-54
- 423 Structural and Electrophysiological Remodeling of the Failing Heart. **2009**, 81-91
- 422 Newer Insights into the Biochemical Physiology of the Renin-Angiotensin System: Role of Angiotensin-(1-7), Angiotensin Converting Enzyme 2, and Angiotensin-(1-12). **2009**, 7-17
- 421 Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System. **2010**, 121-133
- 420 The Cell Biology of the SARS Coronavirus Receptor, Angiotensin-Converting Enzyme 2. **2010**, 23-30 2
- 419 Molecular tools in drug research \square translational medicine. **2010**, 241-260

- 418 Vitamin D, Renin, and Blood Pressure. **2010**, 937-953 1
- 417 The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. 635-656 1
- 416 Vasoactive Factors and Blood Pressure in Children. **2011**, 23-40
- 415 Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. **2011**, 161-181
- 414 Pharmacology of Vasopressin and the Renin-Angiotensin-Aldosterone System.
- 413 The Regulatory Effect of Renin-Angiotensin-Aldosterone System on Insulin Secretion. **2013**, 01, 11-15
- 412 angiotensin-converting enzyme 2 3.4.17.23. **2013**, 29-64
- 411 The ACE2/Ang-(1-7) Pathway in Cardiac Fibroblasts as a Potential Target for Cardiac Remodeling. **2013**, 547-557 1
- 410 Pre-primary and Primary Prophylaxis of Variceal Hemorrhage. **2014**, 75-96
- 409 Anti-hypertensive Compounds in Miso.. **2015**, 110, 636-648
- 408 Renin-Angiotensin System. **2015**, 1-51
- 407 Mechanisms of the Renin Angiotensin System Influencing Atherosclerosis. 207-219
- 406 Renin-Angiotensin System. **2016**, 665-707
- 405 Severe acute dehydration in a desert rodent elicits a transcriptional response that effectively prevents kidney injury. 0
- 404 Vasoactive Factors and Blood Pressure in Children. **2017**, 1-19
- 403 Vasoactive Factors and Blood Pressure in Children. **2018**, 27-45
- 402 New Insights into the Pathogenesis of Intradialytic Hypertension. **2018**, 11, 87-99
- 401 CHAPTER 15: Bioactivities and Mechanisms of Egg Protein-derived Peptides. **2019**, 285-304

400 Phosphorus Retention and Elevated FGF-23 in Chronic Kidney Disease. **2019**, 207-221

399 Liver. **2019**, 191-199

398 Intradialytic hypotension: beyond hemodynamics. **2019**, 68, 793-805

0

397 [The renin-angiotensin-aldosterone system as a potential target for therapy in patients with calcific aortic stenosis: a literature review]. **2019**, 59, 4-17

1

396 SARS-CoV-2 receptor mutation in Egyptian population.

1

395 Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs.

394 Prefusion spike protein stabilization through computational mutagenesis.

393 The Effect of SARS-COV-2 Viruses on the Function of Different Organs, Especially the Nervous System. **2020**, 8, 111-121

392 Receptor utilization of angiotensin converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.

391 Multi-organ Proteomic Landscape of COVID-19 Autopsies.

390 COVID-19 İN MOLEKÜLER TANI YÖNTEMLERİNİN GENEL BAKIŞI **2020**, 11, 72-79

389  (COVID-19)

1

388 Role of selective Bioactive Compounds as an Angiotensin Converting Enzyme Inhibitor.

387 Enhancement of SARS-CoV-2 Receptor Binding Domain -CR3022 Human Antibody Binding Affinity via In silico Engineering Approach. **2021**, 9, 156-169

386 Histopathological assessments reveal retinal vascular changes, inflammation, and gliosis in patients with lethal COVID-19. **2021**, 1

2

385 Downregulation of is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma. **2021**, 17, 5033-5044

0

384 Whey-Derived Peptides at the Heart of the COVID-19 Pandemic. **2021**, 22,

0

383 Relationship between kalemia and intensive care unit admission or death in hospitalized COVID-19 patients: A cohort study.. **2022**, 47, 3-10

382	Dynamic Regulation of SARS-CoV-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium.	0
381	Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma. 2020 , 26, e927078	1
380	The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities. 2020 , 26,	0
379	Activation of Kinin B1R Upregulates ADAM17 and Results in ACE2 Shedding in Neurons. 2020 , 22,	4
378	Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease. 2021 , 35, 22-32	2
377	Therapeutic approaches on the interaction between SARS-CoV2 and ACE2: a biochemical perspective. 2020 , 45, 643-650	0
376	COVID-19 and Renal Diseases: An Update. 2021 , 22, 52-67	8
375	COVID-19 and men's reproductive health (literature review). 2020 , 26, 17	0
374	A glance upon Epigenetic and COVID-19. 2020 , 92, e20201451	3
373	nCOVID-19: Its diagnosis, possible preventive measures, therapeutic interventions and management. 2020 , 115-129	
372	A current novel perspective approach for coronavirus disease-2019 pandemic outbreak. 2021 , 12, 311-320	0
371	Understanding the Interplay between COVID-19 and Diabetes Mellitus. 2020 , 08, 1-12	0
370	Laboratory Changes in SARS-CoV-2 Infection: A Review. 2021 , 24, 62-65	
369	The role of angiotensin-converting-enzyme 2 in the age- and sex related poor prognosis of COVID-19. A comment on recent findings on novel coronavirus infection by SARS-CoV-2.	1
368	An ongoing debate: Are the patients receiving angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers more susceptible to COVID-19 ?. 2020 , 25, 79-84	
367	SARS-CoV-2 effect on male infertility and its possible pathophysiological mechanisms. 2021 , 9, e131	4
366	Prognostic value of NT-proBNP in patients with severe COVID-19.	5
365	El origen de COVID-19: lo que se sabe, lo que se supone y (muy poquito) sobre las teorías de complot. 2020 , 31, 3	3

- 364 Is there any relationship between serum zinc levels and angiotensin-converting enzyme 2 gene expression in patients with coronavirus disease 2019?. **2022**, 31, 100991 2
- 363 Phylogenetic and Ancestral Sequence Reconstruction of SARS-CoV-2 Reveals Latent Capacity to Bind Human ACE2 Receptor. **2021**, 89, 656-664 2
- 362 Female fertility under the impact of COVID-19 pandemic: a narrative review. 1-21 0
- 361 Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. **2021**, 13, 0
- 360 Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. **2021**, 351, 109738 4
- 359 An Introduction to SARS Coronavirus 2; Comparative Analysis with MERS and SARS Coronaviruses: A Brief Review. **2020**, 49, 30-37
- 358 The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis. 0
- 357 Comment on paper "the role of angiotensin-converting-enzyme 2 receptor in SARS-CoV-2 infections, and new perspective for future therapies. A brief review on recent literature". **2020**, 9, 0
- 356 Levistilide A reverses rat hepatic fibrosis by suppressing angiotensin II-induced hepatic stellate cells activation. **2020**, 22, 2191-2198 1
- 355 Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulären System. **2006**, 377-407
- 354 Angiotensin II and Its Receptors in the Pathogenesis of Diabetic Nephropathy. **2006**, 3-21
- 353 Discovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach. 3
- 352 Knowledge on the Pathogenesis and New Diagnosing Techniques Approach for Low SARS-CoV-2 Testing Rates: A Case Study of Nigeria. **2020**, 5, em0064
- 351 Male Sex May Be the Defining Factor in Predicting Susceptibility to and Severity of SARS-CoV-2 Infection: A Case Series. 0
- 350 TAMERON (SODIUM AMINODIGYROPHTHALAZINEDIONE) AS A POTENT IAL COMPLEX DRUG FOR THE TREATMENT OF CORONAVIRUS INFECTION COVID-19. **2020**, 6, 67-75
- 349 Pathogenesis-based pre-exposure prophylaxis associated with low risk of SARS-CoV-2 infection in healthcare workers at a designated Covid-19 hospital. 1
- 348 Mechanism of ligand recognition by human ACE2 receptor. **2020**, 2
- 347 Diabetes mellitus and COVID-19: current issues of pathogenesis, clinic and therapy. Literature review. **2020**, 8-21 1

346	Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. 2007 , 3, 125-37	71
345	The renin-angiotensin system and diabetes: an update. 2008 , 4, 787-803	88
344	Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra. 2011 , 2, 257-74	23
343	Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. 2012 , 1, 226-44	20
342	Expression and cellular localization of the Mas receptor in the adult and developing mouse retina. 2014 , 20, 1443-55	13
341	ACE2-Ang (1-7) axis is induced in pressure overloaded rat model. 2015 , 8, 1443-50	8
340	Human umbilical cord mesenchymal stem cells and exosomes: bioactive ways of tissue injury repair. 2019 , 11, 1230-1240	29
339	Pharmacological approaches to the treatment of COVID-19 patients. 2020 , 6,	
338	[Association of age distribution with the expression of angiotensin-converting enzyme 2 in lung tissues in severe acute respiratory syndrome coronavirus 2 infection: reflections from the study of RAS pathway expression in mice]. 2020 , 22, 1119-1124	
337	Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection. 2020 , 34, 120	1
336	Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Cytokine Pathways Involved in COVID-19 After Rhinovirus Infection in Asthma Patients. 2020 , 26, e928861	2
335	Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation. 2021 , 80, 52-61	19
334	Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. 2021 , 8, 54-60	
333	The clinical characters and prognosis of COVID-19 patients with multiple organ dysfunction. 2021 , 100, e27400	
332	SARS-CoV-2 involvement in central nervous system tissue damage. 2022 , 17, 1228-1239	9
331	Public health and management. 2022 , 1-40	
330	Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. 2021 , 164, 69-82	8
329	Susceptibilities of human ACE2 genetic variants in coronavirus infection. 2021 , JVI0149221	2

328	The clinical characters and prognosis of COVID-19 patients with multiple organ dysfunction. 2021 , 100, e27400	1
327	Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19. 2021 , 12, 674074	4
326	Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It.. 2021 , 2021, 9293553	1
325	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. 2021 , 1, 233-258	1
324	Does COVID-19 Affect Adult Neurogenesis? A Neurochemical Perspective.	
323	Anticipated pharmacological role of Aviptadil on COVID-19. 2021 , 1	2
322	Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?. 2021 , 2, 38	2
321	Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19. 2021 , 22,	2
320	COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy. 2021 , 4, e440	3
319	Implications of testicular ACE2 and the renin-angiotensin system for SARS-CoV-2 on testis function. 2021 ,	5
318	Understanding the role of nACE2 in neurogenic hypertension among COVID-19 patients. 2021 ,	1
317	Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. 2021 , 6, 255	5
316	Neurological complications and infection mechanism of SARS-COV-2. 2021 , 6, 406	16
315	ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. 2021 , 12, 6791	9
314	Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. 2021 ,	10
313	SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases. 2021 , 14, 6191-6221	11
312	Interaction between Spike Protein of SARS-CoV-2 and Human Virus Receptor ACE2 Using Two-Color Fluorescence Cross-Correlation Spectroscopy. 2021 , 11, 10697	0
311	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. 2021 ,	0

310	Tracking the amino acid changes of spike proteins across diverse host species of severe acute respiratory syndrome coronavirus 2. 2021 , 103560	1
309	CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. 2021 , 808, 152072	14
308	Interactions amongst inflammation, renin-angiotensin-aldosterone and kallikrein-kinin systems: suggestive approaches for COVID-19 therapy.. 2021 , 27, e20200181	3
307	Urinary angiotensin converting enzyme 2 and disease activity in pediatric IgA nephropathy. 2021 , 68, 292-296	
306	Insights Into the Role of Angiotensin-Converting Enzyme 2 in the Onset of Severe Acute Respiratory Syndrome Coronavirus 2 Pathogenesis. 2021 , 233-252	
305	–Morinda citrifolia– (Noni) Fruit Juice Inhibits SARS-CoV-2 Spike Protein Binding of Angiotensin-Converting Enzyme 2 (ACE2). 2021 , 09, 42-51	2
304	The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs.. 2021 , 12, 805535	5
303	High serum angiotensin-converting enzyme 2 activity as a biomarker of frailty in nursing home residents.. 2021 , 158, 111655	2
302	SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties.. 2021 , 100, 267-277	14
301	Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking.. 2021 , 301, 114424	3
300	High Levels of Pro B-Type Natriuretic Peptides Are Associated with Adverse Outcomes in COVID-19 Disease: A Single Center Experience. 2020 , 2,	
299	Angiotensin-Converting-Enzyme 2 and SARS-CoV2: A Dangerous Liaison. 2020 , 2020, 1	
298	Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Cytokine Pathways Involved in COVID-19 After Rhinovirus Infection in Asthma Patients. 2020 , 27, e928861	2
297	Renin-Angiotensin-Aldosterone System. 2021 ,	0
296	Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. 2021 , 8, 54-60	0
295	Damage to the Vascular Endothelium as a Leading Mechanism of COVID-19 Systemic Pathology. 2021 , 11, 559-566	1
294	Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs.. 2022 , 28, 275-289	2
293	Scavenger receptors in host defense: from functional aspects to mode of action.. 2022 , 20, 2	4

292	Non-immune Prophylaxis Against COVID-19 by Targeting Tolerance for Angiotensin II-Triggered SARS-CoV-2 Pathogenesis.. 2021 , 8, 776903	1
291	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.. 2022 , 18, 459-472	7
290	Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids.. 2022 , 25, 103818	0
289	Prognostic Factors for COVID-19 Hospitalized Patients with Preexisting Type 2 Diabetes.. 2022 , 2022, 9322332	0
288	Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy.. 2021 , 12, 813012	2
287	Docking study of transmembrane serine protease type 2 inhibitors for the treatment of COVID-19.. 2022 , 27-39	
286	Arterial Hypertension. 2022 ,	
285	Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19.. 2022 , 12,	4
284	Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19.. 2022 , 14,	2
283	HiSpike Method for High-Throughput Cost Effective Sequencing of the SARS-CoV-2 Spike Gene.. 2021 , 8, 798130	1
282	Pathogenesis: Hemodynamic Alterations. 2022 , 75-104	
281	Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients.. 2021 , 8, 785744	
280	Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Score-Matched Cohort Study.. 2022 , 11,	1
279	(Pro)renin Receptor and Blood Pressure Regulation: A Focus on the Central Nervous System.. 2022 ,	0
278	Bulbus Fritillariae Cirrhosae as a Respiratory Medicine: Is There a Potential Drug in the Treatment of COVID-19?. 2021 , 12, 784335	0
277	Overexpression of the SARS-CoV-2 receptor angiotensin converting enzyme 2 in cardiomyocytes of failing hearts.. 2022 , 12, 965	2
276	Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants.	2
275	Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.	

- 274 Inhibition of ACE2-Spike interaction by an ACE2 binder suppresses SARS-CoV-2 entry.. **2022**, 1
- 273 Diminazene aceturate, an angiotensin converting enzyme 2 (ACE2) activator, promotes cardioprotection in ischemia/reperfusion-induced cardiac injury.. **2022**, 151, 170746 0
- 272 Research Progress on Relationship between Angiotensin Converting Enzyme 2 and Atherosclerosis. **2022**, 12, 846-851
- 271 Gender Disparity in CoViD19. **2022**, 371-394
- 270 Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19.. **2022**, 2022, 7423537 1
- 269 Are angiotensin converting enzyme (ACE1/ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A single-center cohort study.. **2022**, 26, 133-140 0
- 268 SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids.. **2021**, 24
- 267 Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2.. **2022**, 101710 4
- 266 Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review.. **2022**, 14, 1
- 265 Type 1 diabetes is associated with significant changes of ACE and ACE2 expression in peripheral blood mononuclear cells.. **2022**, 1
- 264 Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation.. **2022**, 151, 170766 3
- 263 Renin-angiotensin system in normal pregnancy and in preeclampsia: A comprehensive review.. **2022**, 28, 15-20 0
- 262 Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. **2021**, 196, 105197 4
- 261 Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites.. **2021**, 11, 24336 2
- 260 SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.. **2021**, 17, e1010175 4
- 259 Molekularni mehanizam patogenog delovanja virusa SARS-CoV-2, uloga ACE2 receptora u generisanju surfaktanta i odrnjenju stabilnosti velikih funkcionalnih povrha. **2021**, 46, 178-184
- 258 Blood Pressure, Proteases and Inhibitors. **2022**,
- 257 Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. **2022**, 53, 51-76 1

256	Diabetes, heart damage, and angiotensin II. What is the relationship link between them? A minireview.. 2022 , 56, 55-65	1
255	COVID-19 and Male Reproduction: A Thorny Problem.. 2022 , 16, 15579883221074816	1
254	COVID-19 Pandemic: What Considerations Should Be Taken during the Assessment and Management of COPD Exacerbation?. 2022 , 10, 71-80	
253	Effects of Exercise Training on the Renin-Angiotensin System in the Kidneys of Dahl Salt-Sensitive Rats.. 2022 ,	0
252	The ACE2 Receptor for Coronavirus Entry Is Localized at Apical Cell-Cell Junctions of Epithelial Cells.. 2022 , 11,	2
251	Molecular and Physiological Aspects of SARS-CoV-2 Infection in Women and Pregnancy.. 2022 , 3, 756362	
250	Simian Immunodeficiency Virus Infection Mediated Changes in Jejunum and Peripheral SARS-CoV-2 Receptor ACE2 and Associated Proteins or Genes in Rhesus Macaques.. 2022 , 13, 835686	1
249	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets.. 2022 , 23,	1
248	Inhibitory mechanism of clioquinol and its derivatives at the exopeptidase site of human angiotensin-converting enzyme-2 and receptor binding domain of SARS-CoV-2 viral spike.. 2022 , 1-10	0
247	In Silico Studies of Phytoconstituents from Piper longum and Ocimum sanctum as ACE2 and TMRSS2 Inhibitors: Strategies to Combat COVID-19.. 2022 , 1	1
246	Does the Fetus Limit Antibiotic Treatment in Pregnant Patients with COVID-19?. 2022 , 11,	0
245	COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences.. 2022 , 10, 824851	5
244	Emerging complications of COVID-19 in a subset of Indian population: a pathological review with clinico-radiological case scenarios. 2022 , 53,	
243	The collectrin-like part of the SARS-CoV-1 and -2 receptor ACE2 is shed by the metalloproteinases ADAM10 and ADAM17.. 2022 , 36, e22234	1
242	SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease.. 2022 , 19, 48	4
241	Virtual Screening of Natural Chemical Databases to Search for Potential ACE2 Inhibitors.. 2022 , 27,	
240	Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2.. 2022 , e2100360	1
239	Theoretical Investigation of the Coronavirus SARS-CoV-2 (COVID-19) Infection Mechanism and Selectivity.. 2022 , 27,	

238	Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate.. 2022 , 13, 868679	1
237	Effect of Calamintha officinalis on Vascular Contractility and Angiotensin-converting Enzyme-2.. 2022 ,	
236	Role of the Microbiome in the Pathogenesis of COVID-19.. 2022 , 12, 736397	0
235	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2.. 2022 , 10, 801870	2
234	Crosstalk between SARS-CoV-2 Infection and Type II Diabetes.. 2022 ,	0
233	Cannabidiol and SARS-CoV-2 Infection.. 2022 , 13, 870787	1
232	It Ain't Over 'Til It's Over: SARS CoV-2 and Post-infectious Gastrointestinal Dysmotility.. 2022 , 1	1
231	SARS-CoV-2 Spike Glycoprotein and ACE2 Interaction Reveals Modulation of Viral Entry in Wild and Domestic Animals.. 2021 , 8, 775572	0
230	A Novel Modulator of the Renin-Angiotensin System, Benzoylaconitine, Attenuates Hypertension by Targeting ACE/ACE2 in Enhancing Vasodilation and Alleviating Vascular Inflammation.. 2022 , 13, 841435	1
229	Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention.. 2022 , 9, 782602	1
228	Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents.. 2022 ,	1
227	Molecular docking between human TMPRSS2 and the serine protease Kunitz-type inhibitor rBmTI-A.	
226	ACE2 gene expression and inflammatory conditions in periodontal microenvironment of COVID-19 patients with and without diabetes evaluated by qPCR.	0
225	Investigating underlying human immunity genes, implicated diseases and their relationship to COVID-19.. 2022 ,	0
224	ACE2 Receptor and Its Isoform Short-ACE2 Are Expressed on Human Spermatozoa.. 2022 , 23,	0
223	The role of membrane and circulating forms of ACE 2 in pathological processes in COVID-19 infection. 2022 , 27, 608-616	
222	ACE2 maybe serve as a prognostic biomarker in breast invasive carcinoma.. 2022 , e24362	
221	A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions.. 2022 ,	1

220	Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2.. 2022 , 105512	0
219	Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme.. 2022 , 13, 840785	0
218	Diabetic kidney disease, a potentially serious issue resulting from collision of the Covid-19 and diabetes global pandemics. 2022 ,	
217	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.. 2022 , 14, 2057832	2
216	Severe acute respiratory syndrome and thyroid: A molecular point of view.. 2022 , 48, 1-4	1
215	Jumping From Fragment To Drug Via Smart Scaffolds.. 2022 ,	0
214	Renin-angiotensin system (RAS) enzymes and placental trophoblast syncytialisation.. 2022 , 547, 111609	2
213	Design and various in silico studies of the novel curcumin derivatives as potential candidates against COVID-19 -associated main enzymes.. 2022 , 98, 107657	0
212	Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.. 2021 , 11, e050051	0
211	Pierce into Structural Changes of Interactions Between Mutated Spike Glycoproteins and ACE2 to Evaluate Its Potential Biological and Therapeutic Consequences.. 2022 , 28, 33	1
210	Coronavirus Disease 19 and Thyroid Disease. 2021 , 32, 179-188	
209	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. 2021 , e023535	3
208	The Effects of Angiotensin II or Angiotensin 1-7 on Rat Pial Microcirculation during Hypoperfusion and Reperfusion Injury: Role of Redox Stress.. 2021 , 11,	
207	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours.. 2021 , 9,	3
206	Effect of Cysteine Oxidation in SARS-CoV-2 Receptor-Binding Domain on Its Interaction with Two Cell Receptors: Insights from Atomistic Simulations.. 2021 ,	2
205	Allosteric control of ACE2 peptidase domain dynamics.. 2022 ,	0
204	ACE2, BAT1, and SARS-CoV-2 spike protein: Structural and functional implications.. 2022 , 74, 102388	0
203	An ACE2-Alamandine Axis Modulates the Cardiac Performance of the Goldfish via the NOS/NO System.. 2022 , 11,	0

202	Immunonutrition and SARS-CoV-2 Infection in Children with Obesity.. 2022 , 14,	0
201	Image_1.pdf. 2018 ,	
200	Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells.. 2022 ,	1
199	SARS-COV-2 - the pandemic of the XXI century, clinical manifestations - neurological implications.. 2022 , 15, 319-327	1
198	Potential Dietary Interventions for COVID-19 Infection Based on the Gut-Immune Axis: An Update Review on Bioactive Component of Macronutrients. 2021 , 12, 105	0
197	Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach.. 2022 , 8, 125-137	
196	HAVA KBLIIVE COVID-19.	
195	SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review. 2022 , 10, 962	0
194	Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway.. 2022 ,	0
193	Extracellular vesicles enclosed-miR-421 suppresses air pollution (PM)-induced cardiac dysfunction via ACE2 signalling.. 2022 , 11, e12222	0
192	In silico mutational analysis of ACE2 to check the susceptibility of lung cancer patients towards COVID-19.. 2022 , 12, 7798	
191	From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases?. 2022 , 13,	1
190	Clinical course and outcomes of COVID-19 patients with chronic obstructive pulmonary disease: A retrospective observational study in Wuhan, China.. 2022 , 101, e29141	0
189	SARS-CoV-2 Infection-Of Music and Mechanics of Its ! A Perspective.. 2022 ,	0
188	Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2.. 2022 , 114, 108201	1
187	Impaired Vagal Activity in Long-COVID-19 Patients. 2022 , 14, 1035	3
186	Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies. 2007 , 12, 639-650	12
185	Nanokit coupled electrospray ionization mass spectrometry for analysis of angiotensin converting enzyme 2 activity in single living cell. 2022 ,	0

184	Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.. 2022 , 23, 180	1
183	The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients.. 2022 ,	2
182	Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach.. 2022 , 8, 127-146	0
181	Engineered Soluble ACE2 Protein and SARS-CoV-2 Variants of Concern (VOCs). 2022 , 03,	
180	Effect on the conformations of spike protein of SARS-CoV-2 due to mutation.	0
179	Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. 2022 , 12,	2
178	The role of angiotensin-converting enzyme 2 (ACE2) genetic variations in COVID-19 infection: a literature review. 2022 , 23,	0
177	Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes. 2022 , 9,	0
176	Identification of vaccine targets & design of vaccine against SARS-CoV-2 coronavirus using computational and deep learning-based approaches. 10, e13380	2
175	Protective neutralizing epitopes in SARS-CoV-2.	3
174	The key role of Calpain in COVID-19 as a therapeutic strategy.	1
173	Compliance with Vaccination against SARS-CoV-2; Information Transmission Based on Scientific Evidence and Its Difficulty. 2022 , 142, 601-609	
172	In silico SARS-CoV-2 vaccine development for Omicron strain using reverse vaccinology.	0
171	A comprehensive review on modulation of SIRT1 signaling pathways in the immune system of COVID -19 patients by phytotherapeutic melatonin and epigallocatechin-3-gallate.	0
170	Pathogenesis and mutagenesis of SARS-CoV-2. 2022 , 81-99	
169	Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection. 2022 , 145-189	1
168	Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication. 2022 , 23,	0
167	Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents. 2022 , 17, e0268806	0

166	Association of underlying comorbidities and progression of COVID-19 infection amongst 2586 patients hospitalised in the National Capital Region of India: a retrospective cohort study.	
165	Effect of Norelgestromin and Ethinylestradiol in Transdermal Patches on the Clinical Outcomes and Biochemical Parameters of COVID-19 Patients: A Clinical Trial Pilot Study. 2022 , 15, 757	0
164	Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.	2
163	Antihypertensive Activity of Prunus armeniaca in Hypertensive Rats. 2022 , 20,	
162	In Silico Molecular Dynamics of Griseofulvin and Its Derivatives Revealed Potential Therapeutic Applications for COVID-19. 2022 , 23, 6889	2
161	Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting. 2022 , 74, 462-505	1
160	On race, human variation, and who gets and dies of sepsis.	0
159	Databases, DrugBank, and virtual screening platforms for therapeutic development. 2022 , 291-334	
158	Effects of the Hormonal Replacement Therapy with Estrogen and Progestins on the Vascular Renin-Angiotensin System of Ovariectomized Rats.	
157	Cardiorenal Syndrome in COVID-19 Patients: A Systematic Review. 9,	0
156	Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. 2022 ,	4
155	Children With Short Stature Display Reduced ACE2 Expression in Peripheral Blood Mononuclear Cells. 13,	1
154	Cryo-EM reveals mechanisms of angiotensin I-converting enzyme allostery and dimerization.	
153	Vitamin C is an efficient natural product for prevention of SARS-CoV-2 infection by targeting ACE2 in both cell and in vivo mouse models.	
152	Amino acid sensor GCN2 promotes SARS-CoV-2 receptor ACE2 expression in response to amino acid deprivation. 2022 , 5,	0
151	The Need for Individualized Risk Assessment in Cardiovascular Disease. 2022 , 12, 1140	0
150	Mechanisms of COVID-19 Pathogenesis in Diabetes.	3
149	Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure. 2022 , 305, 120757	1

- 148 Immunohistochemical expression of angiotensin-converting enzyme 2 in superficial and deep maxillofacial tissues: A cross-sectional study. **2022**, 5,
- 147 Angiotensin-(1-9) in hypertension. **2022**, 115183 ○
- 146 Systematic Non-Invasive Experimental Analysis of Olfactory Dysfunction using EBG for COVID-19. **2022**,
- 145 Structural and Dynamic Insights into SARS-CoV-2 Spike-ProteinMontmorillonite Interactions. **2022**, 38, 9186-9194
- 144 ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury. **2022**, 17, e0270920
- 143 Urtica dioica Agglutinin: A plant protein candidate for inhibition of SARS-COV-2 receptor-binding domain for control of Covid19 Infection. **2022**, 17, e0268156 1
- 142 Coronavirus disease 2019, hypertension, and renin-angiotensin-aldosterone system inhibitors. **2022**, 37, 419-423 1
- 141 Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: allosteric communications between and within viral and human proteins. **2022**, ○
- 140 Discovery and Intranasal Administration of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against multiple Omicron sub variants. **2022**, 2
- 139 A Boolean approach for novel hypoxia-related gene discovery. **2022**, 17, e0273524
- 138 ALAMANDINE: A PROMISING TREATMENT FOR FIBROSIS. **2022**, 170848 1
- 137 Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents. 1
- 136 CRISPR-Cas system: from diagnostic tool to potential antiviral treatment. ○
- 135 Soluble ACE2 is Filtered into the Urine. 10.34067/KID.0001622022 ○
- 134 Interactions between the intrarenal dopaminergic and the renin-angiotensin systems in the control of systemic arterial pressure. **2022**, 136, 1205-1227 ○
- 133 A method for Boolean analysis of protein interactions at a molecular level. **2022**, 13, ○
- 132 Activation of angiotensin-converting enzyme 2 ameliorates metabolic syndrome-induced renal damage in rats by renal TLR4 and nuclear transcription factor **B** downregulation. 9, ○
- 131 Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: allosteric communications between and within viral and human proteins.

- 130 The association of ACE I/D polymorphism with the severity of COVID-19 in Iranian patients: A case-control study. **2022**, 34, 201099 ○
- 129 Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. **2023**, 251, 123813 ○
- 128 Food protein-derived bioactive peptides for the management of nutrition related chronic diseases. **2022**, ○
- 127 Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex. 1-11 ○
- 126 Food-derived bioactive peptides: production, biological activities, opportunities and challenges. **2022**, 2, 294-306 ○
- 125 Mechanism of action of drugs used in hypertension. **2023**, 349-367 ○
- 124 The prognostic importance of the angiotensin II/angiotensin-(1 β) ratio in patients with SARS-CoV-2 infection. **2022**, 16, 175346662211225 ○
- 123 Serum Angiotensin II as a Biomarker in COVID-19. **2022**, 1-24 ○
- 122 Brief Pathophysiology. **2022**, 139-146 ○
- 121 MOLECULAR GENETIC CHANGES IN THE TESTIS TISSUES OF COVID-19 PATIENTS. **2022**, 30, 18-24 ○
- 120 A systematic review of the advancement on colorimetric nanobiosensors for SARS-CoV-2 detection. **2023**, 222, 115087 ○
- 119 Correlation of Biomarkers in Severe COVID-19 Patients Cross-sectional Study. **2022**, 10, 2082-2086 ○
- 118 Human ACE-2, MCP1 and micro-RNA 146 as Novel Markers for COVID- 19 Affection and Severity. **2022**, 22, ○
- 117 Impact of COVID 19 on erectile function. **2022**, 25, 202-216 3
- 116 The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences. **2022**, 14, 1906 ○
- 115 Renal, Cardiac, Neurological, Cutaneous and Coagulopathic Long-term Manifestations of COVID-19 after Recovery; A review. 1-29 ○
- 114 Comparative transcriptome analysis reveals molecular adaptations underlying distinct immunity and inverted resting posture in bats. ○
- 113 Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies. **2022**, 12, ○

112	Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System. 2022 , 2022, 1-10	1
111	Is Diminazene an Angiotensin-Converting Enzyme 2 (ACE2) Activator? Experimental Evidence and Implications. 2022 , 383, 149-156	0
110	MIR99AHG inhibits EMT in pulmonary fibrosis via the miR-136-5p/USP4/ACE2 axis. 2022 , 20,	0
109	Acute kidney injury and electrolyte disorders in COVID-19. 11, 283-292	0
108	In Silico Discovery of GPCRs and GnRHRs as Novel Binding Receptors of SARS-CoV-2 Spike Protein Could Explain Neuroendocrine Disorders in COVID-19. 2022 , 10, 1500	1
107	An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension. 2022 ,	0
106	Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. 2022 , 13,	2
105	Sex Difference in MasR Expression and Functions in the Renal System. 2022 , 2022, 1-10	0
104	How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?. 2022 , 23, 10374	1
103	Sequence difference of angiotensin-converting enzyme 2 between nonhuman primates affects its binding-affinity with SARS-CoV-2 S receptor binding domain. 2022 ,	0
102	Effect of heated tobacco products and traditional cigarettes on pulmonary toxicity and SARS-CoV-2-induced lung injury. 2022 , 479, 153318	0
101	Localized delivery of nanomedicine and antibodies for combating COVID-19. 2022 ,	0
100	Determination of soluble angiotensin-converting enzyme 2 in saliva samples and its association with nicotine. 2022 , 114443	0
99	ACE2 and LOX Enzyme Inhibitions of Different Lavender Essential Oils and Major Components Linalool and Camphor.	3
98	Evaluation of 68Ga- and 177Lu-Labeled HZ20 Angiotensin-Converting Enzyme 2-Targeting Peptides for Tumor-Specific Imaging.	0
97	View of the Renin-Angiotensin System in Acute Kidney Injury Induced by Renal Ischemia-Reperfusion Injury. 2022 , 2022, 1-10	0
96	Narrative Review of New Insight into the Influence of the COVID-19 Pandemic on Cardiovascular Care. 2022 , 58, 1554	0
95	Changes of ACE2 in different glucose metabolites and its relationship with COVID-19. 2022 , 101, e31102	0

- 94 Molecular Mechanisms Underlying Twin-to-Twin Transfusion Syndrome. **2022**, 11, 3268 ○
- 93 Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation. ○
- 92 Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants. **2022**, 20, 657 1
- 91 Negative Effects of Chronic High Intake of Fructose on Lung Diseases. **2022**, 14, 4089 ○
- 90 Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction. **2022**, 23, 12516 1
- 89 An IgM-like Inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2. ○
- 88 A Bitter Experience That Enlightens the Future: COVID-19 Neurological Affection and Perspectives on the Orexigenic System. **2022**, ○
- 87 Rational drug repositioning for coronavirus-associated diseases using directional mapping and side-effect inference. **2022**, 25, 105348 ○
- 86 Leukocyte metabolism in obese type 2 diabetic individuals associated with COVID-19 severity. 13, ○
- 85 Peptide inhibitors of angiotensin-I converting enzyme based on angiotensin (17) with selectivity for the C-terminal domain. **2022**, 129, 106204 ○
- 84 Synergistic action of organophosphates and COVID-19 on inflammation, oxidative stress, and renin-angiotensin system can amplify the risk of cardiovascular maladies. **2022**, 456, 116267 ○
- 83 In Silico Studies of Synthetic Sulfatide as a Potential Drug Candidate Against Covid-19. **2022**, 43, 238-245 ○
- 82 Cerium dioxide nanoparticles modulate antioxidant defences and change vascular response in the human saphenous vein. **2022**, ○
- 81 Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches. 13, ○
- 80 Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. **2023**, 208, 115370 ○
- 79 SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor. **2023**, 48, 101729 ○
- 78 COVID-19 and Acute Kidney Injury | Direct and Indirect Pathophysiological Mechanisms Underlying Lesion Development. **2022**, 94, ○
- 77 The Biological Causes and Consequences of COVID-19: ACE I/D Polymorphism and In-Silico Screening of Potential Bioactive Phytochemicals Against COVID-19. **2022**, 16, 11779322211390 ○

76	An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. 13,	0
75	An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. 13,	1
74	Angiotensin-(1 β) prevents angiotensin II-induced endothelial apoptosis through CNPY2/PERK pathway.	0
73	COVID in children and the digestive system: clinical and pathogenetic correlation. 2022, 41-49	0
72	The role of angiotensin I converting enzyme insertion/deletion polymorphism in the severity and outcomes of COVID-19 patients. 13,	0
71	Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection.	0
70	Bibliometric and visual analysis of cardiovascular diseases and COVID-19 research. 10,	0
69	Role of angiotensin II in aging. 14,	0
68	A Closer Look at ACE2 Signaling Pathway and Processing during COVID-19 Infection: Identifying Possible Targets. 2023, 11, 13	1
67	Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. 2022, 13,	1
66	Study of frequency and inheritance model of ACE1 I/D and ACE2 rs2285666 polymorphisms in COVID-19 patients with varying severity of lung involvement and its effect on serum cytokines levels.	0
65	Angiotensin-converting enzyme 2 in human plasma and lung tissue. 2023, 32, 6-15	0
64	Genetic Variants and Protective Immunity against SARS-CoV-2. 2022, 13, 2355	0
63	The Renin Angiotensin System at the Time of COVID-19. 2023, 145-156	0
62	Exploring novel targets of sitagliptin for type 2 diabetes mellitus: Network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches. 13,	0
61	The role of calcium and calcium regulating hormonal system in the mechanisms of COVID-19 contagiousness and severity. 2022, 14-22	0
60	Engineered soluble ACE2 receptor: Responding to change with change. 13,	0
59	S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. 2023, 11, 204	1

- 58 Effectiveness of Hydroalcoholic Seed Extract of *Securigera securidaca* on Pancreatic Local Renin-Angiotensin System and Its Alternative Pathway in Streptozotocin-Induced Diabetic Animal Model. **2023**, 2023, 1-14 ○
- 57 Relation of ACE2 with co-morbidity factors in SARS-CoV-2 pathogenicity. ○
- 56 Renin Angiotensin System and Thyroid Hormone Crosstalk: From Experimental Approaches to Clinical Perspectives. **2023**, 23-37 ○
- 55 Emerging Role of ACE-2 in Cerebrovascular and Neurological Disorders: Lessons Learnt from COVID-19. **2023**, 431-447 ○
- 54 Cardiovascular Protective Arm of Renin Angiotensin System. **2023**, 363-375 ○
- 53 A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics. ○
- 52 Indoxyl Sulfate Promotes Metastatic Characteristics of Ovarian Cancer Cells via Aryl Hydrocarbon Receptor Mediated Downregulation of the Mas Receptor. **2023**, 100025 ○
- 51 Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. **2022**, ○
- 50 Pharmacologic Therapeutics for COVID-19. **2023**, 290-318 ○
- 49 The role of the apelin/APJ system in water homeostasis regulation. **2023**, 19, 340-347 ○
- 48 Renin-Angiotensin-Aldosterone system and blood pressure regulation. **2023**, 63-75 ○
- 47 Unveiling the prevalence and impact of diabetes on COVID-19. **2023**, 287-301 ○
- 46 Association between lung function and hypertension and home hypertension in a Japanese population: the Tohoku Medical Megabank Community-Based Cohort Study. Publish Ahead of Print, ○
- 45 Higher Angiotensin I Converting Enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease. ○
- 44 In silico analysis of white turmeric chlorogenic acid compound as angiotensin-converting Enzyme-2 (ACE2) inhibitor for COVID-19 drug candidate. **2023**, ○
- 43 Cardiac Arrhythmias in Post-COVID Syndrome: Prevalence, Pathology, Diagnosis, and Treatment. **2023**, 15, 389 1
- 42 Angiotensin in the gut. **2023**, 669-679 ○
- 41 Morphological aspect of the angiotensin-converting enzyme 2. **2023**, 389-417 ○

- 40 Is the anti-aging effect of ACE2 due to its role in the renin-angiotensin system? Bindings from a comparison of the aging phenotypes of ACE2-deficient, Tsukuba hypertensive, and Mas-deficient mice
- 39 Identification of the regulatory mechanism of ACE2 in COVID-19-induced kidney damage with systems genetics approach. **2023**, 101, 449-460
- 38 Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection. **2023**, 6, e202301969
- 37 In silico study of novel niclosamide derivatives, SARS-CoV-2 nonstructural proteins catalytic residue-targeting small molecules drug candidates. **2023**, 16, 104654
- 36 Diabetes Mellitus and the Kidneys. **2023**, 53, 565-580
- 35 Long COVID Eine neue Herausforderung in der Medizin: Fokus auf Schwangerschaft und Stillzeit. **2023**, 33, 7-12
- 34 Angiotensin-converting enzyme 2 At the heart of the COVID-19 pandemic. **2023**, 186, 906-922
- 33 Risk factors for heart failure in patients with COVID-19. **2023**, 28, 5169
- 32 Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. **2023**, 19, e1011168
- 31 Insights into the Scenario of SARS-CoV-2 Infection in Male Reproductive Toxicity. **2023**, 11, 510
- 30 COVID-19 Biogenesis and Intracellular Transport. **2023**, 24, 4523
- 29 Using PyMOL to Understand Why COVID-19 Vaccines Save Lives. **2023**, 100, 1351-1356
- 28 Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection. **2023**, 11, 612
- 27 Discriminating promiscuous from target-specific autoantibodies in COVID-19.
- 26 Female reproductive health during the COVID-19 pandemic: latest evidence and understanding.
- 25 The renin-angiotensin system in the eye. **2023**, 419-447
- 24 Transgenic animal models for the functional analysis of ACE2. **2023**, 491-503
- 23 Vitamin C promotes ACE2 degradation and protects against SARS-CoV-2 infection. **2023**, 24,

- 22 The role of immune activation and antigen persistence in acute and long COVID. 108155892311580 ○
- 21 Prognostic value of elevated plasma angiotensin-converting enzyme 2 in cardiometabolic diseases: A review. **2023**, 102, e33251 ○
- 20 Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders. ○
- 19 Correlation Between Renin Angiotensin System and Infectious Disease. **2023**, 41-52 ○
- 18 Renin-Angiotensin System: A Potential Therapeutic Target for Colorectal Cancer. **2023**, 451-463 ○
- 17 Comprehensive Bioinformatics analysis of angiotensin-converting enzyme 2 (ACE2). ○
- 16 Implications of Renin-Angiotensin System in Health and Disease. **2023**, 3-15 ○
- 15 Serum Angiotensin II as a Biomarker in COVID-19. **2023**, 917-940 ○
- 14 Dietary fish intake increased the concentration of soluble ACE2 in rats: can fish consumption reduce the risk of COVID-19 infection through interception of SARS-CoV-2 by soluble ACE2?. 1-8 ○
- 13 Unraveling the Underlying Molecular Mechanism of Bilent Hypoxia in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway. **2023**, 12, 2445 ○
- 12 Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?. **2023**, 24, 6253 ○
- 11 SARS-CoV-2 Receptors and Their Involvement in Cell Infection. **2023**, 17, 1-11 ○
- 10 Angiotensin-(1 β) attenuates adriamycin-induced cardiomyopathy in rats via the angiotensin type 2 receptor. ○
- 9 Nanomaterials Responsive to Endogenous Biomarkers for Cardiovascular Disease Theranostics. ○
- 8 Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. **2023**, 6, ○
- 7 ACE and ACE2 catalytic activity in the fecal content along the gut. ○
- 6 A new autophagy-driven protective pathway of Haematococcus astaxanthin against chemical damage in wistar rats with gentamicin-induced acute kidney injury. **2023**, 103107 ○
- 5 Genetic Ablation and Pharmacological Blockade of Bradykinin B1 Receptor Unveiled a Detrimental Role for the Kinin System in Chagas Disease Cardiomyopathy. **2023**, 12, 2888 ○

- 4 The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. **2023**, 14, 98-118 ○
- 3 A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. **2023**, 13, ○
- 2 Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19. **2023**, 111, 259-269 ○
- 1 Cigarette smoke increases susceptibility of alveolar macrophages to SARS-CoV-2 infection through inducing reactive oxygen species-upregulated angiotensin-converting enzyme 2 expression. **2023**, 13, ○